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ABSTRACT

Development of New Radiolabeling Methods and Insights on Ionizing Radiation Interactions
with Nanoparticles
by
Travis M. Shaffer

Advisor: Charles M. Drain and Jan Grimm

Nanoparticles are often combined with radionuclides for various applications, ranging
from waste remediation to imaging and therapy in the medical field. The overarching aim of this
body of work is two-fold. The first aim is development of new radiolabeling methods for various
nanoparticles that allow stable attachment of a variety of imaging and therapeutic radionuclides.
The second portion more fully describes mechanisms of interaction between ionizing radiation
and nanoparticles.
The following advancements will be presented in this dissertation: i) a new radiolabeling
method for silica and silica-based nanoparticles that does not require the use of specific
chelators, with both radiochemical and in vivo evaluation (chapter 2); ii) new chelator-free
radiolabeling methods for multimodal nanoparticles (chapter 3); and iii) investigation into
mechanisms of interaction between ionizing radiation and a library of nanoparticles, leading to
visible and high-energy photon flux modulation (chapter 4). While the primary focus of this
work is for medical applications, these methods may also show use in other fields such as
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remediation and storage of radioactive waste. These potential applications and future directions
are discussed in the conclusions section (chapter 5).
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CHAPTER 1
Introduction
1.1 Introduction
Radioactivity was first described by Becquerel at the end of the 19th century [1], and the
fields of radiochemistry and nuclear physics were born. In the following century, the
fundamental interactions between matter and the high-energy entities emitted by radionuclides
were described. In astronomy, these interactions have shed light on distant, extremely energetic
phenomena, aiding in our understanding of the universe [2, 3]. Within the solar system,
interactions of high-energy emissions from the sun and the earth’s magnetic field have been
investigated [4]. In one of the defining moments of the 20th century, the processes of fission [5]
and fusion [6] have led to applications both militarily and as high energy, low-carbon emitting
energy sources.
Beyond these applications, the field of medicine has also seen a revolution aided by
ionizing radiation sources such as radionuclides. Indeed, when Roentgen published his first Xray study, he chose his wife’s hand as the figure [7], hinting at the medical applications of
ionizing radiation. Ionizing radiation has revolutionized our ability to non-invasively image and
treat areas of interest in vivo. X-ray photons in the form of X-rays and computed tomography
(CT) scans are routinely used in hospitals worldwide [8]. In diagnostic nuclear medicine,
radiotracers have allowed sensitive, non-invasive imaging that reveals locations and burdens of
disease [9]. Therapeutically, radiation (beam) therapy, brachytherapy, and targeted
immunotherapy are all widely used in clinical oncology [10].
The following work develops new methods of attaching radionuclides to nanoparticles
for imaging and potential therapy, along with investigating mechanisms of ionizing radiation
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with nanoparticles. To appreciate these applications, an understanding of the basics of particle
physics involved in nuclear decay, classifications of radioactive decay, the principles of nuclear
imaging and therapy, and common radionuclides used in medicine is necessary.
1.2 The Standard Model of Particle Physics
The energy released by radioactive decay is often orders of magnitude greater than those
in chemical reactions (keV and higher compared to eV in chemical reactions). To understand
radioactive decay, a brief discussion of subatomic particles and force carriers is necessary. In
modern physics, the Standard Model has proven useful in describing elementary particles and
forces [11]. While chemistry typically works in the realm of electrons, protons, and neutrons, the
Standard Model offers a fuller description of elementary particles. In the language of particle
physics, baryons are heavy particles and include protons and neutrons. Baryons are further
composed of quarks but these will not be discussed further. Mesons are of intermediate mass and
include K- and π-mesons. Leptons are light and include electrons, neutrinos, and muons.
Baryons and mesons are also known as hadrons, as they take part in the strong nuclear force. All
of these particles have spin, an intrinsic property of elementary particles. If particles have nonintegral spins (ex. ½) they are known as fermions, whereas particles with even spins are known
as bosons, such as photons and mesons. Bosons are carriers of forces, such as the weak, strong,
and electromagnetic forces [12].
1.3 Nuclear Shell Theory
A simple answer of why radioactive decay occurs is the nucleus “wanting” to be at a
lower energetic state than its current state. While true, this answer is broad and avoids the details
of how the decay happens. Subatomic particle physics is important in the understanding of why
radioactive decay occurs. For example, if protons and neutrons were elementary particles, then
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beta emission would be quite difficult to explain. As they are composed of quarks, they can emit
decay particles to enter a lower energetic state. Here, nuclear shell theory will be discussed,
although alternative theories exist [13]. Protons and neutrons are the components of nucleus,
known as nucleons. Like electrons, they can be thought of as occupying different levels, or
shells [14]. Protons and neutrons occupy different sets of shells, and pair up as electrons do.
When the outer shells of the protons or neutrons are filled, the nucleus is exceptionally stable.
These nuclei that have “magic numbers” are analogous to the closed shells of noble gases [15].
When both protons and neutrons are magic numbers, the nuclei are deemed “doubly magic, an
example being tin-132 (Figure 1.1). Another factor in stability of a nucleus is the proton-toneutron ratio. If a nucleus has a ratio of protons to neutrons that is far from the valley of stability
(Figure 1.1, black), radioactive decay occurs to bring it closer to the line of stability.

Figure 1.1. Chart of the nuclides. The black squares are stable nuclei, whereas the yellow
squares decay with various half-lifes. Generally, the further away from the black line a square is,
the more unstable the nucleus is. The “magic numbers”, where nuclei are exceptionally stable,
are shown for protons and neutrons, respectively. From reference [16].
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1.4 α, β, and γ decay
There are three terrestrially common types of radioactive decay: alpha (α), beta (β), and
gamma (γ) (Figure 1.2). α decay is the emission of a He+2 nucleus while β particles can be
further subdivided into three categories: positron (β+, the antimatter of electrons), high-energy
electron (β−), and electron capture. Lastly, γ radiation is the emission of a high-energy photon
from the nucleus [17]. Because radioactive decay is a statistical process, radioactive elements
have a characteristic half-life (𝑡!/! ), which is the amount of time for half of the starting
radioactive atoms to decay to the daughter:
𝑡!/! =

𝑙𝑛2
𝜆

where 𝜆 is the radioactive decay constant. Radioactive decay is almost never influenced by
outside (of the atom) forces, such as its chemical state, temperature, or pressure, with exceptions
requiring highly artificial laboratory settings such as ultra-intense laser fields [18]. To determine
the amount of radioactivity remaining after a certain amount of time, the radioactive decay
correction equation is used:
𝐴 = 𝐴! 𝑒

!(

!.!"#!
)
!! !

where 𝐴 is the decay-corrected radioactivity, 𝐴!   is the starting radioactivity, 𝑡 is the time elapsed
since 𝐴! , and 𝑡!/! the half-life of the radionuclide. Decay correction is used throughout this
work.
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Figure 1.2. The three terrestrially common types of radioactive decay. Alpha decay is
characterized by the ejection of a He2+ atom during decay. Beta decay occurs by the ejection of
an electron or positron. The beta decay depicted here is for the positron with simultaneous
neutrino ejection. In gamma decay, a high-energy photon is generated as the atom relaxes to a
lower energy state. From reference [17].
α decay
The mechanism of α decay involves the phenomenon of quantum tunneling, as α particles
do not have sufficient energies to escape the strong force, and classical mechanics cannot be used
to describe α emission [19]. α particles ejected from the nucleus experience both repulsive
electromagnetic force (as both the nucleus and the α are positively charged) and the strong force.
As α particles are the only entity emitted from the nucleus during decay, they have discrete
energies, typically 4-10MeV.
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β decay
β decay occurs when a proton transforms into a neutron (for positron or electron capture)
or a neutron into a proton (β-). Unlike α emission, debate if the β energy spectrum consisted of
discrete energies or a continuous spectrum persisted for nearly thirty years after the discovery of
the β particle [20]. It was shown in the 1920’s by Ellis that the β emissions were indeed a
continuous spectrum, with the βmax being the difference in energy between the initial and final
nuclear energy [21]. The reason behind this continuous spectrum had to wait until the discovery
of the neutrino. The neutrino, a massless or nearly massless particle, was predicted by Pauli in
1930 [22] to account for the continuous β energy spectrum and experimentally discovered in
1956 at Savannah River [23]. Neutrinos (ve) and anti-neutrinos (v̅ e) are emitted during positron
and β- decay, respectively, and explain why the β spectrum is continuous rather than discrete.
Neutrinos are also formed during nuclear processes that occur in stars such as the sun, and are
detected using Cerenkov instruments (among other ways), a concept that will be discussed in
chapter 4.
Another essential discovery occurred around this time. Starting in 1928, Paul Dirac
recognized that particles such as electrons should have corresponding antiparticles with the same
mass but opposite charge [24]. Dirac’s predictions of the existence of anti-particles (i.e.
antimatter) was shown experimentally by CD Anderson in 1933 with the discovery of the
positron [25]. Positrons are the anti-particles of electrons, and annihilate when interacting with
them, releasing energy in the form of photons or mesons upon annihilation [26]. Understanding
positrons interactions with matter is essential for various types of imaging, discussed in the
subsequent chapters.
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γ decay
γ-decay results in the emission of a high-energy photon from the nucleus. This results
from a nucleus in an excited (i.e. metastable) state relaxing to a lower state, which emits a highenergy photon. Because the emitted photon is the energy difference between an excited and
lower nuclear energy state, precise measurement of this photon is used to establish nuclear
energy-level structures [27].
Decay schemes
Radioactive atoms can decay via multiple mechanisms. For example, 18F decays 97% of
the time via positron emission and 3% of the time via electron capture. This is shown through
decay schemes of radioactive elements, with an example of 89Zr decay shown in Figure 1.3. In
chapter 4, the decay schemes of medical radionuclides will be discussed in depth. Therefore,
decay schemes of all of the radionuclides used in this work are found in the Appendix section.

Figure 1.3. Simplified decay scheme of 89Zr. 89Zr decays via electron capture (EC) or positron
emission (β+) to 89mY, which subsequently relaxes to 89Y with the emission of a 909keV photon.
From reference [28].
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1.5 Principles of PET imaging
Positron emission enables positron emission tomography (PET), first demonstrated in
1950’s by Gordon Brownell and Charles Burnham at Massachusetts General Hospital [29]. Later
in the 1970’s, Michael Phelps and Edward Hoffman constructed improved PET scanners with
hexagonal detectors [30, 31]. These and subsequent advances in detector technology have lead to
the current PET scanners used both clinically and for small animal imaging [32].
PET imaging is possible because an emitted positron will annihilate with its matter
counterpart, the electron, causing the emission of two 511 kev photons emitted nearly 180° apart
(511 keV is the energy equal to the rest energy of the electron and positron). Therefore, PET
imaging allows quantitative, non-invasive imaging in a calibrated PET scanner. The attenuation
of the 511 keV photons by tissue can lead to lower signals in dense tissues; therefore, attenuation
corrections using Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) can be
applied to PET images [33].
The 511 kev photons are detected by a ring of detectors around a field of view (FOV) that
enables coincidence detection. Coincidence detection is the registration of two signals 180° from
each other within a certain time frame (ex. 6 ns). The spatial resolution of PET imaging depends
on both the hardware of the system and the positron energy (and therefore range prior to
annihilation) [34]. The influence of positron range on PET imaging spatial resolution has long
been noted [35] and studied for image reconstruction purposes extensively [36]. The possibility
of improved resolution through lowering the positron range will be discussed in chapter 5.
Two recent innovative advances in PET imaging are worth noting. The first is using the
decay properties of certain radionuclides for increased sensitivity of imaging along with allowing
PET imaging of multiple PET tracers at the same time. Certain radionuclides, such as 124I, emit a
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photon and a positron simultaneously. The three photons can be detected using triple coincidence
detectors, delineating positron annihilation from 124I from other positron emitters such as 18F [37,
38]. This allows simultaneous imaging of multiple positron emitters. The second advance is
using the magnetic field of MR in a PET/MR instrument to reduce the positron range in one
direction. As a positron is a charged particle, it is influenced by magnetic fields. By orienting the
MR field, PET resolution is improved through reducing the range of the positron [39, 40]. These
examples illustrate the advances in imaging that are possible through careful consideration of the
particle physics of nuclear decay, a topic that will be discussed in Chapters 4 and 5.
1.6 Principles of SPECT imaging
High-energy photon emitters allow single photon emission computed tomography
(SPECT). SPECT works by a rotation collimator detecting photons in the appropriate energy
range, typically detecting <0.01 % of emitted photons. A high-energy photon emitted from a
SPECT tracer enters a collimator and interacts the scintillation crystal in the collimator, which
registers a signal. The camera rotates around the FOV and reconstructs a 3D image. Planar
scintigraphy (2D) operates with the same principle, but with a stationary detector [41].
1.7 Principles of radiotherapy
Therapy utilizing ionizing radiation traditionally can be separated into external, internal,
and systemic (injected) radiation therapy. Here we focus on internal and systemic radiation
therapy, such as radioimmunotherapy or brachytherapy. These therapies use radionuclides,
which emit ionizing radiation, to kill cells. Typically α and β- emitters are used for radiation
therapy, with each type of tracer offering advantages. α particles have high energies (typically 410 MeV) and due to their mass interact with matter and have a relatively short range (50-
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100 µm) in tissue [42]. Conversely, β- emitters have relatively longer therapeutic ranges (0.6310mm), as their probability of interactions are lower than α particles [43].
1.8 Radionuclides for medical applications
In order for radionuclides to be useful in medicine, they are often attached to a ligand dependent
on their purpose. An important consideration for probe development is matching the
pharmacokinetics (pK) of the ligand with the half-life of the radiotracer (i.e. short pK, short halflife). If the pK of the ligand is short but the radiotracer long-lived, the patient is exposed to
unnecessary dose. If the pK of the ligand is long (days) and the radiotracer half-life short
(minutes), then the desired biological process cannot be imaged. For imaging, the amount of
radioactive ligand injected is in nanomolar-picomolar concentrations, and as such, is assumed
not to perturb the properties of the system. This is known as the radiotracer principle
Small molecules such as ammonia, water, glucose analogs, and peptides are tagged with
shorter-lived radiotracers such as nitrogen-13 (13N), oxygen-15 (15O), carbon-11 (11C), or
fluorine-18 (18F). The utility of the glucose analog 2-(18F)fluoro-2-deoxy-glucose ([18F]-FDG)
was demonstrated Fowler in the late 1970’s [44, 45] and approved for use in oncology and for
assessment of myocardial hibernation in the late 1990’s [46], paving the way for its widespread
clinical use. One radiotracer garnering increased interest is the PET tracer 68Ga (t1/2 = 68 m),
which can be eluted from a 68Ge generator [47]. Generator-based systems do not require the
extensive infrastructure that cyclotrons do, allowing widespread adaptation. The advantages and
limitations of 68Ga as an imaging agent will be shown in Chapters 2 and 3. Ligands with pK
profiles that warrant longer imaging (4-24 h) are often labeled with technetium-99m (99mTc),
copper-64 (64Cu), or yttrium-86 (86Y). Ligands with long pK profiles (>24 h), such as antibodies
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and nanoparticles, are tagged with radiotracers such as zirconium-89 (89Zr) and various iodine
isotopes.
1.9 Concluding remarks
Radioactivity is used for both imaging and therapy in the medical field, as discussed
broadly above. PET and SPECT each offer advantages and disadvantages for in vivo imaging in
terms of cost, sensitivity, resolution, and radionuclide availability [48]. An understanding of the
interactions of each type of ionizing radiation with matter is essential for accurate imaging and
dosimetry. Furthermore, consideration of the chemical properties of the various radionuclides is
necessary for stable attachment to ligands of interest for imaging and therapy. To this end, new
strategies for attaching radiometals to simple nanoparticles for in vivo applications are covered
in chapter 2. Attaching radiometals to more complex nanoparticles that allow multimodal
imaging is covered in chapter 3. Lastly, the interaction of radioactive decay particles and photons
with nanoparticles that result in visible photon production is covered in chapter 4.
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CHAPTER 2

Radiolabeling simple nanoparticle systems
This chapter contains results adapted from publications in Nano Letters [1], Wiley
interdisciplinary reviews. Nanomedicine and nanobiotechnology [2], and submitted to Nano
Letters [3]. Accordingly, the figures and text in those sections are the result of collaborative data
collection and writing with the co-authors.
2.1 Introduction
Radioactivity has been used in the medical field since shortly after its discovery due to its
unique properties discussed in chapter 1. The different types of radioactive decay allow multiple
approaches to non-invasive quantitative imaging and therapy. While biomolecules such as
antibodies and peptides are often radiolabeled with radionuclides, nanoparticles (NPs) are
increasingly popular platforms for in vivo use. This chapter first reviews the current state of
nanomaterials and bioimaging. Next, methods of radiolabeling nanomaterials are discussed, with
elaboration of the four common radiolabeling methods. This is followed by new radiolabeling
methods developed for radiolabeling of silica-based simple nanoparticles (i.e. the NP is not a
contrast agent prior to radiolabeling) with various radiometals, including 89Zr, 68Ga, 111In, 90Y,
177

Lu, and 64Cu.

2.2 Nanomaterials and Bioimaging
In biomedical imaging, nanoparticles (NPs) can provide or enhance the distinction of
normal from diseased tissue, whether that be tumor margins for image guided surgery, sentinel
lymph node drainage in metastatic cancer, or even identifying sites of inflammation.
Traditionally, radiotracers have been attached to small molecules or antibodies with the aim of
identifying sites of disease as well as diagnostic markers to show efficacy of a particular therapy.
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In cancer therapy, ideally these radiolabeled agents exhibit additional therapeutic properties,
which can be either drugs or therapeutic radionuclides (e.g. 90Y or 177Lu). NPs have also
emerged as clinically relevant platforms not only for radiotracers, but also as therapeutic agents.
While much remains to be discovered about the toxicology of NPs compared to the larger bulk
state for a given material, it is known through preclinical studies that some NPs can be taken up
in tumors via an upregulated macropinocytosis mechanism, providing a window for imaging and
therapy optimization in tumors [4]. Functionalizing unlabeled NPs with affinity tags for specific
receptor handshakes can enrich NPs at the desired target. Tethering of imaging agents to NPs
such as radionuclides enables tracking the distribution in vivo through methods such as positron
emission tomography (PET), single photon emission computed tomography (SPECT), or
Cerenkov luminescence (CL). While many NPs for imaging exist in the preclinical space, few
have advanced into the clinic. Designing NPs with mechanisms for endocytosis and endosomal
escape to intracellular targets are hallmark challenges in NP delivery systems. Radiolabeled
NPs, with high specific activity, advantageously can be used for imaging, minimizing particles
necessary for imaging a particular tissue feature. Furthermore, NPs have the potential to carry
high levels of radioactivity per particle providing directed internal radiotherapy when targeted.
Imaging agents that are simultaneously therapeutic are known as theranostics. In the case of the
β- radionuclides used for CL imaging such as 177Lu and 90Y, the radionuclide is both the imaging
agent as well as the therapeutic, though other radionuclides could be used in combination with
therapeutic NPs to achieve a theranostic agent.
NP properties are critical to the successful biodistribution of an imaging agent, and if
chosen improperly, can lead to off target delivery and toxicity. Classically for small molecules,
understanding the uptake and biodistribution is dependent on physiochemical parameters often
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described as “Lipinski’s rule of Five” [5], covering guidelines such as fewer than 5 hydrogen
bond donors, fewer than 10 hydrogen bond acceptors, a molecular mass less than 500 daltons,
and partition coefficient greater than 5. Lipinski’s rules were established to achieve drugs with
Absorption, Distribution, Metabolism, and Excretion (ADME) sufficient to reach the target while
limiting off target effects and extreme delivery methods. In stark contrast, NPs are much larger
orders of magnitude and their biodistribution is dependent on entirely different properties such as
size, aspect ratio, charge, stiffness, and surface chemistry (e.g. determining the properties of the
NP’s coating) [6]. Furthermore, particle opsonization serves as an elimination mechanism for
NPs rather than a depot as seen in plasma bound small molecules that protect the small molecule
from direct renal elimination or metabolism. Through the advances in material science and
bioengineering, NPs with bio-relevant properties have emerged to better direct the
biodistribution of NPs for selective radioimaging and therapy.
A material is considered a NP when at least one dimension is on the order of 10 to 100
nm. NP are synthesized through various methods, which predominantly include bottom up
synthesis of liposomes [7], micelles [8], polymersomes [9], dendrimers [10], carbon nanotubes
[11], and inorganic NPs [12] for example. Many NPs in use today are spherical, though rods,
tubes, disks, and worms also are being evaluated in vivo. The variation in morphology is driven
by several parameters, mainly by concentrations of lipid or polymer energetics for assembly, the
packing parameter of the coating monomer used, and the size of the NP core in the case of a stiff
core like metallic NPs (e.g. iron oxide NPs or IONPs, gold NPs or quantum dots). By altering
the chemical composition of the lipid or polymer used a wide variety of particles can be
achieved, from micelles to worms to multi-lamellar vesicles of varying sizes [13]. Different size
ranges have vastly different biodistributions based on mammalian physiology and serve as the

	
  

16	
  

	
  
first important parameter in NP design [6]. Particles less than 5 nm are rapidly cleared via renal
excretion, while particles under 100 nm have shown widespread biodistribution across various
organs [14]. Larger particles of several hundred nm begin to restrict NP distribution to the RES
(mainly liver and spleen), with micron size particles resulting in undesired residence in capillary
beds.
Beyond size, NP shape and charge are key parameters affecting internalization rates of
NPs where rod shaped and positively charged particles were found to result in the greatest uptake
in-vitro [15]. NPs with rod-like morphology have been shown to have higher specific and lower
nonspecific targeting in vivo compared to identical spherical particles [16]. Furthermore, carbon
nanotubes with extremely high aspect ratios and lengths of 200-300 nm have been shown to clear
through the kidneys despite having a dimension much greater than the glomerular filtration
cutoff. This paradoxical phenomenon is thought to occur by flow orientation of the carbon
nanotube tip first through the glomerulus despite the carbon nanotube having a molecular weight
10-20 times the traditional limit for glomerular filtration [17]. Through tuning the size, shape and
charge of the NP, tumor uptake can be favored. Furthermore tumors that show uptake of NPs do
not necessarily show cellular uptake distribution within the tumor. Ex-vivo analysis by flow of
Particle Replication in Non-wetting Templates (PRINT) particles revealed variation in tumor
population uptake based upon particle size with macrophages and other leukocytes representing
the largest populations taking up NPs aside from cancer cells [18]. Identifying the right
subtumoral cell population to target can mean the difference between tracking macrophages and
cancer cell labeling and therapy.
Delivery of NPs has often relied on Enhanced Permeability and Retention (EPR) to
describe passive but selective delivery to tumors with leaky vasculature [19]. More recently,
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EPR effects on spontaneous solid canine tumors were imaged using liposomes radiolabeled with
64

Cu2+. Of the canine tumors tested, an EPR effect was seen in carcinomas but not in sarcomas.

This tumor type dependent uptake without a targeting strategy shows not all tumors are
amendable to EPR-dependent deliveries nor respond favorably to untargeted NP administration
[20]. Where EPR is weak, NPs should be amenable to active targeting and uptake strategies such
as sonoporation [21] to enable permeation beyond the vasculature and into the tumor
environment. For imaging NPs, cellular uptake is not essential to register location but should
have a high enough diffusion to identify tumor margins before the desired imaging time.
As NPs have high surface area to volume ratios, NPs have become ideal platforms upon
which surface charge, polymeric coating, and specific targeting ligands can be added to shape the
NP biodistribution, reduce nonspecific uptake, and mimic a biological handshake. Targeting
ligands for surface conjugation and adsorption can include small molecules [22], peptides [23],
aptamers [24, 25], and antibodies [26], Furthermore, attachment of radiotracers via chelators (for
radiometal incorporation) and prosthetic groups (e.g., for radiohalogen functionalization) may
alter NP properties compared to unlabeled NPs. To minimize changes in surface characteristics,
various methods of radiolabeling without NP surface modification have been devised, and are
typically referred to as “chelator-free” radiolabeling [27].
Newer NPs with targeting ligands on the surface have improved delivery to the site of
interest. Use of stealth-like coatings such as polyethylene glycol (PEG) are widely used as a
passive stealth mechanism [28], but is not impervious to opsonization in vivo and therefore
phagocytosis by the Reticuloendothelial System (RES). Biological coatings that elicit a more
active recognition have been utilized, such as CD47 coated NPs which show longer persistence
ratios in vivo compared to PEG and similarly opsonized NPs [29]. NP design is moving to
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include more active targeting of a diseased system while avoiding unwanted phagocytosis by the
Mononuclear Phagocytic System (MPS).
Another area not often considered in NP design is the effect of particle stiffness on
biodistribution. Comparing equally opsonized soft and stiff NPs showed a greater phagocytic
index for stiff particles. The stiffness of the particles could override a “don’t eat me” signal
provided by surface bound CD47 [30, 31]. Therefore, softer NPs and coatings could have an
advantage in avoiding off-target uptake. Polymeric coatings in this instance can alter the
stiffness of the particle while at the same time serving as a small molecule drug depot and
radionuclide anchor. Through deliberate NP design, NPs can be ideal platforms for a variety of
radiotracers. With the combination of other imaging agents and targeting moieties, imaging
agents and theranostics can be produced with high selectivity from simple NP scaffolds while
more complicated structures can enable multimodal imaging and therapy.
2.3 Nanoparticles used in nuclear imaging
Many of the lipidic, polymeric, carbonaceous and inorganic NP platforms available are
amenable to chemical conjugation for radiolabeling through either direct methods or chelation.
Choice of radionuclide depends on the desired duration of the imaging agent, as well as the
desired type of imaging intrinsic to the radionuclide decay. Radionuclides that are facile for
synthetic routes include 11C, 18F, 76Br and 124I while other radionuclides such as 64Cu, 68Ga, 89Zr,
90

Y, 99mTc, and 177Lu are best attached via chelation or chelator-free surface adsorption.

Liposomes have been widely used with radiotracers and are one of the oldest NP platforms.
Morgan and co-workers pioneered multilamellar vesicles with 99mTc via reduction of
pertechnetate in the presence of liposomes in 1981 [32]. Liposomes are traditionally made
through hydration of lipid films and extrusion through successively smaller membranes to yield
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sub 200 nm NPs with a low polydispersity index. Liposomes have been functionalized with
various radiotracers resulting in free activity sequestered to the liposome bilayer or contained in
a functionalized chelator. Polymeric NPs can also be radiolabeled using similar methods.
Compared to liposomes and polymersomes, inorganic NPs are stiff core particles that are often
made of silica via the Stӧber method, but also include a wide variety of semiconducting quantum
dots that can be used for multimodal imaging. Furthermore “Cornell Dots” (C dots) have also
been synthesized which are either fluorescent [33] or radiolabeled [34]. Other inorganic NPs
such as gold and iron oxide have been extensively used for Surface Enhanced Raman Scattering
(SERS) [35] as well as MR-weighted contrast agents [36]. Carbon nanotubes (CNT) have also
been used as effective carriers for radiotracers given their high surface to area ratio [37].
2.4 Methods of radiolabeling nanoparticles
The type of radionuclide and NP chosen for imaging will determine the incorporation
strategy into the NP. There are four main methods for radiolabeling nanoparticles, shown in
Figure 2.1. Traditional methods for radiolabeling a NP involves the attachment of a chelator
such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or desferrioxamine
(DFO) for radiometal chelation [38], or prosthetic groups such as tyrosine residues of proteins by
using chloramine-t-oxidation (referred to as the IODOGEN method) [34] to the NP surface for
subsequent radiolabeling. Because of the wide use of chelators and prosthetic groups for
labeling antibodies and peptides, these two methods are the main routes of NP radiolabeling.
Radionuclides can also be directly incorporated into the NP without using a chelator or
prosthetic group. Three main methods are used for chelate-free radiolabeling: hot-plus-cold
synthesis, ionic exchange, and cyclotron bombardment [27]. While radionuclide incorporation
during synthesis typically results in stable in vivo constructs, the resulting generation of
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radioactive waste, longer radiolabeling times compared to other methods, and the necessity of
the radionuclide to incorporate into the NP lattice without resulting in a large lattice mismatch
are all limitations. Furthermore synthesis of the particle has to be much shorter than the decay of
the radionuclide to preserve radiotracing functionality. Radiolabeling iron oxide nanoparticles
(IONP) [39, 40], silica nanoparticles (SNPs) and silica-coated NPs [41], and quantum dots
involves pH dependent addition of the radiometal to the NP at elevated temperatures [42].
Chelator free radiolabeling of IONPs was reported through a 120ºC incubation of radiometal
salts in aqueous buffer for an hour [39]. In another example, 198Au-NP were grown from cold
AuNP precursors using “hot-plus-cold” radiolabeling [43] while another method with 64Cu
alloyed AuNPs showed improved radiochemical stability compared to chelator and chelator-free
radiolabeling methods [44]. Lastly, NPs can also be radiolabeled through direct proton or
neutron bombardment of the NP to produce the radionuclide in-situ, although this method
requires an on-site cyclotron [45]. Unique methods of radiolabeling were recently shown with
CNTs harboring ions within defects and were exploited for novel 225Ac incorporation yielding a
chelator free construct [46]. CNTs have served as a backbone for imaging moieties; however,
pristine semiconducting single walled CNTs (SWCNTs) have IR optical properties [47], which
are quenched by some direct CNT radiolabeling methods [37].
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Figure 2.1. Four methods of radiolabeling nanoparticles. (a) Traditional chelators or prosthetic
groups are chemically conjugated to the surface to serve as sites for radionuclide attachment. (b)
Direct synthesis methods whereby cold and hot precursors can be added to produce a
nanoparticle with radionuclides embedded into the nanoparticle lattice. (c) Direct bombardment
of a suitable nanoparticle atom by neutron or proton to yield a radiolabeled nanoparticle. Neither
chelator nor surface chemistry required for radiolabeling. (d) Chelator-free radiolabeling method
whereby a radiometal is directly attached to the nanoparticle surface. From reference [2].
2.5 Hard and soft metal considerations
Stably coordinating a radiometal requires taking into account the properties both of the
metal ionand electron donating groups of the ligand. For softer metal ions such as 64Cu2+, which
is neither a particularly hard nor soft cation, chelators typically feature a mixture of uncharged
nitrogen, sulfur, and oxygen donors such as diacetylbis(N4-methylthiosemicarbazone) (ATSM)
[38]. The most widely used radiotracer, 99mTc, has oxidation states that range from +7 to -1 and
may be chelated with a variety of electron donors depending on the oxidation state of the 99mTc.
For example, scaffolds often used include diamine dithiol with TcV [48], and tricarbonyl
complexes with TcI [49]. For hard, highly charged metals such as 89Zr+4, chelators such as
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Deferoxamine (DFO) [50] and 3,4,3-(LI-1,2-HOPO) (HOPO) [51] are used, with oxygen as the
electron donor of the chelator. Likewise, Ga3+, which is harder than Cu2+, typically binds ligands
containing multiple oxygens, such as (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)
(DOTA). With these properties in mind, general predictions for radiolabeling nanoparticles with
radiometals in a rational manner are possible.
2.6 Silica as a general substrate for chelation of oxophilic species
While the chelator-free radiolabeling methods discussed in section 2.4 eliminate the need
for molecular chelators during nanoparticle radiolabeling, they often remain restricted to specific
radionuclides, rather than being effective general platforms for many species. A generalized
method for producing nanoparticles that are capable of intrinsically binding a wide variety of
radionuclides without additional selective chelation molecules would be highly desirable. It
would provide a “one stop shop” nanoparticle that can be radiolabeled for multiple applications
without being individually modified with different chelators each time. To this end, we first
identified some important properties shared between many common radionuclides as discussed
in section 2.5. The majority of medically relevant radiometals are chelated by electron donors
(e.g., oxygen, sulfur, or nitrogen atoms) arranged in a symmetry that results in a stable
coordination complex [52]. In this regard, it is reasonable to hypothesize that a chelator-free
nanoparticle for intrinsic radiolabeling could be constructed by creating a nanoparticle with
oxygen atoms arranged in a variety of symmetries. A prototypical example of a material meeting
these requirements is amorphous silica, which has the benefits of well-established synthetic
protocols (Figure 2.2) and widespread use in biomedical applications [53, 54]. Furthermore,
SNPs are known to bind heavy metal ions for environmental remediation [55, 56]. Because SNPs
are inexpensive and “generally recognized as safe” by the Food and Drug Administration, they
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make for ideal substrates in a kit like protocol for producing intrinsically labeled nanoparticles
[57].
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Figure 2.2 Reaction steps in the synthesis of SNPs via the Stöber method. Hydrolysis occurs,
typically with an acid or base (such as NH4OH) catalyst. This is followed by a condensation
reaction.
We investigated the ability of amorphous SNPs to bind a variety of medically important
radionuclides with a range of half-lives and emissions. In particular, we explored the labeling
efficiency of 68Ga, 64Cu, 89Zr, 90Y, 111In, and 177Lu under various temperatures, pH, and
incubation times. 89Zr was further investigated using SNPs that had been coated with
polyethylene glycol. The 145 nm SNPs were synthesized according to a modified Stöber method
[53], washed three times in ethanol and then resuspended in buffered solutions at either pH = 5.7,
7.3, or 8.8 (see methods). The SNPs maintained a constant size and did not aggregate during this
process (Figure 2.3).
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Figure 2.3. Pre- and post-radiolabeling nanoparticle characterization. (A) Atomic force
microscopy (AFM) and transmission electron microscopy (TEM) characterization of SNPs
before radiolabeling. (B) AFM and TEM characterization of SNPs after radiolabeling with 68Ga.
The size and shape of the nanoparticles remains unchanged. Scale bars are 100 nm.
The radiochemical yield was assessed both by iTLC and centrifugal nanoparticle
purification (Figure 2.4). When the specific activity is 100 Ci/µmol, all radionuclides tested
demonstrate radiochemical yields of >99% (non-decay corrected, as measured by centrifugal
nanoparticle purification) at pH = 7.3, 70 °C and incubation times less than or equal to 1 h. The
radiochemical yield improves as temperature increases from 4 to 70 °C but does not vary
significantly as a function of pH in the range investigated (pH = 5.7–8.8). Buffer without SNPs
was used as a control for each condition to exclude the possibility of false-positive signals due to
precipitate formation. Every radionuclide except 177Lu shows >95% activity as free in solution,
which is in agreement with previous reports [58]. Because 177Lu exhibits >10% signal associated
with precipitate formation in the buffer control, centrifugation and size exclusion filtration is
necessary in the analysis of 177Lu radiolabeling to ensure that false-positive signals from
precipitates do not occur. Separating the particles from the supernatant shows that all of the
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radioactivity is associated with the nanoparticles, independent of temperature. Competitive
chelation studies with ethylenediaminetetraacetic acid (EDTA) demonstrate that only samples
incubated at 70 °C robustly retain the various radiometals. This suggests that the dominant
influence of the temperature is in overcoming the activation energy required for stable binding,
rather than enabling delivery of the radionuclides to binding sites (i.e., the process is reaction
limited, not diffusion limited). This finding is supported by the observation that the SNPs are
sufficiently porous to enable diffusion of the radionuclides into the nanoparticle interior (Figure
2.5).

Figure 2.4. Radiolabeling and serum stability of SNPs. (A) Instant thin-layer chromatographs of
radiolabeled SNPs. The red asterisk denotes the origin, where the nanoparticles remain, and the
black asterisk denotes the solvent front, where the free activity would be located. Controls of
buffer-only solutions (no particles) were ran with each condition with >95% signal at the free
activity peak. (B) Percent radionuclide bound to SNPs as a function of time and pH. The blue,
red, and green lines indicate radiolabeling at pH = 5.5, 7.3, and 8.8, respectively. (C) Percent
radionuclide bound to SNPs as a function of time and temperature. The blue, red, and green lines
indicate radiolabeling at 4, 37, and 70 °C, respectively. (D) Serum stability of SNPs radiolabeled
at pH = 7.3 and 70 °C, then incubated in 50% FBS at 37 °C.
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Figure 2.5. Pore size of SNPs. Atomic force microscopy of SNP samples reveals porous surfaces
with many pore diameters in excess of 5 nm. Low magnification phase images (left) and highmagnification phase images (right) were acquired in tapping mode as described in the methods.
The porosity of these SNPs is sufficient for diffusion of radionuclides into the nanoparticle
interior, making chelation feasible anywhere within the nanoparticle (i.e. not restricted to the
surface).
While heating the particles to 70 °C precludes prelabeling attachment of temperaturesensitive targeting ligands such as antibodies, other targeting ligands that are stable at this
temperature such as smaller peptides and aptamers may be used. Figure 2.6 demonstrates that
PEGylation of the SNPs does not preclude 89Zr binding. Therefore, attachment of moieties
incompatible with the reported labeling procedure can be facilitated by first radiolabeling SNPs
coated with functionalized polyethylene glycol, then performing straightforward
postradiolabeling reactions. The nanoparticle size and zeta potential before and after
radiolabeling are given in Table 2.1.
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89Zr"+"PEG+SNP"
X"

89Zr"+"PEG"(Control)"
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Figure 2.6. Intrinsic radiolabeling of PEGylated SNPs with 89Zr. The surface of SNPs was
modified by the addition of 2,000 Da polyethylene glycol (PEG) according to the procedure
reported in the methods. The X represents the activity remaining at the origin of the ITLC strip
and the black asterisk (*) represents the activity at the solvent front. Virtually all of the activity
appears at the origin (i.e. where the SNPs remain) in the PEGylated SNP sample, whereas the
control sample containing free PEG without silica exhibits the majority of activity at the solvent
front. These results demonstrate that PEGylating SNPs does not preclude intrinsic radiolabeling.
With these established protocols for achieving chelator-free high specific activities, the
stability of the SNPs under physiological conditions was examined. The serum stability of each
radionuclide was investigated in 50% fetal bovine serum at 37 °C over time periods appropriate
to each isotope’s half-life. All isotopes were stably retained within the SNPs except for 64Cu. In
the case of copper, 60% of the bound isotope leached into the serum after 4 h. Because the
operating principle of intrinsic labeling with SNPs is the affinity each isotope has for the oxygenrich matrix, it is unsurprising that copper is most weakly retained because it is the least oxophilic
of the radiometals tested. In fact, the trend in serum stability of the intrinsically labeled silica
demonstrated excellent correlation with the oxophilicity (i.e., hardness) of the ions [59]. The
marked decrease in the serum stability of 64Cu can be further attributed to proteins present in the
serum that actively chelate copper ions, resulting in pronounced transchelation effects [60]. 64Cu
radiolabeling instability is addressed in the next section.
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Table 2.1. Pre- and post-labeling SNP characterization (n=4)
Radionuclide
Pre-labeling
Post-labeling
Pre-labeling
Post-labeling
mean diameter mean diameter zeta potential
zeta potential
(nm)
(nm)
(mV)
(mV)
68
Ga
144.1 (± 1.42)
142.5 (± 2.07)
-45.2 (± 1.44)
-48.7 (± 4.23)
89
Zr
144.1 (± 1.42)
146.0 (± 6.86)
-45.2 (± 1.44)
-47.7 (± 0.58)
90
Y
144.1 (± 1.42)
145.4 (± 0.30)
-45.2 (± 1.44)
-47.4 (± 3.25)
177
Lu
144.1 (± 1.42)
141.6 (± 2.98)
-45.2 (± 1.44)
-45.1 (± 3.16)
111
In
144.1 (± 1.42)
143.4 (± 0.85)
-45.2 (± 1.44)
-42.1 (± 0.51)
64
Cu
144.1 (± 1.42)
145.0 (± 1.00)
-45.2 (± 1.44)
-47.7 (± 3.34)
The stability and biodistribution of 68Ga- and 89Zr-labeled SNPs was also investigated in
vivo. These radionuclides are particularly interesting because of their increasing clinical
importance in PET imaging, disparity in half-life, and excellent serum stability [61, 62]. Because
nanoparticles are known to generally accumulate in the reticuloendothelial system in amounts
well exceeding 90 % of the injected dose [63], short-lived radionuclides like 68Ga are attractive
in minimizing the cross-dose to healthy organs while still enabling whole-body cancer imaging.
Alternatively, because some nanoparticle formulations remain in circulation for extended periods
and most nanoparticle clearance studies extend for weeks or longer, long-lived isotopes like 89Zr
are essential for investigating the biological response to nanoparticle administration. An
additional benefit of studying these two radionuclides is that the biodistribution of free 68Ga and
89

Zr is easily distinguished in the biodistribution of nanoparticles in that they do not

preferentially residualize in the liver and spleen (Figure 2.7), which is in contrast to other
radionuclides like 64Cu that naturally accumulate in the liver. Male athymic nude mice (8–10
weeks old, n = 3) were injected with 250–350 µCi (9.25–12.95 MBq) of either free 68Ga or 89Zr
while another set was injected with 68Ga- or 89Zr-SNPs (10 nM) in 100 µL of 10 mM pH = 7.3 2(N-morpholino)ethanesulfonic acid solution via the lateral tail vein. The nanoparticle-bound
radiometals demonstrated the known biodistribution of SNPs and remained localized in the liver
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and spleen for the entire period investigated (3 h for 68Ga, 24 h for 89Zr, n = 3 for each) (Figure
2.7) (32). The stark contrast between the free and nanoparticle-bound biodistributions
demonstrates that the SNPs stably retain the radionuclides in vivo (Figure 2.8).
68Ga 1h!
68Ga 1h!

68Ga 3h!
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Figure 2.7. In vivo coronal PET maximum intensity projections (MIPs) of free and silica-bound
radiotracers in athymic nude mice, 250−350 µCi (9.25−12.95 MBq) per injection. (A) MIPs of
free (top) and silica-bound (bottom) 68Ga at 1 and 3 h post injection. (B) MIPs of free (top) and
silica-bound (bottom) 89Zr at 4, 12, and 24 h post injection. The intrinsically labeled SNPs
exhibit contrast in the reticuloendothelial system (liver, spleen), the known biodistribution of
SNPs, whereas the free isotopes demonstrate an entirely different biodistribution. This stark
contrast indicates that the SNPs remain intrinsically labeled in vivo.
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Figure 2.8. Biodistribution of 68Ga- and 89Zr-radiolabeled SNPs 4 hours and 24 hours postinjection, respectively. Both biodistributions are consistent with the known uptake of SNPs. The
minimally elevated levels of 89Zr activity in the bone (< 1 %ID/g) suggest that some radionuclide
leaching may be occurring in vivo, but the total amount of bone uptake is less than reported for
other radiolabeled nanoparticles [58]. These biodistributions are consistent with the observations
from the PET images reported in Figure 2.7.
Because silica serves as a robust platform for binding radionuclides and retaining them in
vivo, the nanoprobes generated by this kit like radiolabeling protocol should be immediately
useful in the many known biomedical applications of nanoparticles. As a proof of concept, we
attempted to use these nanoparticles for lymph node imaging, a clinically important application
where nanoparticles demonstrate great promise [64]. We injected either free 89Zr or nanoparticlebound 89Zr (n = 3 per condition, 3.7–5.5 MBq, 20–30 µL) into the footpad of male athymic nude
mice (see methods section) and performed whole-body PET-CT scans. In all cases, the
nanoparticle-bound radionuclides enabled robust detection of local lymph nodes while the free
radionuclide controls did not (Figure 2.9, 2.10).
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Figure 2.9. In vivo PET-CT (left) and PET-only (right) maximum intensity projections of lymph
node tracking after injection in the right rear paw of athymic nude mice. Injection amounts were
100-150µCi (20-30µL). (Top) Free 89Zr at 14 h and 24 h post injection. (Bottom) SNPs
intrinsically labeled with 89Zr at 14 h and 24 h post injection. The intrinsically labeled SNPs
progressively move through the lymphatic system. White markers identify lymph nodes.
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Figure 2.10. In vivo PET-CT (left) and PET-only (right) lymph node imaging after injection in
the right rear paw of athymic nude mice at 48 h post-injection. (A) SNPs intrinsically labeled
with 89Zr. (B) Free 89Zr. Images at earlier time points demonstrated the same trend, where the
free 89Zr did not accumulate in lymph nodes, while the intrinsically labeled SNPs progressively
moved through the lymphatic system.
In summary, this work has established the ability of amorphous SNPs to intrinsically bind
a wide variety of radionuclides without the need for additional chelators. The in vivo stability
demonstrated herein validates the use of these nanoparticles in well established and future
biomedical applications [65, 66], and it is foreseeable that other particles could be coated with
silica for facile and highly efficient radiolabeling [67]. Moreover, our findings warrant careful
evaluation of radiolabeling procedures for similar nanoparticles that utilize molecular chelators
in order to prevent misinterpretation of labeling mechanisms and efficiency.
We now have a general protocol for radiolabeling SNP that does not require attachment of
specific chelators (Figure 2.11). However, the lack of stability for the softer 64Cu led us to see if
modifications of the SNP can lead to stable radiolabeling of 64Cu.
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Figure 2.11. Scheme for intrinsic radiolabeling of SNPs. The nanoparticles are incubated with
free radionuclide at 70 °C for 15 to 60 min depending on the specific radionuclide, then purified
by centrifugation and resuspension.
2.7 Modification of SNPs for increased stability of soft metals
In section 2.6, we demonstrated that SNP stably bind a variety of clinically relevant
radiometal ions to enable whole-body PET imaging of the nanoparticles in vivo (and
subsequently shown by others), with the stability of the radiometal ion binding to the SNP
dependent on the oxophilicity of the metal [1, 68]. While the hard oxophilic 89Zr and 68Ga
radiometal ions remained stably bound to SNP throughout a variety of challenges and in vivo
experiments, the PET tracer 64Cu dissociated in less than 4 hours. We hypothesized that poor
stability was likely due to the relative softness of 64Cu, as discussed in section 2.5. In this section
we discuss a means to expand the palette of radionuclides used to label SNP to include soft
metals by introducing thiol functionality onto the surface (Figure 2.12), since thiols are known
to stably bind softer metal ions [69, 70].
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Figure 2.12. Reaction schematic of sulfur-SNP. While native SNP (blue) stably bind hard
oxophilic radiometals such as zirconium-89 and gallium-68, thiol-functionalization (yellow) of
SNP allows stable retention of soft, sulfur-avid copper-64. i. NH4OH, ethanol, H2O 45 min, RT;
ii. 0.5 – 33 % (v/v) MPTMS in ethanol, 90 min, 70 °C; iii. 64Cu (200 µCi), pH 7.3, 2 h, 70 °C.
First, SNP with a mean diameter of 130 nm were prepared via the Stöber method [71].
The surface of the SNP were functionalized with thiols by reacting the SNP (7.5 nM) with 3mercaptopropyltrimethoxysilane (MPTMS) at various concentrations (% v/v) in ethanol.
Following washing steps with ethanol, Ellman’s reagent was used to quantify the thiol-to-SNP
ratio of the sulfur-functionalized SNP (Figure 2.13). Dynamic light scattering (DLS) showed
that thiol functionalization had no detectable effect on the hydrodynamic radius, zeta potential,
or polydispersity index (<0.05) (Table 2.2). For subsequent radiolabeling experiments, sulfurSNP with 1.8 × 105 thiols per nanoparticle were used, a value between previous reported data of
2.7 × 104 and 5.6 × 106 thiol per SNP [72, 73].
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Figure 2.13. Quantification of thiol groups per nanoparticle. Ellman’s reagent standard curve
(left) and determination of thiols per nanoparticle (right) with 95% confidence intervals and
standard deviation shown.
Table 2.2. DLS and Zeta potential data for nanoparticle constructs (n=4)
Nanoparticle construct
Mean of average DLS
Mean of average zeta
diameter (nm)
potential (mV)
Native SNP
142.7 ± 0.7
-36.9 ± 2.0
0.5% v/v sulfur-SNP
140.7 ± 0.9
-37.9 ± 1.2
2.0% v/v sulfur-SNP
140.1 ± 2.9
-39.8 ± 0.9
10% v/v sulfur-SNP
143.5 ± 2.3
-40.1 ± 1.1
33% v/v sulfur-SNP
139.3 ± 1.2
-37.4 ± 2.4
We then evaluated the binding affinity of the sulfur-SNP for 64Cu relative to that of the
native SNP. First 64Cu (200 µCi, 7.4 MBq) was added to sulfur-SNP dispersions (100 µL; 10
nM) in 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 7.3) at 4 °C, 37 °C, and
70 °C, or to the control SNP radiolabeled at 70 °C, and a reaction time of 2 hours. 5µl EDTA (50
mM, pH 7.1) was then added to scavenge weakly bound 64Cu. After 15 minutes, the
nanoparticles were pelleted via centrifugation (10,000 rpm, 5 min, 25°C) and the supernatant
containing unbound 64Cu was removed. Relative to the native SNP, sulfur-SNP demonstrated a
significantly higher radiochemical yield of the soft radiometal 64Cu (sulfur-SNP, 94.5 ±1.9 %,
SNP, 74.4 ±1.9 %). Radiolabeling of the sulfur-SNP with 64Cu is temperature-dependent, similar
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to our previous report for labeling of native SNP with hard radiometal ions (Figure 2.14) [1].
While radiolabeling at 37 °C results in radiochemical yields >85 %, the 64Cu detaches from the
sulfur-SNP in serum, demonstrating that elevated temperatures (70 °C) are necessary for stable
radiolabeling.
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Figure 2.14. Radiolabeling of native SNP at 70 °C versus sulfur-SNP at various temperatures.
Only 64Cu-sulfur-SNP heated at 70 °C showed the highest stability to EDTA and serum
challenge. Mean with standard deviation shown.
While the radiochemical yield was greater for sulfur-SNP compared to native SNP, the
stability of each nanoparticle construct to an EDTA challenge and in serum are essential for in
vivo use. Therefore, we assessed the binding stability of 64Cu to sulfur-SNP relative to native
SNP by EDTA challenge and we evaluated serum stability. As seen in Figure 2.15A-B, the
sulfur-SNP are significantly more stable compared to native SNPs. Out to 24 hours for both the
EDTA challenge (90.9 ± 5.8 % versus 34.9 ± 5.8 %) and the serum stability tests (93.0 ± 3.6 %
versus 14.8 ± 3.4 %), the difference in stability is clearly seen by instant thin-layer
chromatography was performed (Figure 2.15). After 10 half lives of 64Cu, nanoparticle
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characterization was performed with TEM, showing that our 64Cu radiolabeling protocol did not
affect the nanoparticle morphology, integrity, or diameter (Figure 2.16).
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Figure 2.15. Sulfur-SNP show significantly increased binding of 64Cu compared to native SNP.
64
Cu shows significantly more stable binding to sulfur-SNP compared to SNP in an (A) EDTA
challenge over 24 hours, and (B) in a serum stability study, a prerequisite for in vivo use. (Data
presented as mean with standard deviation shown; *p<0.05, unpaired Student’s t-test). iTLchromatograph shows (C) sulfur-SNP stably bind 64Cu whereas (D) 64Cu dissociates from native
SNP when challenged in serum, respectively.
Importantly, the addition of thiol groups to the SNP surface does not affect radiolabeling
of 89Zr in the silica matrix, as shown by a serum stability of >95 % over 120 hours (Figure
2.17A). Therefore, thiol-functionalized SNP can still be radiolabeled with 89Zr and used in vivo,
allowing targeting and surface-coating opportunities. This finding is important for future studies
that advance ideas in this study.
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Figure 2.16. TEM of sulfur-SNP prior to radiolabeling (left) and after radioactive decay (right)
show no appreciable change in diameter, as previously reported. Scale bars are 20nm.
To prolong circulation times, nanoparticles are commonly coated with polyethylene
glycol (PEG). We therefore also determined whether conjugation of PEG would affect 64Cu
radiolabeling and stability. PEG (2 kDa; 1 % (w/v)) was conjugated to the sulfur-SNP in 10 mM
MES buffer (pH 7.3) via straightforward maleimide-chemistry post-radiolabeling to determine
the effect of PEGylation on 64Cu binding stability. It was found that PEGylated sulfur-SNP
demonstrated comparable 64Cu-binding to sulfur-SNP (Figure 2.17B). The PEG-sulfur-SNP
showed comparable 64Cu stability to the sulfur-SNP without PEG, which further enables in vivo
use.
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Figure 2.17. (A) Thiol functionalization of SNP does not preclude stable binding of 89Zr. (B)
PEGylation of 64Cu-sulfur-SNP after radiolabeling does not adversely affect serum stability.
Since the radiochemical results supported the stability of 64Cu-sulfur-SNP, we tested both
64

Cu-labeled native SNP and sulfur-SNP in vivo for lymph node (LN) imaging capabilities.

There is no significant difference in the diameter and zeta potential between the sulfur-SNP and
SNP (Table 2.2), so transport through the lymph node system is expected to be similar. If 64Cu
dissociates from the nanoparticle, it naturally accumulates in the liver, spleen, and intestines at
later time points. We injected the footpad of one group of nude athymic mice with 64Cu-SNP and
one group with 64Cu-sulfur-SNP. After 14 hours, PET/CT was conducted on both groups (Figure
2.18A-B) and organs were collected to determine the biodistribution of 64Cu in both groups
(Figure 2.18C). Whereas PET signal was only appreciable observed in the LNs after 64Cusulfur-SNP, relatively high signal in the liver, spleen, and intestines was found for 64Cu-SNP
indicating dissociation and redistribution of 64Cu. Notably, the 64Cu-sulfur-SNP showed similar
in vivo stability as our previously optimized 89Zr-labeled native SNP (Figure 2.19).
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Figure 2.18. PET/CT and biodistribution of 64Cu-sulfur-SNP and 64Cu-SNP. (A) 64Cu-sulfurSNP injected into the footpad allow lymph node imaging with little systemic uptake at 14 hours
post injection, whereas (B) 64Cu-SNP show appreciable liver, spleen, and intestinal uptake. (C)
Quantitative ex vivo biodistribution values show significant differences for all organs except
lymph node (p<0.05, unpaired t-test). Mean with standard deviation shown.
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Figure 2.19. 89Zr labeled native SNP PET/CT imaging (maximum intensity projection) at 14
hours post-injection. These data show demonstrate that radiolabeling of sulfur-SNP to the soft
64
Cu provides similar in vivo stability as native SNPs bound to the hard 89Zr.
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In summary, the addition of thiol-functionality - a soft electron donor - to SNP results in
a significant increase in binding of 64Cu. This method is likely applicable to other soft
radiometals for facile radiolabeling of SNP as well. This approach enables the possibility of
near-term clinical benefit, since silica-based nanoparticles such as the smaller silica-based C-dots
are already in clinical trials [74]. This strategy with cold Cu(II) was recently reported with bulk
mesoporous silica for purification purposes, showing an increase in copper retention through the
addition of thiol groups [75]. Sulfur-SNP radiolabeled with 72As were reported, although a
comparison to native SNP was not [72].
Since the stability of the sulfur-SNP is not affected by coating with PEG after
radiolabeling, other ligands such as targeting peptides or antibodies may be attached after
radiolabeling and this should also not affect 64Cu stability. The effect of sulfurs when
radiolabeling sulfur-SNP with chelators conjugated should be taken into account, since the
sulfur-functionalized nanoparticles itself can stably bind various radiometals. With this work we
build forth on our previous work on the labeling of native SNP with hard oxophilic radiometals,
by demonstrating a straightforward radiolabeling procedure for softer radiometals such as 64Cu
opening new avenues for stable radiolabeling of nanoparticles with a variety of hard and soft
radiometals.
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2.8 Methods
Reagents
All reagents were obtained from Sigma-Aldrich and used as received unless otherwise
indicated.
SNP Synthesis
SNPs were synthesized according to a modified Stöber method. Briefly, 3.75 mL of
ultrapure H2O was added to 25 mL of ethanol followed by addition of 1.25 mL tetraethyl
orthosilicate. The reaction was initiated by the addition of 0.625 mL of 28% ammonium
hydroxide at RT for 30-45 minutes and washed three times in ethanol after the nanoparticles.
Thiol functionalization of SNP
0.5, 2, 10, or 33 % (v/v) 3-mercaptopropyltrimethoxysilane (MPTMS) in ethanol was
added to 100 µL ethanol containing native SNP (7.5 nM) at 70 °C for 90 minutes to introduce
thiol functionality on the nanoparticle surface. The sulfur-SNP were washed three times with
ethanol and stored in ethanol until further use.
Thiol quantification
Ellman’s reagent was used for thiol determination as previously described [76]. Briefly, a
standard thiol curve (168– 5384 µM) was prepared with known concentrations of thiol
(MPTMS). Ellman’s reagent (1 mM) in 0.1 M phosphate buffer (pH 8.2) was prepared and
immediately used. Absorbance at 412 nm was measured to quantify thiol concentration per
sample.
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PEGylation of sulfur-SNP
Thiolated SNPs were reacted with 1 % (w/v) maleimide-terminated poly(ethylene glycol;
2kDa) in 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH = 7.1) for 1 h. The
nanoparticles were washed several times with MES buffer.
SNP Characterization
The hydrodynamic diameter of the SNPs pre- and post-labeling was determined by
dynamic light scattering (DLS) (Nano-ZS, Malvern, Westborough, MA). The same instrument
was used in nanoparticle surface charge measurement (ζ potential) with 100 mM PBS, pH 7.3.
The SNP concentration was measured with an NS500 instrument (NanoSight, Duxbury, MA).
68

Ga-SNP Radiolabeling of SNPs
68

Ga (t1/2 = 68 m) was eluted from a 68Ge-68Ga generator (ANSTO, Australia) as

previously described (65), with 8-9mCi activity per elution. After elution in 500 µL of 0.5 M
potassium hydroxide, the 68Ga hydroxide solution was neutralized with concentrated
hydrochloric acid, immediately added to SNP solutions (10 nM, in 100µL of 10mM buffer) and
incubated at the temperature and pH of interest on a thermomixer at 500 rpm. MES buffer was
used for pH = 5.5 and 7.3 solutions, while HEPES buffer was used for pH = 8.8 solutions. 1µL
samples were taken for radioactive instant thin layer chromatography (rITLC) at various time
points over the course of 1 hour using silica-gel impregnated ITLC paper (Varian), and analyzed
with a Bioscan AR-2000 radio-TLC plate reader. For 68Ga, 0.1 M citric acid was used as the
elution solvent, while 50 mM EDTA (pH = 5) was used for all other nuclides. The solution was
centrifuged at 10000 rpm for 5 minutes, the supernatant removed and counted, and the product
re-dispersed in 10 mM MES in order to achieve purification.
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89

Zr-SNP Radiolabeling
89

Zr (t1/2=78.4 h) was produced at Memorial Sloan Kettering Cancer Center on a

TR19/9 cyclotron (Ebco Industries Inc.) via the 89Y(p,n)89Zr reaction and purified to yield 89Zroxalate as previously described (66). 89Zr-oxalate was neutralized with 1.0 M sodium carbonate
and added to SNP solutions as described for the 68Ga-SNP radiolabeling.
90

Y-SNP Radiolabeling
90

Y (t1/2 = 64 h) was obtained as yttrium (Y-90) chloride in 0.05 N HCl at an activity

concentration of 25 mCi/mL (Nordion). 90Y was added to SNP solutions as described for 68GaSNP radiolabeling.
111

In-SNP Radiolabeling
111

In (t1/2 = 2.8 d) was obtained as Indium (In-111) chloride in 0.05 N HCl at an activity

concentration of 25 mCi/mL (Nordion). 111In was added to SNP solutions as described for 68GaSNP radiolabeling.
177

Lu-SNP Radiolabeling
177

Lu (t1/2 = 6.71 d) was obtained as Lutetium (Lu-177) chloride in 0.05 N HCl at an

activity concentration effective specific activity of 29.27 Ci/mg (PerkinElmer). 177Lu was added
to SNP solutions as described for 68Ga-SNP radiolabeling. Because 177Lu in the buffer control
showed activity at the origin for ITLC analysis (i.e., some radioactivity did not travel with the
solvent front), the amount of 177Lu bound to the SNPs was determined both by centrifugal
nanoparticle pelleting and 100kD spin filtration cutoff filters.
64

Cu radiolabeling of SNP and sulfur-SNP
64

Cu (t1/2 = 12.7 h) was neutralized and added to SNP solutions (10 nM, in 100 µL of

10mM MES buffer, pH 7.3) and a control solution of MES buffer only (10mM, pH7.3) and the
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reaction proceeded at the indicated temperatures on a thermomixer at 500 rpm. To purify 64Culabeled (sulfur)-SNP from unbound 64Cu the dispersion was centrifuged at 10,000 rpm for 3
minutes, the supernatant removed and counted, and the radiolabeled (sulfur)-SNP redispersed in
100 µL 10 mM MES to yield a SNP concentration of 10nM.
Radiochemical Yield of SNP and sulfur-SNP
The radiochemical yield was determined in two ways: 1) EDTA scavenging followed by
pelleting of the nanoparticle solution. The % SNP bound radioactivity was determined as
radioactivity in pellet/all supernatant radioactivity; 2) instant thin-layer chromatography (iTLC).
For iTLC, 1µL sample was spotted on silica-gel impregnated ITLC paper (Varian), allowed to
dry, eluted with 50mM EDTA, and analyzed on a Bioscan AR-2000 radio-TLC plate reader.
Regions of interest were drawn over the origin and the mobile phase for % SNP-bound
radioactivity determination.
Serum Stability
Serum stability experiments were performed at 37 °C in 1:1 fetal bovine serum (FBS,
Gemini Bio-products) : 10 mM MES (pH 7.3) in a total volume 100 µL. Both ITLC and size
exclusion filtration analysis (100kD filters, Miltenyi) was completed at reported time points and
analyzed as described for the radiochemical yield.
Animal Models
All animal experiments were done in accordance with protocols approved by the
Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center
(Protocol number 08-07-014) and followed National Institutes of Health guidelines for animal
welfare.
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89

Zr- and 68Ga-SNP PET imaging in nude mice
Male Nude athymic mice (8-10 weeks old, n = 3) were injected with 250-350 µCi (9.25-

12.95 MBq) radiolabeled SNPs (10 nmol SNP) in 100 µL MES solution via the lateral tail vein.
At predetermined time points (1h, 4h, and 24h) animals were anesthetized with isoflurane
(Baxter Healthcare, Deerfield, IL) and oxygen gas mixture (2% for induction, 1% for
maintenance) and scans were then performed using an Inveon PET/CT scanner (Siemens
Healthcare Global). Whole body PET static scans were performed recording a minimum of 50
million coincident events, with duration of 10-20 min. The energy and coincidence timing
windows were 350−750 keV and 6 ns, respectively. The image data were normalized to correct
for non-uniformity of response of the PET, dead-time count losses, positron branching ratio, and
physical decay to the time of injection, but no attenuation, scatter, or partial-volume averaging
correction was applied. Images were analyzed using ASIPro VMTM software (Concorde
Microsystems).
PET/CT Lymph Node Studies with 89Zr-SNPs
For in vivo SNP-radiometal lymph node imaging studies, 3 mice were injected in the
footpad with 89Zr in saline and 3 mice were injected with 100-200 µCi of 89Zr-SNP (10 mM
MES, 20µL, 3.7-7.4 MBq) for a total of 6 mice. All mice were induced with 2.5 % isoflurane and
maintained on 2-2.5 % isoflurane in preparation for the scans. Whole body scans were performed
using Inveon Multimodality (MM) CT scanner (Siemens) and Inveon dedicated PET scanner for
a total of 15-45 min.
64

Cu-SNP and 64Cu-sulfur-SNP lymph node PET/CT imaging and Biodistribution
Male nude athymic mice (8−10 weeks old, n = 3) were injected with 100-200 µCi (3.7 −

7.4 MBq) of 64Cu-SNP or 64Cu-sulfur-SNP (10 nM SNP) in 10 µL 10 mM MES buffer (pH 7.3)
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subcutaneously into the footpad. After 14 hours animals were anesthetized with isoflurane
(Baxter Healthcare, Deerfield, IL) and oxygen gas mixture (2 % for induction, 1 % for
maintenance) and scans were performed using an Inveon PET/CT scanner (Siemens). Whole
body PET static scans were performed, recording a minimum of 10 million coincident events,
with scan durations of 20 min. The energy and coincidence timing windows were 350−750 keV
and 6 ns, respectively. The image data were normalized to correct for non-uniformity of response
of the PET, dead-time count losses, positron branching ratio, and physical decay to the time of
injection, but no attenuation, scatter, or partial-volume averaging correction was applied. Images
were analyzed using Inveon Acquisition Software (Siemens). For biodistribution studies, mice
were euthanized by CO2 (g) asphyxiation after PET/CT imaging. After asphyxiation, organs were
removed, weighed, and counted in a γ counter calibrated for 64Cu. Counts were background- and
decay-corrected to the injection time, converted to µCi using calibrated standards, and the
percent injected dose per gram (% ID/g) determined by normalization to the total activity
injected.
CT
Whole body standard low magnification CT scans were performed with the X-ray tube
setup at a voltage of 80 kV and current of 500 µA. The CT scan was acquired using 120
rotational steps for a total of 220 degrees yielding an estimated scan time of 120 s with an
exposure time of 145 ms per frame.
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CHAPTER 3
Radiolabeling multimodal nanoparticle systems
This chapter contains results adapted from publications submitted to Advanced Materials [1], in
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology [2], and in collaboration
with Scott Lowe’s research group (MSKCC) (Section 3.9-3.11). Accordingly, the figures and
text in those sections are the result of collaborative data collection and writing with the coauthors.
3.1 Introduction
While the radiolabeled NPs in chapter 2 allow PET, SPECT, and planar imaging,
multimodal NPs offer several advantages over single modal NPs. This is because different
imaging modalities offer distinct advantages and drawbacks, and combinations of modalities
within one NP entity may offer the best of each modality. An imaging modality’s properties are
based on the physics of the modality (such as positron emission), instrumentation, and the design
of the contrast agent. PET and SPECT offer whole-body, quantitative or semi-quantitative
imaging with exquisite sensitivity, but have relatively poor resolution, and ionizing radiation
exposure [3, 4]. Magnetic resonance imaging (MRI) has superior resolution but sensitivity orders
of magnitude lower than nuclear modalities [5]. Optical modalities such as fluorescence,
Cerenkov luminescence, and Raman imaging are both sensitive and high-resolution, but can only
be imaged a few cm deep into tissue [6].
In this section, we develop multimodal NPs that combine radionuclides with Raman- and
MR- active contrast agents. Of paramount importance when attaching the radionuclide to the NP
is preserving the contrast properties of the NP. First, we discuss the properties of the main
radiotracer used in this section, 68Ga. The radiochemical methodology for chelator-free
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radiolabeling of SERRS-active gold-silica NP with 68Ga is then shown. This is followed by in
vivo and ex vivo evaluation of the SERRS-active gold-silica NP using PET, Cerenkov
luminescence imaging (CLI), and Raman imaging. Following this, radiolabeled iron oxide NP
(IONP) systems are reviewed, and a chelator-free radiolabeling method of the clinically
approved IONP Feraheme (FH) is described. Feraheme labeled with either 68Ga or 89Zr is first
discussed in the context of lymph node imaging. This is followed by tumor imaging evaluation in
primary and metastatic colorectal cancer with comparison to the glucose analog 2-deoxy-2[fluorine-18]fluoro-D-glucose ([18F]-FDG).
3.2 Gallium-68 radiolabeling considerations
Gallium-68 is a PET tracer with a half-life of 68.3 minutes, and is commonly produced
on a germanium-68/gallium-68 generator [7]. 68Ge’s half-life (271 d) and decay via electron
capture (emitting negligible ionizing radiation) as seen in Figure 3.1 makes it an attractive
isotope for a generator system. Gallium-68 is typically eluted from the 68Ge generator on a TiO2
column using 0.3N HCl. After elution from the column, 68Ga can either be used immediately (i.e.
direct elution) in 0.3N HCl, or the eluent may be collected on a filter and washed to remove
unwanted metals such as 68Ge, Zn, or Cu (i.e. purified elution) [8]. Purified elution is typically
preferred, as unwanted metals that may affect chelator chemistry and any potential breakthrough
of 68Ge are removed. For purified elution, the filter containing 68Ga is washed followed by
elution of 68Ga(OH)3 using a strong base such as 0.5M KOH or 0.5M NaOH. Once the 68Ga is
collected from the generator, the pH is adjusted and added to the system to be labeled.
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Figure 3.1 Germanium-68 decay scheme to gallium-68. The 271 day half-life of 68Ge makes it
attractive for generator use, analogous to the 99Mo-99mTc generator. From
http://www.nndc.bnl.gov/.
68

Ga decays 89 % through positron emission with a βmax = 1.92 MeV; by comparison, 18F

has a βmax = 0.63 MeV [9]. 68Ga has lower resolution than 18F due to its’ higher β energy, as
mentioned in chapter 1. The high positron branching ratio (89 %) is attractive for in vivo
imaging (Figure 3.2) [10]; by comparison, 89Zr has a positron branching ratio of 23% [11]. 68Ga
has an oxidation state of +3, and is typically chelated with small molecule chelators containing
oxygen and nitrogen, as it is a hard, small, oxophilic cation. In macrochemical systems, at pH >
3, insoluble Ga(OH)3 precipitates out of aqueous solutions, but this species redissolves to soluble
[Ga(OH)4− ] at pH > 7.4. However, at concentrations below 2.5 x10−6 M, precipitation of
gallium-oxide colloids (which are undesirable) is absent; therefore, concentrations are kept much
below this (<10-9 M) for the following work.
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Figure 3.2 Gallium-68 decay scheme to zinc-68. Gallium-68 decays to stable zinc-68 in 68.3
minutes, allowing imaging out to four hours post-injection. From http://www.nndc.bnl.gov/.
3.3 PET/SERRS nanoparticle considerations
High-precision intraoperative imaging is necessary to delineate the true extent of tumor
borders and identify the presence of multiple cancer foci or micrometastases. Failure to remove
these malignant cells is a major reason for local recurrences and metastatic spread [12]. It was
recently demonstrated that surface-enhanced resonance Raman scattering (SERRS) nanoparticles
are capable of providing robust optical contrast to these cancerous sites [13][3]. However, the
high resolution imaging necessary to observe such small deposits limits the amount of tissue that
can be imaged in an acceptable time frame for surgical procedures. A probe that offers wholebody non-invasive imaging along with the superior sensitivity and resolution offered by SERRS
would allow a single nanoparticle construct to be used for both pre-operative mapping and
intraoperative imaging. We hypothesized that radiolabeling SERRS nanoparticles would enable
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pre-operative identification of regions of interest (ROI) that could be rapidly corroborated with a
handheld Raman detector in order to guide the high-precision SERRS imaging. Beyond whole
body imaging, PET offers the potential for non- invasive pharmacokinetic and biodistribution
studies, which are essential for the development of clinically translatable imaging agents and
therapeutics.
Although the radiolabeling of SERRS nanoprobes has been previously reported with 64Cu
for biodistribution studies, in vivo imaging of PET-active SERRS nanoparticles (PET-SERRS
NPs) for clinically relevant applications has not been demonstrated. Moreover, the reported 64Cu
labeling method was limited by the requirement of a molecular chelator [14, 15]. While this is a
conventional radiolabeling method, chelator detachment and transchelation are serious concerns
that can result in PET images that do not correspond to the true particle biodistribution. To avoid
these potential issues, we pursued a chelator-free strategy employing the silica encapsulant of the
SERRS nanoparticles substrate for radionuclide binding. The justification for this approach was
our recent demonstration that “pure” silica nanoparticles (i.e., without a gold core and free of
molecular chelators) bind 89Zr, 68Ga, 90Y, 111I, 177Lu, and 64Cu based upon the affinity of the
radionuclides for the oxygen-rich silica matrix shown in chapter 2. This method was
subsequently demonstrated with mesoporous silica nanoparticles by others [16].
We identified the short-lived PET tracer 68Ga (t1/2 = 68 min) as the ideal candidate
radiolabeling SERRS nanoprobes due to its oxophilicity, availability from commercial
generators, and minimal radiation dose to healthy tissue due to the short half-life. The
consideration of radiation dose to healthy tissue is particularly important for nanoparticle
imaging agents because nearly the entire injected dose ends up in the reticuloendothelial system
(RES). Because of the short circulation time of these nanoprobes, 68Ga remains active for
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imaging at relevant pharmacokinetic time points. The 68-minute half-life ensures that 68Ga is
sufficiently decayed over the course of eight hours to allow SERRS imaging without the fear of
radioactive contamination.
Attaching radionuclides to SERRS NPs must not markedly decrease the SERRS signal.
As SERRS dyes are close to the surface of the gold core, alteration of the NP surface with a
metal ion is a concern. However, at radiotracer levels, there are typically <2 radiometal ions per
nanoparticle, ao can be excluded from adversely effecting the SERRS signal. More importantly
are the conditions of radiolabeling. High temperatures (>100 °C) or harsh agents that may etch
the silica coating or denature the Raman reporter molecule should be avoided. With these
considerations in mind, we aimed to radiolabel a PET/SERRS NP with the PET tracer 68Ga.
3.4 Chelator-free radiolabeling of PET-SERRS gold-silica nanoparticles [1]
We first attempted to radiolabel SERRS nanoparticles with 68Ga by directly applying the
protocol used for pure silica nanoparticles. This began with elution of 68Ga from the 68Ge/68Ga
generator using 0.5 M potassium hydroxide (KOH), followed by neutralization with hydrochloric
acid (HCl) or glacial acetic acid [8]. In contrast to our previous work with pure silica
nanoparticles, the silica encapsulant of SERRS nanoparticles became very porous and even
disintegrated entirely for some nanoparticles (Figure 3.3). Consequently, the radiolabeling was
unsuccessful.
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Figure 3.3. Degradation of silica shells upon non-optimized 68Ga radiolabeling. TEM
reveals that the silica shells become extremely porous and unstable after the 68Ga
radiolabeling procedure that had been optimized for silica nanoparticles. Scale bar is 100
nm.
The decreased stability of a silica shell compared to a pure silica nanoparticle is likely a
reflection of the different conditions under which they are synthesized. In order to selectively
generate silica shells around the gold nanoparticles, the homogeneous nucleation of silica must
be sufficiently disfavored such that heterogeneous nucleation occurs (i.e., shell formation) but
free silica nanoparticles do not grow. This can be achieved by decreasing the rate of hydrolysis
and condensation of silica precursors, for example by decreasing the water concentration during
synthesis. This leads to more broken bonds in the early stages of silica oligomerization and
densification because the ethoxy groups of tetraethyl orthosilicate (TEOS) are not completely
hydrolyzed. Accordingly, homogenous nucleation is slow, but the gold nanoparticles provide
surfaces to catalyze the condensation and aggregation reactions at the beginning of silica
formation, thus enabling preferential nucleation (Figure 3.4). However, the incomplete
hydrolysis of silica precursors leads to broken bonds within the amorphous silica structure and

	
  

59	
  

	
  
greater susceptibility to degradation. Strategies must be developed, therefore, to make the
radiolabeling procedure less harsh.

Figure 3.4. Influence of water content on silica nucleation and growth. (A) Synthesis of silica in
the absence of gold nanoparticles. Silica was synthesized by a Stöber method in ethanol using
(from left to right) 1.5 M, 3.0 M, and 4.5 M water for 1 h at room temperature. (B) Synthesis of
silica in the presence of gold nanoparticles. Even though the water content is sufficiently high to
homogeneously nucleate silica (from left to right, 3.25 M, 5.0 M, 7.5 M), the catalytic effect of
the gold nanoparticle surface with respect to the condensation and aggregation of silica nuclei
favors shell formation over silica nanoparticle growth. The syntheses in (B) only proceed for 25
min, compared to 1 h in (A). As the water content is increased beyond 5.0 M, free silica
nanoparticles grow within 25 min. Alternatively, if the 3.25 M or 5.0 M syntheses were allowed
to progress for 1 h a substantial amount of free silica nanoparticles would form. Scale bars are
100 nm in (A) and 50 nm in (B).
Given that the rate of silica dissolution is catalyzed by the presence of potassium ions, we
hypothesized that a radiolabeling procedure free of potassium would be less damaging to the
silica shells. Rather than eluting the 68Ga generator with potassium hydroxide (KOH), we
directly eluted the generator with 0.3 N HCl and neutralized the eluent with ammonium

	
  

60	
  

	
  
hydroxide (NH4OH) (Figure 3.5). The NH4+ cations are softer and bulkier than K+, and therefore
do not intercalate into the silica matrix as well. We then incubated the SERRS nanoparticles (10
nM) with the 68Ga solution (500 µCi, 18.5 MBq) for 5 minutes at 25°C and observed greater than
95 % of the radioactivity associated with the nanoparticles. The silica shells were observed to be
intact after radiolabeling, and the nanoparticles remained SERRS active (Figure 3.6) and serum
stable.

Figure 3.5. Chelator-free radiolabeling of SERRS nanoparticles. The new protocol for chelatorfree radiolabeling successfully labels silica shells. By directly eluting the 68Ge/68Ga generator
with HCl and neutralizing the solution with NH4OH the problematic K+ cations are replaced by
softer, bulkier NH4OH cations that do not catalyze silica dissolution.
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Figure 3.6. Characterization of optimized PET-SERRS nanoprobes. (A) TEM of PET-SERRS
nanoparticles after radiolabeling with the optimized 68Ga protocol. (B) SERRS spectrum of PETSERRS nanoparticles. (C) Instant thin layer chromatogram of PET-SERRS nanoparticles 5
minutes after addition of 68Ga at room temperature.
3.5 In vivo evaluation of PET/SERRS NPs
We began our in vivo evaluation of the PET-SERRS NPs by attempting to image lymph
nodes near the periphery of an orthotopic 4T1 breast cancer tumor. Lymph node imaging is
important for intraoperatively identifying the most likely sites of cancer metastases. We
previously showed that radiolabeled silica nanoparticles can image lymph nodes in vivo [17], but
the ability of a silica shell to retain radionuclides in vivo has not yet been demonstrated. The
PET-SERRS NPs were injected subcutaneously at the tumor periphery and into the tumor itself.
PET imaging 4 h post-injection revealed that much of the signal remained concentrated near the
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tumor, suggesting that most of the PET-SERRS nanoparticles had not migrated from the
injection sites. Interestingly, the cervical LN could be visualized via PET imaging with strong
contrast at the 4 h time point (Figure 3.7A). Although the axillary LN is the sentinel node for
murine breast tissue, the size and location of the implanted tumor completely obstruct the
axillary LN from imaging. The cervical LN drains multiple regions, including the upper
extremities, so the accumulation of PET-SERRS nanoparticles in the cervical LN occurs because
one or more peripheral injection sites falls in the region it drains [18, 19]. Although direct
visualization of the breast’s sentinel LN was obstructed, the cervical LN imaging illustrates that
LN tracking can be achieved in vivo with PET-SERRS NPs.
Intraoperative imaging of the cervical LN confirmed the presence of SERRS
nanoparticles. The characteristic spectrum of the PET-SERRS nanoparticles is detectable with a
handheld Raman detector (Figure 3.7B-C) [20], and enables near real-time analysis of regions of
interest for the presence of nanoparticles. Using the handheld detector, we identified the presence
of the PET-SERRS NP fingerprint spectrum in the regions that exhibited PET contrast. A raster
scan by a fixed Raman imaging system (Renishaw inVia) was subsequently completed to
generate a map of relative SERRS intensity. The SERRS map demonstrated excellent colocalization with the pre-operative PET imaging signal, confirming that the PET-SERRS
nanoparticles remained intact after subcutaneous injection and migration through lymphatic
channels. We used the handheld Raman detector to guide surgical resection of the cervical LN,
first by locating it in vivo, and then by confirming that all SERRS-positive tissue had been
removed. Post-operative SERRS imaging was performed with the fixed Raman system to
corroborate the handheld results, and indeed showed that the lymph node had been completely
resected.
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Figure 3.7 Lymph node tracking with PET-SERRS nanoparticles. (A) PET-CT image 4 h after
the 68Ga-labeled PET-SERRS nanoparticles were injected around the periphery of an orthotopic
4T1 breast tumor. (B) SERRS spectrum of PET-SERRS nanoparticles can be tracked in vivo
with a handheld Raman detector. The cervical LN exhibits the characteristic peaks of the PETSERRS nanoparticle (top), which are not present in outside of the LN (bottom). Accordingly, a
quick handheld scan can be performed to guide location and resection of the LN. (C) After
resection, the handheld detector is used to confirm that the SERRS spectrum is only detected in
the excised tissue (top), such that clean margins exist in the resection bed (bottom).
Because the PET-SERRS nanoparticles naturally accumulate in the RES, we
hypothesized that they would be well suited for imaging liver cancer. In particular, the rapid
uptake of nanoparticles in healthy RES tissue and comparatively much lower uptake of
nanoparticles in cancerous tissue has proven sufficient to delineate tumors in vivo [21, 22].
Because the cancerous regions should contain fewer PET-SERRS NPs than the surrounding liver
tissue, the presence of cancer is expected to manifest in filling defects (i.e., regions of little to no
contrast surrounded by regions of high contrast) during both PET and SERRS imaging. This was
recently validated with non-radiolabeled SERRS nanoparticles [23].
We tested these hypotheses in mice that had been genetically engineered to develop
hepatocellular carcinomas (HCC). PET-SERRS NPs (150 µL, 10 nM, labeled with 500 µCi, 18.5
MBq 68Ga) were intravenously injected via tail vein and PET scans were performed 3 h postinjection (Figure 3.8A). The PET contrast exhibited several distinct filling defects throughout
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the liver, as hypothesized, suggesting the presence of tumors. We surgically exposed the livers of
the cancer-bearing mice and performed high-resolution SERRS scans in a simulated
intraoperative setting. Even without SERRS contrast, some large tumors with sizes and locations
corresponding to filling defects of the PET scan were clearly visible. The SERRS map
demonstrated pronounced filling defects where tumors were present, and correlated strongly with
the pre-operative PET signal (Figure 3.8C-E). The co-registration of PET and SERRS signals in
the liver indicate that the PET-SERRS nanoparticles remain intact after I.V. injection and
circulation. To ensure that the PET signal corresponded with the healthy tissue throughout the
volume of the liver, PET/MR was also conducted. The filling defects observed in the PET signal
matched the tumor MR signal, confirming that the PET-SERRS NPs delineated healthy versus
cancerous tissue throughout the liver (Figure 3.9 A-C).

Figure 3.8. Pre-operative staging and intraoperative imaging of liver cancer using PET-SERRS
nanoparticles. (A) PET contrast provided by PET-SERRS nanoparticles reveals clear filling
defects. (B) Intraoperative photograph of liver from the mouse imaged in (A). Solid tumors are
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visible by naked eye due to their large size and light discolorations. The location of the tumors
matches the filling defects from the PET scan. (C) Maximum intensity projection (MIP) of the
PET signal correlates with the healthy regions of the liver, revealing the presence of cancer
where filling defects occur. (D) SERRS image of the tumor-bearing liver reveals high-resolution
map of the healthy liver, providing intraoperative contrast. The correlation between PET signal
and SERRS signal indicates that the nanoparticles remain intact and active in vivo. (E) Overlay
of photograph and SERRS map shows that the filling defects in the SERRS signal correspond to
cancer.
The stability of the PET-SERRS NPs reported herein, and their utility for in vivo imaging
justify further investigation into their use as whole-body, combined pre- and intra-operative
multimodal contrast agents. The ability of PET-SERRS NPs to provide contrast for whole-body
identification of pre-operative ROIs and handheld localization of intraoperative ROIs minimizes
the necessary field of view for high resolution SERRS imaging, thus making it more plausible in
an acceptable timeframe for clinical applications. Moreover, this work validates the use of silica
encapsulation and chelator-free labeling as a general method to radiolabel nanoparticle
substrates.
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Figure 3.9. PET-MR imaging of liver cancer using PET-SERRS nanoparticles. A mouse with
genetically engineered hepatocellular carcinoma (HCC) was injected with 400 µCi of 68Galabeled PET-SERRS NPs. After 3 hours, micro-PET-MRI was performed and the data analysis
and PET-MRI co-registration were completed using VivoQuantTM software (InviCro LLC,
Boston, USA). Shown are axial sections through the upper abdomen. A) Axial T1-weighted MR
image through the liver, demonstrating a hypointense region (dashed-line circle), which was later
confirmed to represent a HCC on pathological examination. Arrowhead = gallbladder. B) PET
image with a signal void (arrow) corresponding to the location of the HCC. C) MRI-PET
overlay.
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3.6 Radiolabeling iron-oxide nanoparticles
As with SERRS NP, iron oxide NPs (IONPs) allow multimodal imaging capabilities
when a PET or SPECT radiotracer is attached. IONPs have been mostly used as MR contrast
agents but can also serve as platform for multimodal imaging. Combining MR agents with
radiotracers take advantage of the best aspects of each imaging modality, such as quantitative
results from PET and morphological T1 or T2 weighted contrast in MRI. Traditional MR
contrast agents involve chelated paramagnetic gadolinium for T1 contrast adjustment, whereas
IONPS have been used for T2 contrast. Maintaining MR contrast of the IONP during the
radiolabeling process is of paramount importance. Appendix B discusses MR imaging in greater
detail.
Strategies for radiolabeling IONP fall into three categories: 1) Attachment of a chelator
or prosthetic group to the surface of the IONP, 2) hot-plus-cold synthesis, and 3) chelator-free
ion exchange or surface absorption [24]. Like other NPs, attaching chelators or prosthetic groups
is the most common radiolabeling technique due to their use with biomolecules. However, recent
work has focused on chelator-free methods of radiolabeling due to potential issues of chelator
detachment that will be discussed in section 3.7. 69Ge was intrinsically radiolabeled onto an iron
oxide NP for multimodal SPION radiotracing for PET/MR [25]. Using this PEGylated 69Ge
SPION, in vivo uptake in the liver via PET as well as T2*-MRI was seen with no observable
accumulation in the kidney. Kidney uptake with NP > 10nm is typically indicative of
detachment of the radiotracer. Furthermore these NP were injected into murine foot pads to show
lymph node drainage over 20 hours. With a similar strategy, chelator-free 68Ga radiolabeling of
PEG functionalized, silica coated iron oxide nanorods revealed high radiochemical stability
comparable to chelator analogues produced using a similar technique as was shown in chapter 2
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[26]. Increased T1 and T2 relaxivities were observed with the PEGylated, chelator-free nanorods
with subsequently high radiochemical stability for 68Ga in serum over 3 hours for chelated and
chelator free radiolabeled nanorods. Intrinsic multimodal imaging using MR NP was also
recently achieved through direct synthesis of 59Fe SPION NPs from cold precursor seeds, and
example of hot-plus-cold synthesis. Through direct incorporation of the radionuclide in the
synthesis, minimal changes to MR relaxivity properties were observed. [27].
Many of the NPs reported in radionuclide imaging studies are not FDA approved, and as
such require long-term safety and efficacy studies before they can be used as imaging agents in
patients. One approach is to use already available and FDA-approved NPs as platforms for drug
delivery and radiolabeling. On such example is the FDA approved iron oxide NP Feraheme
(FH) that was utilized as a drug delivery vehicle without significant modification to the NP.
Here, FH was used as an environment sensitive nanophore based on drug release from the
dextran particle coating. Loading FH with a 131I labeled HSP90 inhibitor, FH served not only as
a T2 contrast agent sensitive to the concentration of drug released, but radiolabeling allowed
biodistribution studies as well. This combination showed enhanced tumor delivery compared to
radiolabeled drug alone [28]. In a similar fashion, Ferumoxytol was used as a MR NP platform
for 89Zr radiolabeling. Using well-known EDC coupling of DFO to free carboxyl groups on the
dextran shell, the authors were able to radiolabel without alteration in particle size and serum
stability to 24 hours. These radiolabeled Ferumoxytol particles were used in high resolution
PET/MR imaging studies for the detection of sentinel lymph nodes and the monitoring lymph
node drainage. This study is discussed in depth in section 3.7.
Multimodal imaging with radiolabeled NPs give researchers and hopefully in the near
future clinicians the power to move between imaging modalities, where each method yields
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information about the biology of the environment around the NP. Current advances report
hexamodal imaging with single NP systems highlight the sophistication of NP design possible
[29]. Hexamodal NPs reveal the complexity required to produce a translatable particle, making it
harder to bring though the clinic for each imaging modality. Here single imaging modality NPs
can be sufficient for clinical development as seen by the advancement of C dots in the clinic.
While these methods rely heavily on imaging and are not mentioned as therapeutic agents,
radiolabeling with therapeutic isotopes such as 90Y, 131I, 177Lu, and 225Ac opens the ability for
imaging agents to become radionanomedicines as well.
3.7 Previous work with 89Zr-radiolabeled iron oxide nanoparticles
Radiolabeling the IONP Feraheme (FH) with 89Zr was recently achieved in the Grimm
Laboratory through surface modification [30]. As FH has an iron oxide core with a
carboxymethyl dextran coating, the carboxyl groups were first aminated, followed by
attachement of the chelator deferoxamine (DFO) with an isothiocynate amine-reactive group.
Full reaction details of this and other common conjugations are found in appendix B. The
reaction details for DFO attachment to FH are shown in Figure 3.10.

Figure 3.10. Radiolabeling FH through surface attachment of a chelator. The surface of
Ferumoxytol (FH) was first aminated using EDC chemistry, followed by attachment of the
chelator DFO. This allows radiolabeling with 89Zr. From reference [30].
The surface-labeled 89Zr-FH was used for lymph node imaging through drainage of either
footpads or tumor-bearing prostates. It showed superior sensitivity compared to both non-
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radiolabeled FH (MR contrast only) and the clinically standard 99mTc colloids. However, two
notable details are shown in Figure 3.11. Firstly, the footpad injections showed appreciable
kidney uptake (>10 %) at all time points. This is indicative of DFO-89Zr detachment, which is
typically undesirable. FH, with a diameter of 18-36 nm, is not renally cleared in appreciable
amounts. Secondly, at the earliest time point tested (4 hr), high LN contrast is seen. This hints at
the possibility of using a radionuclide with a shorter half-life for PET imaging to limit ionizing
radiation dose and the amount of time a patient is radioactive. Appreciable lymph node uptake at
1 and 2 hours were mentioned but no data was reported; therefore, it was unclear from the study
what is the earliest imaging time point for clear LN delineation.

Figure 3.11. Biodistribution of surface-bound 89Zr-FH at 4-48 hours post-injection into the
footpad. Note that at the earliest time point (4 h) high uptake of 89Zr-FH in both the brachial and
axillary LN is seen. The kidney activity (>10 %) at all time points indicates that 89Zr-DFO is
detaching from FH, which is typically undesirable. From reference [30].
3.8 Chelator-free 68Ga and 89Zr radiolabeling of iron oxide nanoparticles
As seen in section 3.7, detachment of chelators from NP results in PET imaging of the
chelator rather than the NP, and is undesirable. Therefore, as with silica and silica-coated NP in
chapter 2, the strategy of heating oxophilic radiometals with FH was used. Unlike silica-based
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NP, the radiometal is thought to bind to the iron oxide core of FH rather than the carboxymethyl
dextran coating based on cold chemistry experiments [31]. First, 89Zr-oxalate was neutralized
with sodium carbonate to pH 7.4-8.0. This was then added to FH in H2O or 10mM MES buffer
(pH 7.8) or buffer solution without FH as controls. These solutions were reacted for 2 hours at 95
°C. The 89Zr-FH solutions were allowed to cool for ten minutes, after which 20 uL of 50 mM
EDTA solution was added to scavenge any weakly bound 89Zr. After 20 minutes of scavenging,
purification was completed using either PD-10 columns or size-exclusion spin filtration (50 kD
cutoff), which both methods showing similar radiochemical yields (Figure 3.12).

89Zr%

pH%7.3,%95°C%
120%minutes%

EDTA%scavenge%
RT,%20%minutes%

PuriﬁcaDon%

Figure 3.12 Schematic of radiolabeling dextran-coated iron-oxide nanoparticles. The
radionuclide is thought to bind stably to the iron oxide core, with <10 % bound to the dextran
coating. Weakly bound radionuclide is removed through EDTA scavenging.
As section 3.7 showed, imaging at early time points is likely possible for radiolabeled
FH. Therefore, the same radiolabeling process was tested for the 68Ga. Here, radiolabeling at 95
°C for 30 minutes was used, as the short half-life of 68Ga does not allow longer radiolabeling
incubation without a drastic decrease in specific activity. As the radiolabeling process needs to
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leave the properties of FH intact (such as diameter and surface charge), these properties were
assessed pre- and post- radiolabeling. Both direct and purified elutions of 68Ga were tested with
FH, as described in section 3.2. Neither elution method saw significant changes in the size or the
surface charge of FH (Figure 3.13), indication that both elution methods are available for FH
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radiolabeling. Details of methods are found in the methods sections at the end of this chapter.

Figure 3.13. DLS and Zeta of FH. Dynamic light scattering showed no appreciable change of
diameter with either purified or direct elution. Purified elution is preferred for clinical
translation, and therefore was tested for surface charge differences. No appreciable change is
seen compared to non-radiolabeled FH.
3.9 Lymph Node imaging with 68Ga and 89Zr iron oxide nanoparticles
Following the successful radiolabeling of FH with 89Zr and 68Ga without the need for
surface modification, 89Zr-FH’s application as a LN imaging agent was tested. 89Zr-FH (10uL,
220uCi) was injected into the footpad of nude mice (n=4) and PET/CT imaging conducted at 1
hour post-injection (Figure 3.14A). Notably, LN drainage is seen, with liver uptake increasing as
the particles pass through the lymphatic system. No appreciable bone uptake (<2 %) is seen,
indicating 89Zr is not coming free from FH. At 3 hours, the mice were imaged using Cerenkov

	
  

73	
  

	
  
Luminescence (CL), shown in Figure 3.14B. CL occurs when a charged particle, such as the
positron from 89Zr, travels faster than the velocity of light in a medium such as tissue. Further
details on the Cerenkov mechanism are found in Chapter 4. At 4 hours post-injection, the mice
were euthanized and an ex vivo biodistribution study was conducted (Figure 3.13C). Notably,
low kidney uptake (<2 %) was seen, addressing the limitation of the previous work shown in
section 3.7 using surface-bound DFO.
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Figure 3.14. 89Zr-FH LN imaging using PET and CLI. (A) PET/CT imaging of 89Zr-FH at 1
hour post-injection, clearly delineating various lymph nodes with drainage to the liver. Notably,
kidney uptake is not seen, a potential disadvantage of previous work. (B) Cerenkov
luminescence imaging at 3 hours post-injection allows visible photon imaging of the LN for
potential surgical guidance. (C) Ex vivo biodistribution studies quantify organ uptake.
The early passage of FH through the lymphatic system encouraged the development of
radiolabeling FH with the short-lived radionuclide 68Ga. With a half-life of 68.3 minutes,
imaging out to 3 hours is feasible. Therefore, we conducted the same LN imaging study as
described for 89Zr-FH on 68Ga-FH with the addition of a dynamic early time point scan. Figure
3.15 shows dynamic scans 0-30 minutes post-injection to determine the earliest time point for
LN imaging. As seen in Figure 3.15C-E, passage through the lymphatic system begins around
20 minutes post-injection.

	
  

74	
  

68Ga"FH%dynamic%scan%

	
  
A"

B"

5"10%min%

C"

10"15%min%

D"

15"20%min%

E"

20"25%min%

25"30%min%

Figure 3.15. 68Ga-FH dynamic LN imaging. (A-E) Dynamic scans show activity distribution at 5
minute increments, with sentinel LN uptake seen at 15 minutes post-injection. Sentinel LN
circled in white.
PET/CT and CL on 68Ga-FH was also conducted at 1 and 3 hours, respectively (Figure
3.16), and showed a robust LN signal comparable to 89Zr-FH. A comparison in photon radiance
between 89Zr-FH and 68Ga-FH is shown in Figure 3.17. Notably, activity levels of 68Ga-FH are
much lower than 89Zr-FH due to the rapid decay of 68Ga, yet the CL radiance of 68Ga is twice
that of 89Zr due to the higher β energy of 68Ga.
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Figure 3.16. 68Ga-FH LN imaging. (A) PET/CT at 1 hour post-injection shows similar
biodistribution to 89Zr, with clear lymph node delineation. (B) Cerenkov luminescence imaging
(scaled the same as 89Zr-FH image) clearly shows the draining lymph node at 3 hours postinjection.
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With this work, we have radiolabeled FH with both 89Zr and 68Ga and conducted LN
imaging. Potential limitations of chelator detachment were avoided with 89Zr-FH, and CL
imaging was also conducted, allowing optical readout of LN uptake, of possible use for surgical
resection guidance.
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Figure 3.17. Cerenkov luminescence of 89Zr-FH versus 68Ga-FH. The Cerenkov output of 68Ga
is higher than that of 89Zr due to the 68Ga’s higher β energy.
3.10 Mouse models of Colorectal Cancer
As LN imaging was achieved with both 68Ga- and 89Zr- FH, other, more complex in vivo
systems were next investigated. One motivation for this is that through imaging tumor uptake of
FH, it may be possible to predict efficacy of nanoparticle-loaded drug delivery, as recently
shown by the Weissleder group [32]. With this in mind, and the fact that nanoparticles are often
used in oncology for both imaging and drug delivery, cancer was chosen as the disease model.
For mouse cancer models, subcutaneous xenografts are often used; however, these models may
not accurately reflect natural tumor progression and the mouse strain is often an
immunocompromised strain to allow implantation. A more robust method is testing a probe on at
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least one primary, spontaneous cancer model (ex. transgenic) and ideally one metastatic model
[33].
Colorectal cancer (CRC) was chosen as the cancer type, as 1) it comprises around 40 %
of all cancers diagnosed yearly [34], 2) 30-50 % of patients with CRC relapse [35], and 3)
combination chemotherapy has shown improvements in median survival rates [36], an area
where drug-loaded nanoparticles may improve delivery with a decrease in off-target side effects.
A number of CRC cell lines exist, including HT-29, HCT-15 (human colorectal
adenocarcinoma), and CT26 (mouse carcinoma) [37]. However, recent molecular biology
advances in CRC have allowed transgenic mouse models that better recapitulate human disease
and progression.
Recent work has shown how mutations in such genes as adenomatous polyposis coli
(APC), Tp53, and Kras lead to CRC progression and metastatic lesions [38]. APC in particular
has been extensively studied in CRC, as 80 % – 90 % of colorectal tumors contain inactivating
mutations in the APC tumor suppressor [39]. APC negative regulates the Wnt/β-catenin signal
transduction pathway; when APC is mutated or down regulated, β-catenin increases [40],
resulting in β-catenin cytoplasmic accumulation and nuclear translocation [41]. This leads to
increased Wnt signaling output and modulation of target genes implicated in cell proliferation,
migration, differentiation, and apoptosis [42]. P53 is a well-known tumor suppressor commonly
down regulated in many cancers as it is involved in DNA damage response [43]. When it is
mutated or otherwise dysfunctional, DNA damage can accumulate, leading to increased DNA
mutations, which may lead to tumor formation or progression. KRas, and oncogene, is also
commonly mutated in colorectal cancer, with a recent study showing at least 1 mutation in 42.3
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% of CRC samples [44]. Typically in CRC, KRas mutations occur after an APC mutation,
leading to adenoma formation [45].
A doxycycline-inducible mouse model was recently generated by the Lowe laboratory to
investigate the role of APC on the development of CRC [46]. At the time, it was unclear if APC
disruption was necessary for only initiation of CRC or required maintaining CRC progression.
Through a series of elegant experiments, it was shown that APC disruption was necessary for
APC maintenance through the use of a dox-inducible APC mouse model. While experimental
details are found in the methods section, doxycycline- [47] and tetracycline- [48] inducible
mouse models have been used for over two decades and are a well-established method.
As these mice express green-fluorescent protein (GFP), it is possible to perform
endoscopies to image GFP-expressing stem cells in the large intestine using GFP filters and
bright field imaging (Figure 3.18).

Bright'ﬁeld'
A"

GFP'
B"

Figure 3.18. Endoscopy of GFP APC mice at 7 weeks post-tamoxifen administration. Both
bright field and GFP imaging clearly shows expression of shRNA that block APC, resulting in
CRC tumor formation, delineated with the white arrow.
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The Lowe laboratory prepared the primary CRC and lung metastasis models. Lung
metastases were prepared through injection of luciferase-, GFP- expressing CRC cells in the tail
vein and allowed to progress for 14-16 weeks post-injection. Primary CRC were allowed to
progress 4-6 weeks after tamoxifen treatment prior to imaging experiments. As the lung
metastatis model expressed luciferase, bioluminescence imaging was used to track tumor growth
over time (Figure 3.19), and ex vivo results showed robust metastatic growth at 12 weeks
(Figure 3.20). Primary CRC was tracked through endoscopy at 1 and 4 weeks post-birth.

A"

B"

C"

Figure 3.19. Luciferase imaging of lung met models over time, mice in random order. (A) No
luciferase expression is seen at 4 weeks post-injection. (B) At 12 weeks post-injection, tumors
formation is seen in 5 of 9 total mice. (C) By 16 weeks, 7 of 9 mice showed luciferase expression
in the lung.
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Figure 3.20. Ex vivo lung metastasis of luciferase and GFP expressing cells. (A) Bright light
image with ruler, (B) bright light image (alone), (C) GFP microscopic image.
3.11 Comparing [18F]-FDG and radiolabeled iron oxide nanoparticles for imaging primary
colorectal cancer
With a robust in vivo model selected, imaging comparisons between the glucose analog
[18F]-FDG and radiolabeled FH were conducted. [18F]-FDG is taken up by metabolically active
tumor cells (along with other Mouse&3&
organs such as18the
heart, brain, and muscle). As seen in Figure
FDG&PET/CT&
3.21, [18F]-FDG shows tumor
uptake but also high background5"hour"
at 1 and 5 hours post-injection.
1"hour"

A"

B"

Figure 3.21. [18F]-FDG uptake in a primary CRC. (A) [18F]-FDG uptake in primary CRC mice at
1 hour and (B) 5 hour post-injection.
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Zr-FH was next prepared as described in section 3.8 and injected into the same mouse cohort

two days after 1[18F]-FDG imaging to allow the complete decay of 18F (t1/2 = 110 min). As seen
in Figure 3.22, CRC tumor uptake is seen at 5 hours post injection all the way to 42 hours postinjection. Biodistribution allowed ex vivo quantification (Figure 3.23), with tumor uptake

Mouse&3&89Zr,FH&PET/CT&

around 10 % Id/g, high for non-targeted nanoparticles.
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Figure 3.22. 89Zr-FH PET/CT imaging in primary CRC models at various time points. PET/CT
at (A) 5 hours, 24 hours, (B) and (C) 42 hours post-injection.
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Figure 3.23. 89Zr-FH biodistribution in primary CRC. Ex vivo quantification of organ uptake of
89
Zr-FH at 42 hours post-injection. High tumor (and RES) uptake is seen, likely through a
combination of the EPR effect and monocyte trafficking to the tumor site.
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3.12 Comparing [18F]-FDG and radiolabeled iron oxide nanoparticles for imaging CRC
lung metastases
As with primary CRC, lung metastatic models were imaged using multiple methods.
Luciferase imaging was completed over time as shown section 3.10. At 16 weeks after tumor cell
injection, luciferase and [18F]-FDG imaging was conducted (Figure 3.24), with [18F]-FDG

Luciferase*and* FDG*imaging*

uptake matching luciferase expression. 89Zr-FH also18
showed lung uptake over background at the
4-hour time point (Figure 3.25).
A"

B"

C"

A"

Figure 3.24. Luciferase and [18F]-FDG imaging of lung metastasis. (A) Luciferase and (B) [18F]FDG imaging of a mouse with CRCLung%metastasis%model%
lung metastasis, also shown for a different mouse in (C) and
(D).
A"

B"

Figure 3.25. 89Zr-FH of a lung metastasis at 4 hours post-injection. (A) PET/CT of 89Zr-FH at 4
hours post injection, with (B) PET only also shown. Note lung uptake.
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3.13 Discussion of nanoparticles with CRC for imaging and therapy
While CRC lung metastasis mouse models showed transient uptake at 4 hours postinjection, later time points did not show sustained tumor uptake (data not shown). There are two
likely reasons for this. The first is the difference of mouse strain (and tumor model); the lung
metastasis model is injected into nude athymic mice. These mice, lacking a thymus, will have a
different immunological response compared to wild type mice. As Feraheme is mainly taken up
by immune cells in the tumor microenvironment (and elsewhere) [32, 49], it is possible this has a
negative effect on tumor uptake. Wild type mice are not able to be injected with the cells used
for the lung metastasis model, as the luciferase may invoke a lethal immunological response. The
second possibility for less tumor uptake in the lung met model is the location of the tumor.
Primary CRCs are known to be immune cell (such as macrophage) rich, the main type of cell that
takes up FH in tumors. Lung met model immune cell makeup is not well established, and may
have much fewer immune cells. This data, while encouraging, shows that further information is
needed on the tumor uptake mechanism. This work is best done with a combination of
radiolabeled FH for whole body time course imaging (as shown) and fluorescently labeled FH
for ex vivo microscopy.
3.14 Methods
SERRS nanoparticle synthesis
Gold nanoparticles were synthesized by addition of 7.5 ml 1% (w/v) sodium citrate to
1000 ml boiling 0.25 mM HAuCl4, then concentrated by centrifugation (10 min, 7500 x g, 4°C)
and dialyzed overnight (3.5 kDa MWCO; 5L 18.2 MΩ.cm). The dialyzed gold nanoparticles
(140 µL; 2.0 nM) were added to 1 mL absolute ethanol in the presence of 50 µL
tetraethoxyorthosilicate (Sigma Aldrich, 99.999%), 20 µL 28% (v/v) ammonium hydroxide
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(Sigma Aldrich) and 2 µL IR-780 dissolved in N,N-dimethylformamide. After 25 minutes of
shaking (375 rpm) at ambient conditions in a plastic container, the SERRS-Nanoprobes were
centrifuged, washed three times with ethanol, and redispersed in water to yield 5 nM SERRSNanoprobes.
Radiolabeling protocol for PET/SERRS nanoparticles
68

Ga (t1/2=68 m) was eluted from a 68Ge-68Ga generator (ANSTO, Australia) as

previously described[8], with 555-740 MBq (15-20 mCi) activity per elution. 68Ga was eluted as
either a direct elution in 0.4 N HCl, or as purified elution in 0.5 M potassium hydroxide. The
68

Ga HCl solution was neutralized with 28% ammonium hydroxide while the 68Ga hydroxide

solution was neutralized with concentrated hydrochloric acid. Upon neutralization, 37 MBq (1.0
mCi) of 68Ga was immediately added to silicate gold nanoparticle solutions (10 nM, in 100 µL of
10 mM pH = 7.3 MES buffer) and incubated at 70°C on a thermomixer at 500rpm for 30-60
minutes. Purification was completed by centrifugation at 10,000 rpm for 120 seconds followed
by resuspension.
In vivo experiments
All animal experiments were done in accordance with protocols approved by the
Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center and
followed National Institutes of Health guidelines for animal welfare.
PET/CT imaging
At predetermined time points (1 h, 4 h, and 24 h) animals were anesthetized with
isoflurane (Baxter Healthcare, Deerfield, IL) and oxygen gas mixture (2 % for induction, 1 % for
maintenance) and scans were then performed using an Inveon PET/CT scanner (Siemens
Healthcare Global). Whole body PET static scans were performed recording a minimum of 50
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million coincident events, with duration of 10-20 min. The energy and coincidence timing
windows were 350−750 keV and 6 ns, respectively. The image data were normalized to correct
for non-uniformity of response of the PET, dead-time count losses, positron branching ratio, and
physical decay to the time of injection, but no attenuation, scatter, or partial-volume averaging
correction was applied. Images were analyzed using ASIPro VMTM software (Concorde Microsystems). Whole body standard low magnification CT scans were performed with the X-ray tube
setup at a voltage of 80 kV and current of 500 µA. The CT scan was acquired using 120
rotational steps for a total of 220 degrees yielding and estimated scan time of 120 s with an
exposure of 145 ms per frame.
Cerenkov luminescence imaging
Mice were anesthetized as described previously. Open filters were used for optical scans.
120-300 second scans were completed, camera set to F8, field of view B.
Handheld SERRS detection
All handheld Raman measurements were performed using the MiniRam Raman handheld
scanner (B&W TEK, Inc., Newark, DE) equipped with a 785 nm laser. Raman spectra were
collected with an acquisition time of 1 s and analyzed with B&WSpec 4.01.26 Software (B&W
TEK).
Fixed-microscope SERRS imaging
All fixed Raman scans were performed using a Renishaw inVia Raman microscope with
a 300mW 785 nm diode laser and 1-inch charge-coupled device detector (1.07 cm-1 spectral
resolution). The SERRS spectra were collected with a 5 × objective (Leica) and the laser output
measured at the objective was 100 mW at 100% laser power. Scans were typically performed at
100 mW laser power, 1.5-s acquisition time, using the StreamLine high-speed acquisition mode.
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The Raman maps were generated by means of a DCLS algorithm (WiRE 3.4 software,
Renishaw).
PET-MRI
A mouse with genetically engineered hepatocellular carcinoma (HCC) was injected with
400 µCi of 68Ga-labeled PET-SERRS NPs. After 3 hours, micro-PET-MRI was performed (T1weighted) on a nanoScan PET/MRI system (Mediso USA, Boston, MA) and the data analysis
and PET-MRI co-registration were completed using VivoQuantTM software (InviCro LLC,
Boston, USA).
Radiolabeling protocol for Feraheme with 89Zr or 68Ga
Feraheme (Ferumoxytol, FH) is a formulation of iron oxide nanoparticles at 30mg/mL iron, with
a diameter of 17 to 31nm. FH was prepared at a concentration of 0.25 mg/mL in either MES
buffer (10 mM, pH 7.8) or chelex-treated H2O. 89Zr-oxalate was neutralized with 1.0 M sodium
carbonate and added to 0.1mg FH (400 µL). 68Ga was neutralized with either ammonium
hydroxide (28 %) for direct elution or 6N HCl for purified elution. This was heated at the desired
temperature (typically 95 °C) on a thermomixer at 600 rpm. Purification was achieved using
either PD-10 columns (GE Healthcare) or spin filters (Millipore, 30 kD). Particles were
resuspended in saline prior to injection.
Primary CRC and lung metastasis mouse models
Primary and lung metastatic CRC models were prepared by the Lowe laboratory as described
previously [46]. The primary CRC model was generated by combining a stem cell restricted 4hydroxytamoxifen (4OHT)-inducible CreER strain (Lgr5-GFPIRESCreER) with a Cre-dependent R26-CAGs-LSL-rtTA3 (LSL-rtTA3) strain. In these mice, a single
treatment with 4OHT initiates LoxP-recombination in stem cells of the small and large intestine,
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inducing long-lived, rtTA3 expression in a small percentage of individual crypts and villi. The
addition of doxycycline results in TG-Apc.3374 (shAPC) expression, knocking down APC and
activating Wnt expression. Doxycycline was administered via food pellets (625 mg/kg) (Harlan
Teklad). 4-hydroxytamoxifen (4OHT, Sigma Aldrich, 70 % Z-isomer) was delivered by a single
intraperitoneal injection (0.5 mg/mouse) at 5–6 weeks of age.
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CHAPTER 4
Ionizing radiation-nanoparticle interactions
This chapter contains results adapted from publications in review at the Journal of Nuclear
Medicine [1] and in revision at Nature Nanotechnology [2]. Sections 4.8-4.12 (unpublished)
were conducted with Edwin C. Pratt, Grimm Laboratory. Accordingly, the figures and text in
those sections are the result of collaborative data collection and writing with the co-authors.
4.1 Introduction
In the previous chapters, methods to stably attach radionuclides to nanoparticles of
various types were developed. Here, we take a closer look at the interactions between ionizing
radiation (IR) and matter that results in the emission of visible photons. First, we revisit our
discussion from chapter one on particle physics, focusing on the ways high-energy photons and
charged particles dissipate their energy through interactions with matter. We next review
methods these IR interactions are leveraged in the clinical setting for optical imaging, with IR
sources including photon and charged particle beams and radionuclides. From there we narrow
our focus to nanoparticles and radionuclides, discussing the standard view on interactions
between IR and nanoparticles in the medical field: namely, Cerenkov luminescence interactions
with nanoparticles. However, in section 4.8 we bring forth a new view on IR-nanoparticle
interactions that result in visible photon output. We test a library of nanoparticles with a
multitude of radionuclides of various decay schemes to elucidate the mechanisms of interaction
that may result in visible photon emission. This is covered in depth with a conclusion on the
outlook of nanoparticle-IR combination considerations in medicine and imaging.
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4.2 High-energy photon interactions with matter
As high-energy photons and charged particles traverse matter, they dissipate energy in a
manner dependent on the energy of the photon or particle, the atomic number (Z), and the
density of the surrounding matter. Photons at energies used in medical imaging interact with
surrounding matter though four mechanisms, seen in Figure 4.1: 1) Photoelectric effect, 2)
Compton scattering, 3) Coherent Scattering, 4) Pair production.

A"

B"

C"

D"

Figure 4.1. Interactions between high-energy photons and matter. These include (A) Compton
scattering, (B) Photoelectric effect, (C) pair production, and (D) coherent scattering
Both the photoelectric effect and Compton scattering are mechanisms that can directly
result in the emission of a visible photon in matter. The photoelectric effect occurs when an
electron is ejected from an atom via absorption of the energy of a high-energy photon, which
disappears in the process. Compton scattering involves the transfer of a portion of the photon
energy to an electron, with the electron ejected from the atom and the high-energy photon
scattered at a lower energy in the process. The photoelectric effect predominates with relatively
low photon energies and high atomic numbers (Z) of interacting matter. With both the
photoelectric effect and Compton scattering, an outer shell electron fills the vacancy created by
the ejected electron that results in visible or X-ray photon emission. Coherent scattering is an
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elastic process and generally occurs when the energy of the radiation is small compared to the
ionization energy of the material. Pair production is the creation of an elementary particle and its
antiparticle, for example creating an electron and positron, but requires high-energy photons of at
least 1.022 MeV.
4.3 Optical imaging of high-energy photon interactions
Because γ-emitting radiotracers allow for both planar scintigraphic and tomographic
SPECT imaging, other imaging techniques are not typically considered. However, other methods
exist; for example visible photon emission from γ-emitting radiotracers has been known in the
nuclear physics field for many decades [3]. All ionizing radiation sources such as the 140 kev
photons emitted by

99m

Tc result in the ionization and excitation of the medium, such as water.

Relaxation of water molecules and transition of excited OH radicals results in the emission of
visible light, and is known as radioluminescence. These visible photons were recently utilized to
allow optical imaging of clinical γ-emitters. Here, optical imaging with

99m

Tc, the work-horse

gamma emitter used widely for SPECT and planar imaging, was first shown using a phosphor
screen that converted the high-energy photons into visible light, which was imaged in a preclinical optical IVIS system. The resolution with the optical system is better than 1.3 mm when
the source depth is less than 10 mm, highlighting the depth dependence of optical methods [4].
Subsequently, visible photons arising from the interactions of the

99m

Tc γ with tissue were

imaged, obviating the necessity for a phosphor screen. Here, investigators tested

99m

Tc systems

including pertechnetate, and complexes with albumin macroaggregates, dimercaptosuccinic acid,
phytate colloid, and ethylenediamine tetramethylene phosphonic acid. Radioluminescence with
variations in the emission spectrum was observed for each of the

99m

Tc systems. The visible

signal exhibited a half-life of 6-7 hours that corresponds to the half-life of 99mTc (t1/2=6.02h) and
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demonstrates that the visible light was from 99mTc and not a contaminant in the 99mTc solution. In
vivo optical imaging was shown in the study with

99m

Tc-phytate colloids, but the benefits over

SPECT imaging are not readily apparent [5]. In another optical imaging demonstration,

99m

Tc-

pertechnetate was used to image thyroid and salivary glands through uptake by the sodiumiodide symporter [6].
While visible light emission from SPECT radionuclides is an interesting phenomenon,
the low flux of visible photons (8 × 106 versus ~104 average radiance (p/s/cm2/sr) for scaled
activity amounts of 18F via CL and 99mTc via radioluminescence, respectively) [7] makes in vivo
optical imaging quite difficult.

A variety of nanoparticles, deemed nano-scintillators, can

enhance the visible photon output from γ emitters and X-rays; however, these systems are only in
the pre-clinical stage and have significant barriers to translation, so will only be briefly discussed
herein. The most common nano-scintillators contain luminescent rare-earth elements such as
terbium and europium. High-energy photons interact with the nano-scintillators to excite
electrons, which can relax both radiatively by emitting a visible photon and non-radiatively.
Clinical feasibility is uncertain since toxicity issues arising from the composition, size, and
biodistribution of the nanoparticles need to be investigated prior to applications. A detailed
review on nano-scintillators in pre-clinical use was recently published [8].
External high-energy photons
Another source of high-energy photons is external sources, such as photon beams or Xrays commonly used in clinical and pre-clinical practice. X-ray fluorescence computed
tomography (XFCT) is frequently used in pre-clinical models and is the subject of a recent
review [9]. Here, we focus on optical imaging in conjunction with linear particle accelerators
(LINAC). Clinical photon beam source energies operate in the megavoltage region, resulting in
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electrons with energies exceeding that of the Cerenkov threshold in tissue (220 kev) being
ejected from atoms. The ejected electrons result in CL, allowing Cerenkov Luminescence
Imaging (CLI). Using CL, both intensity-modulated radiation therapy and volumetric-modulated
arc therapy were evaluated using real-time video-rate optical dosimetry [10]. A more elaborate
system involving linear accelerators is Cerenkov excited fluorescence tomography, where the
generated CL excites fluorophores in a sample. As the light from CL is blue-weighted, the use of
fluorophores that emit in the red or NIR allows deeper imaging depth at the cost of the increased
complexity of injecting a dye prior to beam therapy [11, 12].
4.4 Charged particle interactions with matter
Charged particles, such as those from β- and α-particle emitting radiotracers, can interact
with surrounding matter through five mechanisms seen in Figure 4.2: 1) Excitation, 2)
Ionization, 3) Bremsstrahlung, 4) Cerenkov, 5) Annihilation (positron only). Excitation results in
an electron occupying an excited state, which will subsequently relax to the ground state.
Ionization results in the ejection of an electron from an atom, similar to the photoelectric and
Compton effect seen with high-energy photons. Bremsstrahlung occurs when a charged particle
is attracted (or repulsed) by the positive atomic nucleus, altering the momentum of the charged
particle, and thus resulting in the release of the lost kinetic energy as emission of photons. The
Cerenkov mechanism occurs when a charged particle travels faster than the velocity of light in a
medium, resulting in visible photon emission, deemed Cerenkov luminescence (CL).
Annihilation occurs when the antimatter of an electron, the positron, interacts with an electron,
causing the electron-positron pair to annihilate and two 511 kev photons to be emitted at almost
180° apart.
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Figure 4.2. Interactions between high-energy β particles and matter. (A) Excitation, (B)
Cerenkov radiation, (C) Ionization, (D) positron annihilation, and (E) Bremsstrahlung.
Both high-energy photons and charged particles can result in more complex interactions
than presented here, such as the formation of Auger electrons and secondary ionization. Though
these mechanisms can complicate interpretation of in vivo imaging, translatable ex vivo
calibration methods and simulations in preclinical models can result in acceptable sensitivity and
resolution for in vivo optical imaging.
4.5 Optical imaging of charged particle interactions
β- and α-emitting radiotracers: Cerenkov
Optical imaging of β and α emitting radiotracers was demonstrated through various
mechanisms of energy dissipation by charged particles. The most common way that ionizing
radiation is optically imaged is through β and α radiotracers in the form of CL, for three reasons:
CL is typically of significantly higher intensity than radioluminescence from γ emitters; CLI
allows imaging of β- and α emitters, which are typically quite difficult to image; CLI is possible
with most clinical radiotracers, obviating the need for additional imaging agents. Since CL is
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blue light weighted and current clinical use of CLI relies only on a given radiotracer without
endogenous enhancement entities, only imaging close to the surface is possible. However, some
amount of overlying tissue depth is actually beneficial in that it allows for CL to be generated in
the direction of the tissue surface; for example, 18F generates CL over the length of ~1 mm, and
90

Y over more than 4 mm [13]. To address this depth limitation, increased imaging depth has

been achieved pre-clinically through pairing radiotracers with photoluminescence molecules or
nanoparticles that absorb blue light and emit more penetrating red [14]. One might envision
better detector systems coupled with better imaging software to increase depth and resolution.
The first CLI clinical studies utilized the PET tracer [18F]-FDG in endoscopic studies and
detection of nodal disease [15, 16], while another study imaged 131I thyroid uptake in one patient
[17]. These proof-of-concept studies utilized widely used radiotracers to correlate images
obtained through traditional nuclear medicine instrumentation with CLI as a means to quantify
the efficacy. Conversely, a unique application demonstrating the benefits of CLI is imaging
therapeutic radiotracers. The β- emitter 90Y has a βmax of 2.28 Mev leading to a high CL intensity,
over 35 times that of 18F [18]. 90Y’s high CL intensity, along with the difficulties of imaging it
with traditional detection methods due to the absence of suitable gamma emissions and low
amount of positron emissions, make it an ideal candidate for CLI. Recently in a pre-clinical
model, it was shown that

90

Y could be quantitatively imaged using CLI [19]. The

90

Y-labeled

gastrin-releasing peptide receptor antagonist 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid – AR (DOTA-AR) was injected into prostate cancer xenograft models and imaged out to 72
hours post-injection using CLI. Quantification of tumor uptake using CLI correlated with ex vivo
measurements, thus offering means for dosimetry as well as an alternative to PET imaging of the
very low amount of positrons emitted from 90Y. Another potential application of CLI is imaging
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of

90

Y microspheres used for radioembolization. In future studies, the microspheres could

incorporate fluorescent molecules that absorb CL and emit in the NIR, allowing non-invasive
NIR imaging of the spheres as an alternative to current methods of PET/CT imaging and SPECT
bremsstrahlung imaging [20].
α-emitters such as

213

Bi and

225

Ac are used therapeutically through conjugation to

antibodies, nanomaterials, and peptides [21, 22]. Since these nuclides emit an α particle,
conventional imaging can only be achieved utilizing indirect methods, such as the injection of an
imaging radiotracer attached to the same targeting ligand, followed by injection of the α-emitter
with the assumption the biodistribution is similar. Unfortunately, the energy of the α-particle is
too low to allow direct Cerenkov luminescence. However, the α-decay can still be visualized
with CL through the β-emitting daughter decay products of

225

Ac, which generate CLI [21].

Another application of this approach was recently demonstrated. Here, 225Ac-DOTA-c(RGDyK)
was injected into U87mg human glioblastoma xenograft mice and CLI conducted at 24 hours
post-injection, showing probe specificity via a blocking study [23]. As α-emitters continue to be
investigated as radiotherapeutics, imaging strategies such as CLI should prove useful for
dosimetry and radionuclide localization.
Perhaps one of the most ideal settings for optical imaging of ionizing radiation is
endoscopy of radiotracers that emit CL, coined Cerenkov luminescence endoscopy (CLE).
Interference from ambient light is not such a large issue with endoscopic imaging. The
applicability of CLE was shown pre-clinically with [18F]-FDG using an optical fiber bundle
connected to a CCD [24] and later with both

90

Y and

18

F [25], with both studies using

subcutaneous tumor models. CLE was rapidly translated to the clinic for distinguishing and
quantifying cancerous lesions of the GI tract in patients, just three years after the pre-clinical
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studies [15]. Here the clinical radiotracer [18F]-FDG was used and PET/CT positive lesions
corresponded with CLE positive legions; however, the imaging was obtained in a contact mode
with the endoscope in contact with the lesion.
β- and α-emitting radiotracers: Scintillation
While CL is widely used for in vivo optical imaging, scintillation offers another route for
charged particle optical imaging. Here, a material is used that produces optical photons upon
interacting with ionizing radiation. In an endoscopic application, a scintillation balloon was used
to image atherosclerotic plaques in diabetic, hyperlipidemic mice injected with [18F]-FDG [26].
The left common carotid artery was ligated whilst the nonligated right carotid was the control.
Using a scintillating balloon-enabled fiber-optic radionuclide imaging system, the ligated artery
was shown to have increased [18F]-FDG uptake than the control, corresponding with ex vivo
autoradiography. The scintillation balloon system has a resolution of 1.2 µm, thereby
overcoming some of the issues with PET imaging of atherosclerotic plaques such as the small
size of plaques and [18F]-FDG uptake obscuration by adjacent myocardium.
Proton and electron beams
Of increasing interest for radiation therapy are proton and electron beams. At the energies
typically used (keV-MeV), they also produce Cerenkov light. In perhaps one of the most
interesting optical detection examples of ionizing radiation, patients treated with electron beam
radiation in the retina reported seeing visible light during treatment, hypothesized to be CL [27].
In a phase I study, 12 patients undergoing postlumpectomy whole breast irradiation from a
LINAC were imaged in real-time using CL [28]. The authors showed that CLI can be used for
treatment monitoring, patient positioning and motion tracking. In a more recent study, total skin
electron beam therapy for treatment of cutaneous lymphomas was monitored with CLI and
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significantly lower doses were found applied to the legs compared to the torso, indicating a direct
clinical relevance [29].
Proton beams are increasingly used in radiation therapy, and offer unique imaging
opportunities. Because of the MeV energies of the proton beam, nuclear reactions are possible;
for example the positron emitters

15

O and

11

C, are formed during proton beam therapy.

Subsequently, PET/CT or Cerenkov imaging can be conducted on patients to determine dose and
location. PET/CT after proton irradiation was performed on nine patients to image the generated
isotopes, with imaging started within 20 min of proton beam therapy. PET/CT imaging results
showed an average quantitative agreement of 5–30 % between calculated and measured PET
distributions in the space and time domains [30]. Since both

15

O and

11

C are positron emitters

with relatively high energies, both result in appreciable CL emission, which was imaged with
high resolution in proton beam tissue phantoms [31].
4.6 New microscopy opportunities with charged particles
Microscopy offers superior resolution, sensitivity, and co-staining of biomarkers
compared to standard in vivo imaging. For ex vivo radionuclide imaging, autoradiography is
typically used on tissue samples and slices, with the resolution dependent on the energy of the
emitted radiotracer. A new method of ex vivo detection of ionizing radiation was demonstrated
recently, and deemed radioluminescence microscopy (RLM). RLM combines a sample
containing ionizing radiation with a scintillator plate wherein the interactions between the two
result in visible photons, which are imaged using a standard fluorescence microscope. In the first
demonstration of RLM, single cell resolution was demonstrated with live cells cultured on a 100
mm-thin CdWO4 scintillator plate with [18F]-FDG [32]. Following this work, improvements in
signal-to-background through the use of optical reconstruction of the beta-ionization track
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(ORBIT) techniques led to increased sensitivity and resolution with no dependency on the betaparticle energy [33]. RLM hardware improvements were also investigated through the
optimization of the scintillation layer that generates visible light upon ionizing radiation
interactions [34]. Here, a conventional scintillation plate composed of CdWO4 (500 µm
thickness) was compared with a Lu2O3:Eu thin scintillation plate (6-10 µm thickness), with the
latter showing increased sensitivity and resolution in an [18F]-FDG in vitro model. This was
enabled by the thinner Lu2O3:Eu plate having a higher photon yield, and emissions in the greenred region of the visible spectrum where typical charge-coupled devices have greater quantum
efficiency (compared to blue emissions by CdWO4). In a practical demonstration of RLM, 3'deoxy-3'-18F-fluorothymidine (18F-FLT) uptake was imaged in MDA-MB-231 cells grown under
different serum conditions and compared to fluorescence microscopy of 5-ethynyl-2'deoxyuridine (EdU) incorporation in fixed cells, a standard measure of cell proliferation [35].
Under serum deprivation few cells (1 %) incorporated EdU whereas

18

F-FLT uptake was low,

but above background and heterogeneous, with a subset of cells being positive. Under 20%
serum conditions the frequency distribution of 18F-FLT uptake in single cells was bimodal, with
61 % of cells in the 18F-FLT-high subpopulation. RLM allows imaging of radiolabeled molecules
on living cells at a single cell level; this enables examination of individual cellular uptake rather
than average uptake in a whole population.
While the prior examples were completed using in vitro samples, RLM was also used
with ex vivo tissue samples, directly analogous to autoradiography [36]. Here,

89

Zr-rituximab

was used to image human CD20 expression in a huCD20 transgenic mouse model, which
expresses CD20 on B cells. PET imaging of

89

Zr-rituximab showed uptake in the spleen as

expected, and ex vivo RLM and autoradiography both showed 89Zr-rituximab in the red pulp on
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the spleen. A comparison between RLM and conventional storage-phosphor autoradiography
demonstrated that the former has superior sensitivity and resolution, with RLM requiring 80%
less decays for 4X imaging. RLM of

64

Cu-rituximab in vitro showed a binding ranging from

background to 1200 radionuclides per cell, demonstrating the heterogeneity of CD20 expression
in the Ramos cells. RLM’s advantages compared to conventional autoradiography makes it
attractive for applications where sensitivity and resolution are important, such as imaging of
radiolabeled tracers when there is cell heterogeneity and simultaneous imaging of both
fluorescence and RL.
4.7 Current views on ionizing radiation with nanoparticles: The Cerenkov effect
The Physics of Cerenkov Luminescence
Because of the various mechanisms in which high-energy subatomic particles reach an
energetic equilibrium with their surroundings, determining how luminescence is produced from
these interactions was no easy task. Here we limit discussion to beta (β) particles (i.e. electrons
and positrons, the positively-charged antimatter counterpart of the electron) as most Cerenkov
luminescence emitters used in nanoscience originate from β-emitting radionuclides or electron
beams. For a more general consideration of other high-energy particle (e.g. α-particles) and
gamma interactions with matter, readers are recommended a recent comprehensive text [37].
Here, we use the classical description of the Cerenkov mechanism (i.e. treating the electron or
positron as a point charge), which most CL research has been based upon. Notably, recent work
demonstrated that treating the Cerenkov mechanism as a quantum wave packet results in certain
deviations from the classical description, such as spectral cutoffs and discontinuity [38].
Through a series of elegant experiments by Cherenkov it was shown that visible light is
generated when a charged particle travels through a dielectric medium faster than the phase
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velocity of light in that medium [39]. This relationship is described in equation (1), where the
phase velocity (𝑣) of a charged particle must equal or exceed the velocity of light (𝑐) in the
medium, and 𝑛 is the index of refraction. When this relationship is met, Cerenkov light is
produced.
!
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(1)

The photon flux resulting from the Cerenkov mechanism is described by the Frank-Tamm
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the wavelengths of interest (λ1, λ2), the kinetic energy of the charged particle (β), and the index	
  
of refraction (n) through which the charged particle passes, with α=1/137 as the fine structure
constant. The Cerenkov spectrum is continuous in the visible region, decreasing in a 1/λ2
relationship from the UV/blue range through the visible range [40]. In the X-ray region of the
spectrum, the refractive index falls below unity and therefore CL ceases [18]. This UV-weighted
Cerenkov light is seen as a blue glow around nuclear reactors fuel rods, only visible due to the
high levels of radioactivity present.
With increasing refractive index of the traversed matter, the energy necessary to generate
CL (i.e. the Cerenkov threshold) decreases. Subatomic particles emitted during radioactive
decay produce a wide range of energy spectra, with some particles under the Cerenkov threshold
(261 keV for electrons in water) and some exceeding it. With a higher refractive index, there
exists a greater difference in the phase velocity of light and the particle velocity, resulting in
increased photon flux [18]. From the Frank-Tamm equation, a single-charged particle traveling
at c (i.e. β=1) emits 320 photons in the visible spectrum per cm of water [41].
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While the Frank-Tamm equation is accurate for homogeneous solutions, it contains a
number of simplifying assumptions. These include (1) the particle traveling at a constant velocity
(reduced velocity from interaction with the medium isn’t taken into account) (2) a homogenous
medium, and (3) scattering and absorption by the medium having no effect. Typically only
~0.1% of the energy loss by the traveling particle is from Cerenkov radiation; the vast majority
of energy loss results from other interactions such as ionization and excitation of the medium
[42].
Another phenomenon, coined transition radiation by Ginzburg and Frank in 1945, results
in optical and X-ray photon emission (at intensities even lower than CL). Transition radiation
occurs when charged particles travel between material boundaries of differing dielectric
characteristics, emitting photons at the boundary of the media [43]. The intensity of the emitted
photon flux is dependent on the Lorentz factor of the particle (which itself is related to the
relative velocity of the particle), with values quite low for energies lower than 10 MeV, and thus
not considered for the applications presented here [44].
The mechanism of CL involves polarization of the atoms in the traversed medium, with
subsequent relaxation of the induced dipole state and photon emission (Figure 4.3a) [45, 46]. As
the charged particle travels faster than the speed of light in the medium, there is a coherent wave
front of relaxation (Figure 4.3b), known as Huygens’s principle, resulting in emission of
photons. The emitted photons propagate at a forward angle, creating a cone of light, in the
particle's direction of travel (Figure 4.3c). This angle (θ) is dependent on the velocity of the
particle (β) and the refractive index (n(ω)) at a specific frequency and is defined in equation (3).
Through this relationship, determining the Cerenkov cone angle allows calculation of the
charged particles’ energy.
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To summarize, atoms in the medium are polarized by a charged particles’ field, and emit
photons when the polarized atoms return to their original state. If the velocity of the particle is
lower than that of light in the medium, there is no emission of light through the Cerenkov
mechanism. Higher particle velocities and refractive indices of the medium result in more
photons emitted, with the Cerenkov light UV-weighted.

Figure 4.3. The Cerenkov mechanism for blue-weighted luminescence. a, A charged particle
traveling faster than light in a medium polarizes the medium (top). As the medium returns to its’
ground state, blue-weighted light is emitted in a forward direction (bottom). b, Analogous to a
sonic boom, coherent waves are produced through the Cerenkov mechanism, leading to a
photonic wave front. c, Cerenkov light is emitted by the medium in which a charged particle
travels. The conical angle of polarized Cerenkov light is dependent on the velocity of the charged
particle.
Cerenkov imaging using clinical agents
Most of the experimental Cerenkov applications until the turn of the 21st century
consisted of detection of cosmic particles such as neutrinos [47] or particle velocity calculations
using the angle of emitted Cerenkov light. The mid-twentieth century brought the discovery of
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both the antiproton and heavy particle J, aided by unique Cerenkov characteristics [48, 49].
Whilst CL has long been utilized in particle physics, the application of the Cerenkov
phenomenon was recognized in biomedical research only in 2009. Robertson et al. first observed
CL originating from an animal injected with a clinical radiotracer and designated the technique
Cerenkov Luminescence Imaging (CLI) [50]. Following this demonstration of the feasibility of
imaging CL with pre-clinical optical imaging instruments, the Cerenkov characteristics of
numerous medical radionuclides were investigated [13, 51, 52]. The blue-weighted CL was
directly used to image biological targets using small molecules [53] and antibodies [21]. CL
therefore allows for the optical imaging of clinical radiotracers, providing a unique multimodal
system where the same agent is detectable with two independent modalities. This offers several
advantages and compliments to traditional nuclear imaging: (1) The use of optical cameras is
much more cost-effective than expensive nuclear imaging instruments, (2) Imaging times are
typically much shorter, and (3) several subjects can typically be imaged in parallel pre-clinically.
Some radionuclides that are typically quite difficult to image in vivo (such as the β- emitter 90Y)
may be quantitatively imaged using CL[19]. CL may also be used for surgical intra-operative
imaging, allowing one probe for both whole-body imaging and surgical guidance [54]. Indeed,
endoscopy has recently been demonstrated both pre-clinically [55] and clinically [15], showing
how rapid clinical translation can occur when imaging CL emanating from clinically-approved
agents. Besides the opportunity of using clinical radiotracers for optical imaging, CL also offers
opportunities to implement unique imaging and therapeutic systems in combination with
nanoparticles.
While CL has already been used for non-invasive imaging in patients [16, 17] and
extensively in pre-clinical models using clinically available radiotracers, the field had to
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overcome various challenges. The first is the spectrum of CL, with the highest intensity in the
UV region and rapidly decreasing at longer wavelengths. As tissue absorption and scattering is
highest at shorter wavelengths, detection of CL deeper than a few centimeters is very difficult.
Another major challenge is the low level of CL (ca. a billion times less than ambient light) [56].
This very low photon flux means that ambient light needs to be blocked and long acquisition
times of several minutes are required to obtain acceptable signal to background. In a clinical
setting, patient movement during long acquisition times could result in image degradation.
Pairing nanoparticles and CL in life sciences
The UV weighted spectrum of CL has found an ideal partner in nanoparticles, namely in
secondary Cerenkov emission fluorescence imaging (SCIFI) [57], also known as Cerenkov
radiation energy transfer (CRET) [58]. Here, UV-weighted CL is generated during decay of a
radionuclide, which subsequently interacts with a nanoparticle, commonly one that exhibits
photoluminescence resulting in the emission of longer-wavelength photons (Figure 4.4). Due to
their excitation by blue light, high quantum yield, and large Stokes shifts, quantum dots are
optimal for pairing with Cerenkov emitters. Combining QDs with Cerenkov emitters results in a
significant red-shift of the original CL signal, which allows for better in vivo imaging due to the
superior tissue penetration of that part of the spectrum [59]. CRET or SCIFI also forfeits the
need for external excitation light as the excitation originates internally from the injected
radiotracer, reducing autofluorescence of tissue and improving signal to background ratios. This
in turns allows superior signal depth penetration and sensitivity when compared to standard
fluorescence imaging [57]; therefore this approach has been explored extensively. These
nanoparticle-Cerenkov systems can be broadly grouped into three categories: Cerenkov emitters
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separate from nanoparticles, emitters bound to the nanoparticle surface, and emitters
incorporated into the nanoparticle lattice (Figure 4.5).

Figure 4.4. CL offers new in vivo imaging opportunities through combination with
nanoparticles. The three signals obtained from a CL-fluorescent nanoparticle (e.g. quantum dot)
system: the blue CL, the red-shifted fluorescence and the PET signal, serving as internal standard
for quantification, making this a unique, truly multimodal quantitative system. High-energy
electron-nanoparticle systems result in blue CL and red-shifted fluorescence only.

Figure 4.5. Three types of Cerenkov light-NP interactions: Unbound Cerenkov emitters (left),
surface-bound Cerenkov emitters (center), and intrinsically self-illuminating crystals (right).
Unbound Cerenkov emitters offer ease of translation through the possibility of using clinical
radiotracers such as [18F]-FDG, but require co-location in space and time in vivo. Surface-bound
Cerenkov emitters do not have the co-location limitation, but may result in possibly undesired
signal from nonspecific distribution of the radiolabeled nanoparticle. Intrinsically selfilluminating particles offer superior in vivo stability, but are the choice of nanoparticleradionuclide system is limited by the possibility of lattice mismatch between the radionuclide
and the nanoparticle elements.
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Unbound Cerenkov emitters
Early work combining nanoparticles and Cerenkov emitters utilized the widespread
clinical PET radiotracer [18F]-FDG together with quantum dots. The Cerenkov spectrum of [18F]FDG alone showed the characteristic 1/λ2 spectrum, whereas quantum dots mixed with [18F]FDG showed a decrease in the UV region and a peak in the red region, corresponding to the
expected shift [58]. This peak resided once the [18F]-FDG decayed. Liu et al. expanded this
concept to investigate three CdSe/ZnS core/shell QDs (QD655, QD705, and QD800) with the βtracer

131

I, both in vitro and in vivo. The QD/131I solutions exhibited much higher optical

intensities in vivo than

131

I alone due to the red-shifted spectrum demonstrating the utility of

CRET or SCIFI to modulate the CL into light that is more penetrating through tissues. The QDs
allowed multiplexed optical imaging due to the separate emission peaks of each QD [59].
In an interesting expansion on the concept of SCIFI, Hu et al. demonstrated that
europium oxide nanoparticles (EO) could be excited by interactions between radionuclides and
EO. These interactions involve not only visible photons from the Cerenkov mechanism in an
aqueous solution of [18F]-FDG but also gamma-ray photons such as the 511keV photons from
positron annihilation originating from

18

F or 140keV photons from

99m

Tc [60]. The authors

coined this technique radiopharmaceutical-excited fluorescence imaging (REFI), which operates
via a similar mechanism as previous work with dual-excited, rare-earth microparticles (REMPs)
[61]. Through excitation by both mechanisms, the depth of imaging in tissue phantoms and in
vivo was shown to be superior compared to only CL. In a similar study, barium-yttrium-fluoride
nanoparticles were doped with either europium or terbium and exhibited similar properties [62].
As these nanoparticles utilize both gamma and Cerenkov photons for a greater optical signal

	
  

108	
  

	
  
intensity and depth penetration, the combination of radiotracers and rare-earth NP for in vivo
optical imaging is an area ripe for further investigation.
Surface-bound Cerenkov emitters
While pairing clinical radiotracers with nanoparticles is attractive due to availability and
easier clinical translation, both entities (nanoparticle and radionuclide) need to co-localize to
obtain the desired effect. While this is easily accomplished in vitro, it presents a challenge for in
vivo applications. As tissue absorbs much of the UV-weighted Cerenkov light, and typical
Cerenkov thresholds for

18

F are only met for less than a millimeter distance travelled by the

positron prior to annihilation [13], appreciable tumour uptake of both probes is necessary to see
the desired wavelength shift. To circumvent this, radiotracers can be attached directly to the
surface of the nanoparticle, which are capable of high cargo loads. This concept abrogates the
somewhat disadvantageous necessity of co-localization of the particle and the radiotracer in vivo
at the same point in time and space but also results in possibly undesired signal from nonspecific
distribution. To this end, a variety of nanoparticles have been developed, all carrying their own
radionuclide as an internal excitation beacon. Typical methods of radiotracer attachment include
a chelator or prosthetic group attached to a nanoparticle surface coating [63], liposomes or
micelles that contain both nanoparticles and the radiotracer [64, 65], and up-converting
porphyrin-phospholipid coated inorganic nanoparticles [66]. Recent work has optimized
radiometal attachment to nanoparticles without the need for surface modification with a chelator
or prosthetic group [67]. A variety of particles including amorphous silica nanoparticles [68, 69]
and iron oxide nanoparticles (IONP) [70] have been radiolabeled with multiple radiotracers in
this way.

	
  

109	
  

	
  
Demonstrating this principle, superparamagnetic iron oxide nanoparticles were
radiolabeled with the PET tracer

68

Ga for triple-modal (PET/MR/CLI) sentinel lymph node

imaging. With the high Cerenkov intensity of

68

Ga due to its’ high β+ energy, Cerenkov

luminescent-guided resection could be possible [71]. Liposomes have also been radiolabeled
with the PET tracer

124

I (t1/2 = 4.2d) for dual-modal CLI and PET imaging, allowing later

imaging time points [64]. As liposomes such as Doxil and Caelyx are already FDA approved for
drug delivery, using liposomes for imaging is attractive for clinical translation [72].
An interesting hybrid system of microspheres that contained a high refractive index liquid
(RI=1.54) and quantum dots was recently developed [73]. Quantum dots were loaded together
with wintergreen oil and the PET tracer

64

Cu into microspheres. This approach allowed for an

increase in Cerenkov signal intensity in tissue phantoms compared to free activity due to the
better penetrating red-shifted spectrum of CRET/SCIFI and also to some effect the increased the
higher RI of the oil within the liposome. However, this phenomenon is concentration-dependent,
and therefore such increases are unlikely to be seen in vivo due to a much greater distance
between the particles compared to a well plate. Additionally, the particles had a 1,500 nm
diameter, which would preclude most in vivo uses, as would injection of Wintergreen oil into
patients. While recent advances in intrinsically radiolabeled nanoparticles have allowed greater
in vivo stability, the main method of attachment of radionuclides to nanoparticles is still via
chelators or prosthetic groups. This can result in detachment of the radiotracer from the
nanoparticle, which both precludes nanoparticle interaction with CL but also may result in offtarget ionizing radiation and misleading images. Currently in the clinic, radiolabeled nano- and
microparticles are used for sentinel lymph node imaging, with 99mTc colloids the most ubiquitous
radiotracer. As 99mTc-colloids do not emit CL, the development of a CL-emitting nanoparticle for
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routine clinical use would expand lymph node imaging from nuclear to multimodal (i.e. nuclear
and optical), aiding in surgical resection.
Intrinsically self-illuminating nanocrystals
As a further step in refinement, radionuclides can also be incorporated directly into the
crystalline structure of a nanoparticle. This can be done by methods such as addition of the
desired radiotracer during nanoparticle synthesis or ionic exchange, where a radionuclide
exchanges with its cold elemental counterpart [67]. An interesting alternative to this
radiolabeling route is using a cyclotron beam for intrinsically radiolabeled nanoparticles [74].
However, due to the necessity of an onsite cyclotron this route is impractical for most locations.
An advantage to this intrinsic radiolabeling route is increased stability, especially in vivo, along
with the possibility of very high specific activity concentrated within the nanoparticles, resulting
in a high CL flux. One potential downside of this approach is the possibility of crystalline
mismatch if the radioactive element greatly differs from the element that makes up the rest of the
particle’s lattice, resulting in radionuclide detachment. Examples of radio-doped lattices are rare
earth fluorine nanocrystals [75] as well as gold [76], iron oxide [70], and copper nanoparticles
[77]. Avoiding issues of crystalline mismatch, fluorescent gold nanoparticles have been doped
with 198Au, allowing both nuclear and optical imaging with the same nanoparticle [78]. 198Au is a
SPECT tracer that also emits a high-energy β-, allowing for both whole-body imaging and
therapeutic use. Due to its relatively high energy (βmax = 0.961MeV), the β- emission also results
in appreciable CL. By incorporating 198Au directly into the gold lattice, the radionuclide remains
stable in vivo; additionally, the incorporation did not require surface modification (as when a
chelator is used). However, the authors did not use the CL as an excitation source for the
nanoparticle itself. A similar radiolabeling technique was utilized to radiolabel gold nanospheres,
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rods, disks, and cages with

198

Au. By incorporating the radionuclide into the lattice, each

nanostructure’s biodistribution could be evaluated in vivo, using CLI and SPECT imaging
without surface modification. The pharmacokinetics as well as the tumour distribution of the
variously shaped gold nanoparticles were evaluated using CLI and showed heterogeneous
regional uptake in the tumour dependent on the particle shape [76].
Copper-64 is another metal that often used for lattice doping due to its amenable half-life
(t1/2 = 12.7h) and facile lattice incorporation. Gold nanoclusters were labeled with 64Cu through
reduction with hydrazine and incorporation into the nanoparticle lattice rather than the protein
coating of these clusters. These gold nanoclusters were shown to be stable in vivo and allowed
both PET and Cerenkov imaging out to 24 hours post-injection [79]. In another demonstration of
CL with quantum dots,

64

Cu was doped into CdSe/ZnS quantum dots via ion exchange for

PET/SCIFI [80], and has also been directly incorporated into CuInS/ZnS quantum dots,
alleviating any potential crystalline mismatch issues [81]. When surface-coated with
polyethylene glycol (PEGylated), the CuInS/ZnS quantum dots showed optimal radiochemical
stability in vivo and tumour uptake as high as 10.8% injected dose per gram (%ID/g). While
quantum dots are a popular choice for SCIFI, relatively few studies use lattice doping with
radioactivity for labeling. This is likely due to crystalline mismatching, the necessity of surface
modification prior to in vivo use, and increased radioactive waste using this method. However,
CL nanocrystals would be attractive for clinical uses due to their high stability and multimodal
nature. By developing methods that eliminate post-radiolabeling modification and thereby
making GMP feasible, CL nanocrystals have a greater chance to reach the clinic, e.g. for facile
imaging and detection of sentinel lymph nodes in oncologic surgery.
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Cerenkov-activatable diagnostic probes
While shifting Cerenkov’s spectrum with nanoparticles provides distinct advantages for
in vivo imaging, the systems thus far described emit signal regardless of their biological context,
i.e. they are “always on”. This is the typical state of radiotracers that emit a high-energy decay
signal, i.e. the 511 keV annihilation photons from positron annihilation, which cannot be
modulated. Therefore, activatable “smart” imaging systems using radiotracers were until recently
not possible. However, Cerenkov offers the unique opportunity to modulate a radioactive decay
signal, the Cerenkov luminescence, for the first time. By using appropriately designed
nanosensors, modulation of the signal through spectral shifting, absorption, or direct
photoactivation by Cerenkov luminescence has become possible, leading to a new class of smart,
functional nanoparticles.
Though not a nanoparticle, in a first proof of concept, CL was used to photoactivate
caged luciferin in a breast cancer animal model expressing luciferase [82]. This technique
demonstrated the advantage of internal excitation of a fluorophore in the interior of a tumour,
where external light sources may not reach. Here a bioluminescence signal was only obtained
when CL was present. A nanosensor system modulated CL through quenching via a direct
energy transfer between a radiometal and quantum dots [63]. A distance-dependent quenching
effect was shown using varying lengths of DNA conjugated with the copper chelator DOTA. The
copper-DNA contructs were shown to quench quantum dots via either a photoinduced electrontransfer process or energy transfer (or a combination of both) that was dependent on the distance.
This has allowed activatable imaging agents where displacement of a DNA strand with the
Cerenkov emitter bound to a QD could “turn on” QD emission.
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While Cerenkov light is typically used to excite fluorophores, it was demonstrated that
the absorption curve of iron oxide nanoparticles overlays the CL spectrum almost perfectly,
which makes the nanoparticles ideally suited to absorb the Cerenkov emission, decreasing signal
and resulting in negative CL contrast [83]. Thorek et al. demonstrated this concept in vivo with
nanoparticles targeting the human somatostatin receptor subtype-2 (hSSTr2). Dual tumourbearing mice with one tumour expressing hSSTr2 and one tumour not expressing the biomarker
were first injected with hSSTr2-targeted nanoparticles. This was followed by injection of [18F]FDG with PET and CL imaging. hSSTr2-positive tumours had a decrease in CL due to
nanoparticle quenching, whereas tumours absent of hSSTr2 showed no change in CL.
Nanoparticles therefore provide, for the first time, the opportunity to modulate a radiation-based
decay signal in different ways through its Cerenkov signature. Using this technique,
multiparameter non-invasive tumour marker imaging is possible.
In another activatable system, nanoparticles were utilized to create a Cerenkov-excited
smart nanoconstruct that was switched on by enzymatic activity in vivo. Here, gold nanoparticles
were used to quench a fluorochrome (FITC) through resonance transfer. The fluorochrome’s
Cerenkov-mediated excitation only became available after its enzyme-mediated release from the
gold nanoparticle thus recovering the Cerenkov-excited fluorescence and indicating enzymatic
activity in vivo. Through this method, matrix metallopeptidase-2 (MMP-2) enzyme activity,
implicated in tumour aggressivness, was not only imaged in vivo with lower background
compared to traditional optical techniques but was also quantifiable directly, using a combination
of optical and PET imaging [57]. The quantitative PET signal provides an internal standard for
Cerenkov imaging that allows the determination of the expected light output.

	
  

114	
  

	
  
Cerenkov activatable therapeutic nanoprobes
The use of a common diagnostic clinical radiotracer (e.g. [18F]-FDG) with nanoparticles
could allow therapeutic opportunities during routine PET imaging. Here, CL can also be used
with photon-activatable therapeutic entities. Similar to internal activation of fluorescent agents,
CL has recently been used together with nanoparticles to overcome the current depth limitation
of light-activated therapy. Kotagiri et al. combined PDT agent-nanoparticle constructs with
positron emitters for Cerenkov radiation-induced therapy, or CRIT. CL from [18F]-FDG
activated radical formation from titanium dioxide (TiO2) nanoparticles doped with an additional
photosensitizer, titanocene (Tc) in both aerobic and anaerobic environments. The nanoparticles,
termed nanophotosensitizers, were targeted to tumours via transferrin attached to the surface, and
the PDT from the combination of TiO2 and [18F]-FDG showed a significant survival benefit
compared to either of the agents alone. This work utilized the internal CL to photoactivate the
nanoconstruct for oxidation-based therapy, for the first time liberating photodynamic therapy
from the need of an external excitation source, similar to the internal excitation of fluorochromes
[84]. This approach is attractive due to the utilization of photodynamic therapeutics with clinical
radiotracers already in routine use and would allow expansion of photodynamic therapy to
multimetastatic disease where a targeted radiotracer provides the internal excitation for the
photoactivatable therapeutic agent. The low intensity of CL is still a current limitation, requiring
highly energetic particles or high activity levels.

Maximizing the optical gain from a

radionuclide is an important aim of future CL work.
4.8 Mechanisms of ionizing radiation interactions with nanoparticles
When Cerenkov emitters are combined with NP and imaged in pre-clinical optical
imaging instruments, an increase in optical photon signal compared to the radionuclide alone is
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sometimes observed. This is often attributed to the NP exhibiting photoluminescence [81],
absorbing the blue-weighted Cerenkov light and emitting in longer-wavelength regions. These
perceived increases in luminescence in pre-clinical optical instruments are often explained
through the nonlinear spectrum efficiency of detectors, which are less efficient in the blue than
the green-red spectrum. However, other mechanisms considerably contribute to the production of
visible and high-energy photons that are considered here.
One such mechanism is low-level blue photon emission from the excitation and
ionization of H2O (or similar medium) that the radionuclide is in. This phenomenon, sometimes
referred to as chemiluminescence, has long been known in the nuclear chemistry field[3, 85], and
has gained renewed interest through the possibility of visible photon imaging with the SPECT
tracer

99m

Tc[86] and proton beams[87]. When combined with photo luminescent NPs, the blue

photons are absorbed by NP which emits in the green-red region. Another consideration needs to
be considered if the γ-photon has energies of >220kev, as it is possible for ejected electrons from
the medium to emit electrons energetic enough to cause CL in tissue (i.e. >220keV). However,
most medical radiotracers do not emit these high γ levels, and even relatively high-energy γ
emitters such as cobalt-60 (>1.1Mev) have Cerenkov emissions from secondary electrons that
are considerably lower than chemiluminescence[3].
A second mechanism is the interaction of IR with the NP itself, and referred to as β or γ
scintillation. While γ scintillation[61, 62] and beta scintillation[88] has been considered with rare
earth NP, β excitation is often overlooked in other NP systems and in molecular imaging
research. Here we investigate this mechanism and show its’ relevance for a variety of NP used in
vivo.
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Experimental considerations
Two recent studies have investigated scintillation of europium oxide nanoparticles (EO)
and gold nanoclusters, respectively. However, the experimental setup for these types of
experiments are quite difficult. One study was conducted as shown in Figure 4.6. Here,
Eppendorf tubes with

18

F or

99m

Tc (positron and gamma emitters, respectively) were placed

10mm from Eppendorf tubes filled with EO. As seen in Figure 4.7, the maximum positron range
of 18F is < 2mm in water and plastic. As the Eppendorf tube is 1mm thick and the length of water
each positron passes through on average >1mm, the vast majority of 18F positrons do not leave
the plastic. Therefore, the experimental setup as shown in Figures 4.6 and 4.7 cannot take into
account positron (and electron) scintillation. Another method is needed for these lower energy β
emitters.

Figure 4.6. Interactions between 18F and 99mTc decay daughters and europium oxide
nanoparticles that result in visible photon output. a, 18F with EO 10mm apart, and b, 99mTc with
EO 10mm apart. Row 1 has nothing between the two tubes, Row 2 has the radioactive tube
covered with black paper, Row 3 has an aluminum sheet to block positrons only, Row 4 has lead
blocking all interactions, and Row 5 has nothing. The visible photon flux of a and b are
quantified in c and d, respectively. From reference [60].
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Figure 4.7. A schematic of the experiment shown in Figure 4.6. A) The 10 mm distance
between the Eppendorf tubes is shown. B) For 18F and other low-energy positrons and electrons,
the maximum range is less than 2mm in water and plastic. Therefore, this experimental setup
does not allow interactions between positrons (and electrons) and EO.
With gold nanoclusters, the radionuclide

18

F was added directly into a well plate with

gold nanoclusters. This addresses the issue of positron range seen in the previous example, as the
solutions are mixed together. The authors stated that β scintillation was demonstrated because
there was an increase in photon flux when using an open filter on the IVIS instrument. However,
as seen in Figure 4.8, this is not a valid claim. The authors compared photon flux of the
radionuclide alone (Figure 4.8A) with radionuclide mixed with the gold nanoclusters (Figure
4.8B) and saw an increase. However, as seen in Figure 4.8C and discussed in the previous
sections, CL is blue-weighted. This is where the IVIS has the least efficiency, below 20 % under
350 nm (Figure 4.8D). Therefore, if a photoluminescent nanoparticle is placed with CL emitter,
the increase in photon flux with an open filter could very well be due to the photoluminescent
NP absorbing blue light (where the IVIS has low efficiency) and emitting in the green-red
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(where the IVIS has high efficiency). The IVIS only has calibrated filters between 500-840 nm,
so this approach unfortunately will not show if a particle is a scintillator.

A$ 1.0X$photon$ﬂux$

B$

C$

D$

Cerenkov$Spectrum$

1.5X$photon$ﬂux$

IVIS$quantum$eﬃciency$

Figure 4.8. Experimental setup used to show scintillation of NP with radionuclides that result in
Cerenkov luminescence. A) Blue-weighted CL is given off by interactions between decay
daughters of radionuclides and the medium. B) When a photoluminescent NP is placed with a
CL emitter, it typically absorbs CL and emits in the green-red region. C) The Cerenkov spectrum
for 68Ga is shown, with other radionuclides demonstrating the same pattern. D) The IVIS
spectrum quantum efficiency, most efficient in the green-red, least efficient <400 nm and >850
nm. C is from reference [40], D from reference [89].
To address this issue of β range and IVIS efficiency, we determined that using nonCerenkov emitters mixed with NP would be the optimal protocol for determining γ and β
scintillation, as shown in Figure 4.9. Thankfully, there are two common radionuclides that meet
these criteria. For determination of γ scintillation of NP,

99m

Tc can be mixed with NP and the

IVIS image taken. For β scintillation, various pure β emitters exist, although some of them have
βmax over the CL threshold of 261 kev (in H2O). 35S has a βmax of 167 keV, well below the CL
threshold but still with high enough energy to cause appreciable scintillation if present. This is
important from a practical point of view, as very low energy pure β emitters such as 3H may not
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cause enough excitation of scintillating NP to be detected with the IVIS system, or large amounts
of radioactivity would be necessary. Therefore, for experiments to determine if the library of NP
were scintillators,

99m

Tc and

35

S were first used. Table 4.1 shows the NP tested based on use

with radionuclides and previous literature on NP scintillators.

A"

B"

β"#

β"#

C"

D"

γ#

γ#

Figure 4.9. Experimental scheme. A) Shows the control β- radionuclide in H2O, which emits
negligible visible light. B) Shows the same radionuclide mixed with a scintillating NP, resulting
in visible light output. C) Shows a control γ emitter in H2O, whereas D) shows the same γ
emitter incubated with a γ scintillator. This setup avoids the pitfalls of previous methods.
Nanoparticle
SNP (SiO2)
Ge
TiO2 (Anatase)
HfO2
Eu2O3
Gd2O3
YAG:Ce

Table 4.1. Size, Absorbance, NP Characterization Table
DLS (nm)
Absorbance
Kedge
Vendor
(500nm)
Theory
(keV)
142.1±7.4
1.85
Synthesized
50.5±22.7
11.11
American Elements
385.6±100
0.1289
4.98
American Elements
23.7±0.8
0.0913
65.35
American Elements
59.4±3.7
0.3454
48.52
Sigma-Aldrich
38.3±13.1
0.2595
50.25
Sigma-Aldrich
23.9±0.7
0.051
40.45
Nanostructured &
Amorphous
Materials Inc.

4.9 Pure γ and β emitters with nanoparticles
Addition of 30 µCi of

99m

Tc to the NPs produced a 30-40-fold increase in radiance with

HfO2 and Eu2O3 respectively (Figure 4.10C). Alternatively gamma excitation of the NPs from
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positron annihilation was also assessed for each radionuclide but lower radiance enhancements
were seen compared to direct addition of

99m

Tc. Previous work has suggested CL and gamma

radiation as the main sources of excitation [60]. As shown in Figure 4.10, gamma excitation and
CL interactions with Eu2O3 do contribute to total photon flux. However, modeling the rootmeans-square displacement of 18F and 90Y in water was found to be on the order of 0.25 and 1.5
mm respectively [13] implying that cuvette and separated well plate experiments to isolate β
particle contributions underrepresent the direct interaction of the beta particle to the NP.
To account for the pure β interaction with the NPs, the pure β emitters 35S and 3H were
added to wells containing Eu2O3. As seen in Figure 4.10D, 35S as well as 3H yielded enhanced
radiances above NP background as well as the representative activity in H2O.

35

S radiances for

SNP, TiO2 (anatase), HfO2, Eu2O3, Gd2O3, and YAG:Ce represent enhancements of 2, 39, 58,
2750, 1390, and 690 times that of H2O. Importantly, In a comparison to the clinical radiotracer
18

F,

35

S radiances of HfO2, Eu2O3, Gd2O3 and YAG:Ce represent 0.1, 6, 3 and 1.5 times

radiance in H2O respectively at 30 µCi.

18

F

While the NPs do have a high refractive index,

potentially allowing some CL to be generated, the radiance increase observed is unlikely to be
determined by CL as less than 15 % of the 35S β particle energy spectrum has sufficient velocity
for CL in Eu2O3. In addition the low volume occupancy of these NPs (<1 %) make the CL
mechanism more unlikely to be the main contributor and given that TiO2 phases have high
refractive indices yet produce less light than Eu2O3 suggest other mechanisms the CL are
contributing to total radiance. 3H (βmax = 18 keV) cannot produce CL with any of the NPs tested;
however enhanced radiance was seen for Eu2O3 and Gd2O3 upon addition of radioactivity.
To further investigate possible mechanisms of optical photon production, luminescence
spectra was collected for each of the NP with radioactivity from 500-840 nm (20 nm filter
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widths). IVIS spectra of Gd2O3 and Eu2O3 were found to produce distinct visible emission peaks
characteristic of Eu3+ (620 and 700 nm) and Gd3+ f-f transitions [90] while other NPs such as
HfO2 and YAG:Ce did not produce any distinct emission peaks in the 500-840 nm window, but
rather broad light emission. The emission peak for HfO2 at 495 nm is just below the IVIS filter
range and as such could not be fully resolved with the factory installed filters[91]. YAG:Ce has a
photoluminescence peak at 540-560 nm [92] but is weak compared to Gd2O3 and Eu2O3.

Figure 4.10. a, IVIS reported radiance of NPs tested with positron emitters [18F]-FDG and 68Ga
at 30 µCi per well. Particles without activity included as a reference. b, Radiance of NPs with
high energy electrons 177Lu and 90Y. c, Addition of pure gamma emitter 99mTc also contributes to
increased radiance with several NPs tested. d, Addition of pure beta emitting 3H and 35S with sub
CL energy (in H2O) also result in enhanced radiance on IVIS. Corresponding well plate images
for 3H and NPs.
4.10 Clinical radionuclides and nanoparticles
Recently molecular imaging research has widened to include CL using radionuclides that
emit particles with relativistic velocity. Common radionuclides for CL include positron (18F,
68

	
  

Ga), high-energy electron (177Lu,

90

Y) as outlined in Table 4.2 while pure gamma emitters

122	
  

	
  
(99mTc) represent non-CL ionization. CL radiance depends on the refractive index and the
velocity of the charged decay particle as defined in the Frank-Tamm formula (Equation 2). As
β decay is accompanied by the ejection of a neutrino, the energy of β emission from a
radionuclide is an energy spectrum rather than a discrete energy. As the β spectrum energies
range from 0 to the β max, portions of their energy spectrums are below the Cerenkov threshold.
Radionuclides with greater portions of their energy above the CL threshold yield higher CL
radiances in H2O. While the Frank-Tamm equation (1) correlates refractive index (n) of the
medium with radiance [50] only recently has a heterogeneous medium been tested with
microparticles filled with high refractive index wintergreen oil and quantum dots [70]. Physics
research has focused on novel scintillating materials for increased sensitivity of Cerenkov
detectors [93]. Here we leverage various scintillating nanomaterials that can be used with any
radionuclide to produce light in the visible region.
Table 4.2. Radionuclides used with corresponding decay mechanisms and energies.
In vivo
β energy
γ energy
Radionuclide
β decay
γ decay
imaging
(average)
(average)
modality
3
H
β5.68
35
S
β48.76
177
Lu
β149.35
γ
208
SPECT, CL
32
P
β
695.03
18
+ +
F
εβ
249.8
γ±
PET, CL
89
Zr
ε+β+
395.5
γ±
909
PET, CL
68
+ +
Ga
εβ
836.02
γ, γ±
1077
PET, CL
90
Y
β933.7
γ
1761
CL
99m
Tc
γ
140
SPECT
Information populated from the Nuclear Science References database [94]. γ± denotes positron
511 keV photons upon annihilation.
As the aim is to investigate interactions between types of ionizing radiation and NP for
optical imaging, we stratified our experiments by the type of radiation emitted (electrons,
positrons, and high-energy photons) against an array of NPs. As the clinical radionuclides chosen
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contain multiple high-energy modes of photon emission (such as γ emission and 511 keV
photons from positron annihilation), we explored the contribution of pure gamma emitting
radionuclide

99m

Tc (γ = 140 keV), alongside pure beta minus emitting radionuclides 35S (βmax =

167 keV) and 3H (βmax = 18.6 keV).

35

S and 3H were chosen as their βmax are below the CL

threshold of H2O (261 keV), allowing investigations of β interactions without the complicating
factor of Cerenkov luminescence. Both β and CL interactions were examined with

32

P (βmax =

1709 keV). Lastly, β, CL, and γ interactions were investigated with 18F, 68Ga, 177Lu and 90Y (βmax
= 2280 keV).
NP were prepared at a fixed concentration of 1x 1012 NPs per mL and characterized for
size, charge and absorbance for each NP type. The radiance of the CL radionuclides used trends
with the average energy of the ejected particle. We next addressed whether the addition of
commonly used NPs such as SNP, and TiO2, as well as transition metal and rare earth NP such as
HfO2, Eu2O3, Gd2O3, and YAG:Ce to clinical radionuclides would further enhance the radiance
of the radionuclide in H2O. Figure 4.10A-B show the radiance enhancement for high-energy
electrons, 90Y and 177Lu, and positron emitting [18F]-FDG and 68Ga respectively. In both panels,
the addition of 30 µCi to each of the NPs tested yielded higher radiance values than the
radionuclide in H2O and the NP without activity in solution. Of the NPs tested, Eu2O3 and
Gd2O3 exhibited the largest enhancement in radiance compared to an identical concentration of
the radionuclide in water. Enhancements using 30 µCi of

177

Lu, [18F]-FDG,

68

Ga and

90

Y in

Eu2O3 were found to be 180, 27, 5.7 and 5.2 times that of H2O respectively. Enhancements were
greater for lower energy radionuclides given the lower radiance of the radionuclide in H2O.
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Figure 4.11. Spectra of NPs on IVIS a) and b) with 30 µCi [18F]-FDG per well n=3 wells. c)
Characteristic X-Ray spectra with pure β- emitter 32P showing qualitative abundance and
increasing Kα and Kβ energy with increasing atomic number, Z. x5 inset for YAG:Ce represents
the detection of cerium dopant characteristic X-rays. d) Identical characteristic X-rays generated
using 99mTc.
4.11 New views on ionizing radiation interactions with nanoparticles
There are numerous mechanisms by which β particles can distribute their energy to an
environment that subsequently leads to visible photon generation. As β particles quantitatively
are the main product from nuclear decay of the radionuclides in Table 4.2 (except

99m

Tc), it is

surprising that these particle interactions have not been considered more beyond CL when
combining nanoparticles and radiotracers for imaging.

Possible mechanisms of β particle

interactions that can produce photons outside of CL include excitation, ionization,
bremsstrahlung, and transition radiation as depicted section 4.3. Water (H2O), with an atomic
number of 8 for oxygen represents lowest and most abundant atomic number of the atoms in a
human, while particles with Si+4, Ti+4, Ge+4, Eu+3, and Hf+4 have increasing atomic numbers of
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14, 22, 32, 63 and 72 respectively. β energy loss according to the Bethe-Bloch equation depends
on the material density and square of the atomic number, such that HfO2 and Eu2O3 represent the
highest beta energy loss particles of the group. Beta energy loss between positrons and electrons
according to the Bethe-Bloch equation are equivalent, however more recent work by Kim shows
significant deviations below 10 MeV energies for energy losses and bremsstrahlung from a high
speed electron or positron [95].
The fraction of beta energy converted to bremsstrahlung increases with atomic number
and radionuclide energy; thus 3H is expected to contribute a lower percentage of the total decay
energy to bremsstrahlung for EONP compared to

90

Y. Bremsstrahlung occurs when a charged

particle changes momentum through attraction or repulsion with the nucleus. This is distinct
from ionization mechanisms and the L shell electron. Bremsstrahlung is predominantly generated
by β- and β+ particles given their high velocity and their relative mass to an electron (compared
to a proton). Previous reports have shown that bremsstrahlung can be imaged on a gamma
camera [96, 97], and recently with the aid of a phosphor screen optical images of bremsstrahlung
could be resolved, though of low resolution [98]. Here the direct ionization of high atomic
number elements enables a focused emission superior to bremsstrahlung imaging with inherent
capability for multiplexing provided the detection crystal is of sufficient resolution.
Gamma interactions highlighted include the photoelectric effect, when energy is
transferred between a high-energy photon to an electron, and Compton scattering, when a highenergy photon ejects an electron from the interacting atom. The photoelectric effect dominates
below 100 keV but also under higher energies provided the target atom has a higher atomic
number. As the energy range of radionuclides tested emit energy primarily below 1 MeV and the
NPs tested exceed an atomic number of 20, the majority of the high energy photon interactions
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are expected to be due to the photoelectric or Compton effect and not pair production. Recently
Stanton reported in a europium doped Y2O3 NP that X-ray scintillation governed by the
photoelectric effect produced higher photon intensity in the 500-700 nm region than a
comparable radiation dose at higher energy where the Compton effect regulated scintillation
[99]. For characteristic X-rays that are below 100 keV, the photoelectric effect should be the
main mechanism by which these X-rays interact in the surrounding medium.
4.12 Conclusions and outlook
With increased energy sensitivity of radiation detectors, beyond NaI, we hope to be able
to resolve smaller keV differences allowing SPECT imaging and identification of radiolabeled
NPs. For now identification of NPs simply by the presence of characteristic X-rays represents a
new way to image NPs that does not directly require radiolabeling of the NP. An additional
consideration in PET imaging reconstruction is the stopping power for a positron is strongly
dependent on the atomic number of surrounding matter whereby higher atomic numbered atoms
lead to shorter positron ranges. Using a tandem SPECT-PET configuration could allow
tomographic correction for PET reconstruction.
Combining radionuclide and NPs for in vivo use is popular because of the high specific
activity, payload and multimodal possibilities such a system allows. The visible light emanating
from beta-emitting radiotracers has allowed pre-clinical and clinical luminescence imaging, but
the photon flux is quite low. Here, NPs are shown to not only enhance total radiance but also
emit at discrete wavelengths. Through the marriage of NPs with radionuclides, we have enabled
optical imaging of two new radionuclides, 3H and 35S, and set the stage for optical imaging of all
beta-emitting radionuclides.

By investigating the possible mechanisms by which NPs can

transform relativistic energy, we were able observe characteristic X-rays and yield a new
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imaging handle in SPECT that depends only on the interaction of a radionuclide with the NP.
The role of the beta particle interacting with NPs cannot be emphasized more as an additional
source of IR for endoradiotherapy. These findings with various NPs have broad implications in
nuclear detection, preclinical optical imaging, and design of high atomic number NPs for
imaging and therapy.
4.13 Methods
Nanoparticle preparation
The majority of the nanoparticles were purchased from either American Elements or
Sigma Aldrich with the exception of synthesized silica nanoparticles which were prepared via a
modified Stöber method [68]. Nanopowders were suspended in an aqueous solution of 60 % by
weight glucose with the aid of a 500 W tip sonicator to create a monodisperse nanoparticle
suspension.
Nanoparticle characterization (SI. Absorbance, Photoluminescence)
Nanoparticle morphology and diameter were determined using both a Jeol TEM and a
Malvern Zetasizer Nano ZS DLS. A Malvern Nanosight NS500 instrument was used to
determine particle concentration in addition to optical refractive index using particle tracking
statistics as outlined by van der Pol [100]. The absorbance and photo-luminescence was
determined on a SpectraMax M5 plate reader via quartz cuvette using 1x 1010 particles per mL or
lower and extrapolated when exceeding 1OD.
Radiotracer production (SI)
Hydrogen-3, phosphorus-32, sulfur-35, lutetium-177, and yttrium-90 were purchased
from PerkinElmer as liquid solutions. When appropriate, solutions were brought to neutral pH
prior to addition to nanoparticle solutions. Zirconium-89 was produced on the MSK cyclotron
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and purified as zirconium oxalate. This was neutralized with sodium carbonate prior to use.
Gallium-68 was produced on a germanium generator and eluted in 0.3 N HCl. This was
neutralized with 28 % ammonium hydroxide prior to use. Fluorine-18 was obtained from the
MSK nuclear pharmacy in the form of 18F- fluoro-2-deoxyglucose ([18F]-FDG).
Beta, Gamma and X-ray interactions for visible light modulation
24 well black walled plates from Greiner were used for IVIS optical imaging.
Nanoparticle solutions were prepared as previously stated at 1x 1010, 1x 1011 and 1x 1012
particles per mL. 1 mL of nanosuspension was diluted with 5uL of the radionuclide of interest,
targeting 30 µCi per well at time of measurement. Imaging was performed on an IVIS Spectrum
at F1 for durations of 60 s to 300 s with an open filter. Spectrum scans were acquired using 20
nm increment filters between 500 and 840 nm. ROIs were drawn over each well and radiance
values were reported in p/s/cm2/sr after background subtraction averaging n=3 wells and decay
correction. Enhancement was normalized to the radiance of an identical activity of radionuclide
in H2O.
High-energy photon measurements
The radionuclide of interest was placed in 1 mL H2O in a 24 well black walled plate upon
which a poly(methyl methacrylate) plate and black paper was then placed. On top of the black
paper another 24 well plate containing in triplicate wells of H2O, 60 % glucose, or NP solutions
was then placed. IVIS imaging was conducted with an open filter at F1 for 300 s per image.
ROIs were drawn over the wells and background subtracted.
X-ray and gamma ray spectroscopy
Measurement of the X-ray and gamma spectrum between 5 and 1700 keV was performed
on a Canberra broad energy Ge detector. 1x 1012 particles in an Eppendorf tube were placed at a
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fixed height in the detector, and activity added such that crystal dead time was between 1-5 % for
gamma and pure beta emitters. Clinical radionuclides were added at similar activities, resulting
in ~60 % dead time. Spectra were qualitatively compared to blank Eppendorfs containing
identical amounts of activity in 60 % glucose only. Channel peaks were calibrated to energies
with the use of an

241

Am 1.0 µCi source found in a Family Gard® FG200 Smoke Detector.

Spectra peaks were compared to atomic transitions of the NP elements using the NIST X-ray
Transitions Database [101].
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CHAPTER 5
Conclusions and future directions
5.1 Clinical possibilities of new radiolabeling methods
The heart of this thesis is the marriage of nanoparticles and radionuclides for medical
applications. Nanoparticle-radionuclide combinations have been used clinically in the form of
99m

Tc colloids for decades. As nanoparticle synthesis has developed, attaching radionuclides

through chelator chemistry became the common protocol. However, the idea of using the
intrinsic properties of the nanoparticle for radionuclide attachment (much like 99mTc colloid
formation) has seen a recent resurgence. Chapters 2 and 3 show that consideration of the
chemical components, such as the electron donor affinity and availability of binding sites, are
important for successful radiolabeling. Silica, silica-coated, and iron oxide nanoparticles all
showed intrinsic radiolabeling possibilities depending on the nanoparticle construct.
Nanoparticles still face a high barrier to clinical translation, especially for diagnostic
purposes. Chapter 3 therefore optimized a radiolabeling method of the clinically approved iron
oxide nanoparticle Feraheme (FH) with the clinical PET tracers 89Zr and 68Ga. This allows both
short-term (68Ga) and longer-term (89Zr) imaging depending on the application. 68Ga-FH showed
applicability with imaging lymph node drainage (allowing both PET and Cerenkov luminescence
imaging) while limiting the potential patient dose. 89Zr-FH allowed imaging out to 3 days,
showing migration of monocytes and macrophages.
5.2 New views on ionizing radiation interactions
Once a radionuclide is attached to a nanoparticle, the interactions between the emitted
particle (or photon) and the nanoparticle are typically neglected. However, as demonstrated in
chapter 4, this is not always a valid assumption. In this work the effect of the emitted particle on
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the nanoparticle in terms of photon output was investigated. Here we showed that consideration
of the mechanisms by which ionizing radiation dissipates its’ energy is vital to better understand
these interactions. For the purposes of optical imaging, ways in which visible photons are
produced through these mechanisms were investigated using a panel of nanoparticles and
radiotracers. This work, while focused on the medical applications, is conceivably applicable to
other fields such as radiation detection and waste sequestration with an optical readout.
While the effect of ionizing radiation on nanoparticles was investigated in this work, the
effect of the nanoparticle on ionizing radiation has yet to be investigated. It would be interesting
to consider how high-electron dense nanoparticles affect particles or photons in terms of
attenuation and range. Perhaps through the use of high-density nanoparticles such as gold, the
positron range of PET tracers could be reduced in high-particle concentration setups such as
lymph node imaging. This could lead to a lower dose from the positron and possibly improved
resolution. Such efforts require the cooperation of medical physics and nanoscience.
5.3 Conclusions
This work demonstrates the necessity of considering the nanoparticle composition when
attaching metallic elements such as radiometals, especially considering the multitude of
radiolabeled nanoparticles in the literature. This mechanism of metal attachment to nanoparticles
helps explain why a greater amount of radiometal ions attach to nanoparticles than expected is
sometimes seen. This work will ideally lead to more stable radiolabeled nanoparticles for in vivo
imaging or therapy. Additionally, a greater understanding of ionizing radiation interactions with
nanoparticles will hopefully be conveyed to the nano-imaging field.
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Appendix A
89

Zr-labeled near-infrared quantum dots for in vivo multimodal imaging

This work was conducted in collaboration with Willem Mulder’s laboratory at Mount Sinai.
A1 Introduction
As discussed in chapter 4, Cerenkov luminescence (CL) is the light generated when
charged subatomic particles (e.g. e+ or e-) travel in a dielectric medium faster than the speed of
light in that medium.1, 2 CL is observed for many clinical used radionuclides (e.g. 18F, 124I, 68Ga)
that emit high-energy particles during their decay.3, 4 It is a relatively weak, but self-luminescent
light, which allows background-free imaging5, 6 and deep tissue photodynamic therapy,7 hence
sparking increasing interest for biomedical applications.8
However, CL has intrinsic limitations for in vivo applications. Since its emission
spectrum is mostly dominant in the UV-blue region (Figure A1.1a),9,

10

CL intensity and

penetration depth greatly suffer from scattering and tissue absorption. A possible solution could
be to use an in vivo spectral converter to down-convert the high energy CL to near infrared (NIR)
light, where a biological optical window is located, thus improving the signal intensity and
penetration depth.
NIR emitting quantum dots (QDs) are obviously one of the best spectrum converters for
CL due to their excellent optical properties.11 NIR QDs have continuous broad absorption spectra
that overlap well with CL, high quantum yields, large spectral shifts and tunable narrow
emissions down to the NIR range. Because of these advantages, in a similar role, QDs have
widely served in many other applications as spectral converters, such as down-conversion for
white-light LEDs,12 displays,13 solar cells,14 and luminescent solar concentrators,15 etc.
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Figure A.1. Spectral conversion of Cerenkov luminescence by NIR QD. a, Cerenkov emission
spectrum is overlaid on top of absorption spectra of components in tissues. The theoretical
Cerenkov emission spectrum is reproduced from ref. 10. b, Emission and absorption spectra of
synthesized CdSeTe/CdSe/CdZnS NIR QD used in the current work. c-d, Emission spectra of
QD micelles and 89Zr oxalate mixtures in PBS. Each sample contains either 80 uCi of 89Zr and
indicated dilution of QD micelles (c), or a fixed concentration of QD micelles and 89Zr with
indicated activity. e. Quantum dot dilution showing linear relationship. The emission intensity
from the NIR QD with different quantum yield, with increasing QD concentration, excited with
80 uCi of 89Zr.
To achieve the spectral conversion in applications requires spatial colocalization of light
sources and spectral converters. A few recent reports have validated this concept and tested for in
vivo optical imaging.6, 16, 17 However, in those works, the quantum dot and radionuclides were
administered as two separate chemical entities. In this case, as QDs and radionuclides normally
have different pharmacokinetics and biodistributions, the spatial overlapping degree of these two
components is low, which limits the spectral conversion efficiency and hampers further in vivo
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applications. Therefore, developing a biocompatible nanoplatform that enables efficient codelivery of radionuclides and QDs to specifically targeted areas is of great interest.18, 19
Here, we first studied in vitro the spectral converting properties of QD on CL, and
investigated the effect of QD on enhancing CL in tissue depth penetration. Thereafter, to apply
this concept in in vivo CL imaging applications, we developed NIR-QD and 89Zr dual labeling of
three types of widely-used self-assembled nanoparticles (NPs), including lipidic NP, polymeric
NP, and nanoemulsion. Finally, we applied them in imaging applications, i.e. sentinel lymph
node (SLN) mapping and Cerenkov-guided resection and tumor visualization in a tumor-bearing
mouse model. In this study, the traditional view of Cerenkov-only excitation (i.e. scintillation
disregarded) is used.
A2 QD spectral conversion of CL
We first synthesized highly efficient and water-stable CdTeSe/CdZnSe/ZnS core-shellshell structured NIR QDs through a modified SILAR method.20 Their emission wavelength was
tuned to around 710 nm and their absorption profile has excellent spectral overlap with the
Cerenkov emission (Figure A1.1b). To investigate the NIR QD’s spectral conversion function
on the CL, we mixed different concentrations of 89Zr oxalate solution and PEG-lipid coated QDs
in PBS in well plates, and recorded the emission spectra using an optical imaging system
equipped with a spectrum of emission filters. As shown in Fig A.1c, with fixed radioactivity and
increasing QD concentration, the shape of the emission spectra changed gradually: the blue
region of the spectra decreased and QD emission rose up correspondingly. On the other hand,
with fixing the QD concentration and gradually increasing the radioactivity, the shapes of the
spectra did not have obvious changes (Figure A.1d). Instead, the overall intensity was raised due
to increase of the light source intensity. These results indicate that the spectral conversion effect
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mainly depends on QD concentration (Figure A.1e) while the total intensity of CL is determined
by the amount of activity used. Since this spectral conversion is achieved through radiative
absorption of Cerenkov light by QDs, which subsequently release the energy at a cost of intrinsic
quenching, the quantum yield of the QD plays an important role in the efficiency of spectral
conversion. In Figure A.1e, the intensity of light produced by QD is plotted against QD
concentration. The converted light is linearly related with the concentration of the spectral
converter, and the slope, which represents the conversion efficiency, is related with the QD’s
quantum yield. These experiments revealed the importance of using QD with high quantum yield
for the purpose of spectral conversion.
A3 Light penetration through tissue phantoms
To test if the presence of QDs improves CL’s tissue depth penetration, we performed
imaging experiments on tissue phantoms, in which experimental conditions are better controlled
compared to in vivo testing. The intensity of the light that penetrated through the tissue phantoms
was imaged by means of QD fluorescence, Cerenkov luminescence with open filter, and
Cerenkov luminescence with a 720 nm emission filter. Images in Figure A.2a provide a direct
impression that increasing tissue thickness attenuated the transmitted light’s intensity in general.
But in the presence of QDs –especially at higher QD concentration– more visible light penetrated.
A quantitative analysis of the tissue attenuation effect is summarized in Figure A.2b, and
through an exponential fitting of the data, the effective attenuation coefficients, µeff, were
obtained.
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Figure A.2. Light penetration experiment on tissue phantoms. a, Fluorescence, Cerenkov
(without filter) and Cerenkov (filtered) images of QD and 89Zr mixtures with increasing tissue
phantom thickness. Each well contains 80 uCi of 89Zr and increasing dilution of NIR QD, 1, 0%;
2, 2%; 3, 5%; 4, 10%; 5, 20%, 6, 30%, 7, 50%; 8, 70% and 9, 100%. b, Intensity of transmitted
light are plotted against the tissue thickness. c-d, Emission spectra of Cerenkov emission from
well No.1 89Zr only (c) and well No. 9 (d) transmitted through tissue with indicated thickness.
Therefore, the penetration depth, δp, which is defined as the tissue depth at which the
light’s intensity falls to 1/e (about 37%) of its original value, were 0.8 mm, 1.38 mm, and 1.70
mm for QD fluorescence, CL from

89

Zr only, and CL with QD conversion, respectively.

Fluorescence signal decayed most drastically with increasing tissue thickness, because both
excitation and emission light are attenuated while traveling through the tissue. To the contrary,
the self-illuminating Cerenkov emission has better preservation of the penetrated light because
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the attenuation only happens on the emission route. Most interestingly, with the presence of QD,
we observed an even better preservation of the signal (Figure A.2a). Spectral analysis on the
Cerenkov emission with and without presence of QD well explains the mechanism: with
increasing tissue thickness, the short-wavelength regions of the emission spectra are more
strongly suppressed than the long-wavelength regions (Figure A.3). As the original Cerenkov
emission spectra dominate in the blue region, at 4 mm tissue thickness the transmitted emission
spectrum is flattened with almost complete signal extinction (Figure A.2c). On the other hand,
adding QDs greatly altered the transmitted emission spectrum profile and, in this case, the
maximum shifted to 720 nm, which was less attenuated with increasing tissue thickness (Figure
A.2d). Even at a thickness of 4 mm, a significant amount of light in the NIR range penetrated
through. Of note, at given tissue conditions, if all the Cerenkov emission were converted to 720
nm light, the estimated theoretical δp value would be 2.27 mm. However, in practice, the δp will
be always lower than this value due to incomplete spectral conversion in a specific system
(Figure A.4).
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Figure A.3. Spectral analysis on tissue phantom experiments. a, Absorption spectra of tissue
phantoms with indicated thickness. b-f, Emission spectra of penetrated Cerenkov emission from
the mixture of 89Zr oxalate and indicated QD dilutions under tissue with thickness of 0 mm (b), 1
mm (c), 2 mm (d), 3 mm (e), 4 mm (f).

Figure A.4. Intensity of transmitted light with indicated wavelength are plotted against the tissue
thickness.
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Although the in vitro optical studies above were carried out using mixtures of QDs and
free 89Zr, in later applications, QDs and 89Zr were both associated on a nanoparticle. We found
no significant difference in spectral conversion when
compared to equivalent mixtures of QDs and free

89

89

Zr was bound to the QD surface

Zr in solution (Figure A.5). It can be

understood that, since the mean travel distance of β+ radiation in solution or in tissue is in the
millimeter range,21 this energy transfer from CL to QD actually does not require the
radionuclides to be bound to QDs.16 It is possible that the energy transfer process for this spectral
conversion is mainly through radiative absorption. In this regard, it is very different from
fluorescence resonance energy transfer (FRET), which is based on nonradiative dipole–dipole
coupling that normally requires the donor-acceptor distance to be less than 10 nm.22

Figure A.5. Emission spectra of 89Zr-QD-MC is compared to mixture of QD micelle and
oxalate solution with the same amount of QD and radioactivity.

89

Zr

A4 Synthesis and Characterization of QD and 89Zr dual-labeled nanoparticles
For in vivo applications, incorporating both QDs and radionuclides into one nanoparticle
platform not only enables co-delivery of both components to the target area with maximized
colocation, but also creates a radiolabeled self-illuminating nanoparticle that allows fluorescent,
Cerenkov and PET multi-modality imaging. Here, we realized this concept on three widely used
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nanoplatforms. The first NP, QD and

89

Zr dual-labeled micelles (89Zr-QD-MC) were prepared

through the self-assembly of a hydrophobic ligand-capped QD core and a PEGlyated-lipids
(Figure A.6a) shell.

Figure A.6. Schematically illustration of NIR QD, 89Zr dual-labeled nanoparticles.
In the lipid corona we incorporated a phospholipid functionalized with the chelator
desferrioxamine, which allows complexation of 89Zr4+ ions (Figure A.7a).23 The second NP, QD
nanoemulsions (89Zr-QD-NE) consist of lipid-stabilized medium chain triglycerides (MCT) with
a high payload of QDs dispersed in the oil phase (Figure A.6b). The size of the nanoemulsion
was mainly controlled by the oil-to-lipid ratio.24 To achieve radiolabeling,

89

Zr4+ ions can be

transferred into the MCT core from aqueous phase using DFO-NCS as a phase transfer agent.
Both

89

Zr4+ and DFO-NCS were added to the PBS buffer containing QD-NE. After

complexation, the

89

Zr-DFO-NCS complex became hydrophobic and was incorporated into the

MCT (Figure A.7b). The third nanoplatform was a polymeric NP based on an amphiphilic block
copolymer-coated QD (89Zr-QD-BP, Figure A.6c). The coating polymer was synthesized by
conjugating PEG2000-NH2 polymer chains and DFO moieties onto poly(maleic anhydride-alt-1octadecene) (PMAO) backbone to achieve PEGylation and DFO. The hydrodynamic diameters
of the three nanoparticles were determined through dynamic light scattering (DLS). All three
	
  

147	
  

	
  
QD-containing nanoplatforms can be pre-synthesized, stably stored in solution for months, and
then radiolabeled with

89

Zr right before imaging applications with high radiochemical yields.

The co-elution of quantum dot trace (absorbance at 650 nm) and radioactive trace on size
exclusion chromatography (SEC) at size over 50 nm indicate the successful association of

89

Zr

and QD with all three nanoparticle platforms (Figure A.7 d-f).

Figure A.7. Schematic illustrations of radiolabeling and co-elusion of QDs and activities in
HPLC for 89Zr-QD-MC (a, d), 89Zr-QD-MC (b, e), and 89Zr-QD-MC (c, f).
To study the stability of quantum dots and radiolabel in serum, the dual-labeled
nanoparticles were incubated with fetal bovine serum (FBS) at 37 °C. Aliquots of the incubation
solution at selected time point was analyzed through SEC (see results in Figure A.8). For all
three types of nanoparticles, no detectable dissociation of quantum dots from the nanoparticles
was observed for over 24 hours. For 89Zr-QD-MC and 89Zr-QD-BP, the association of 89Zr with
the NPs was also strong, with very low leak-out of activity (~6% and ~3% respectively) to other
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serum fractions for up to 24 hours. However,
dissociation of

89

89

Zr-QD-NE was less stable and showed some

Zr (~15%) from the nanoparticle, either being associated to plasma proteins

with an estimated molecular weight of 40 kDa or presenting as free ions.23 This release of small
radiolabeled species was detectable at 1 h point and gradually increased with incubation time.
Collectively, the FBS incubation results suggest that these dual-labeled nanoparticles are
sufficiently stable for in vivo applications.

Figure A.8. Serum stability of dual-labeled nanoparticles. Size-exclusion chromatograms of
radioactive trace for 89Zr-QD-MC (a), 89Zr-QD-NE (b), and 89Zr-QD-BP (c) after incubated with
fetal bovine serum for 0 min, 1, 4, and 24 h.
A5 Cerenkov sentinel lymph node (LN) mapping
The successful incorporation of QD and radionuclides onto one bio-compatible platforms
enables considerable in vivo applications. Here we applied and evaluated them for lymph node
mapping and tumor imaging through injection at three different sites in a tumor-bearing mouse
model. The lymphatic system is a vital part of the immune system and plays an important role in
the pathology of many inflammatory diseases and cancers. Sentinel lymph node (SLN) mapping
is widely performed for guiding lymph node dissection and biopsy in the diagnosis of metastasis.
Conventionally, albumin-binding organic dyes (e.g. ICG, isosulfan blue) and radioactive colloids
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(99mTc) are used in the clinic.25 To overcome their limitations in penetration and resolution,
recently new nanoparticle-based imaging agents for SLN mapping have been developed using
various imaging modalities, such as NIR fluorescence,26 photoacoustic,27 and MRI28 etc. As a
new modality, Cerenkov-based SLN imaging has been achieved recently with 18F-FDG, and has
shown its capability of guiding LN resection.29 Here, we tested the LN imaging applications of
QD and 89Zr dual-labeled nanoparticles at two injection sites, namely footpad and peri-tumorally.
We first performed lymph node imaging using all three types of dual-labeled
nanoparticles through footpad injection. After injecting the radiolabeled nanoparticle solution
(50 µCi, 1.89 x 109 mBq, 30 µl) into the rear footpad of anesthetized nude mice (n=3), we
conducted a lymph node imaging time course using PET/CT, fluorescence and Cerenkov
imaging. Representative results from

89

Zr-QD-BP are displayed in Figure A.9, while similar

results were obtained for the other two types of particles. The PET/CT imaging clearly showed
the progress of

89

Zr-QD-BP lymphatic drainage: 30 min after injection we observed the

accumulation of radioactivity in the closest popliteal lymph node. In the next two hours, the
nanoparticles had drained further along the lymphatic vessels and sequentially reached iliac LN,
lumbar LN, and renal LN (Figure A.9b).30 The structure of the nodes and the lymphatic vessels
can be seen clearly, and some uptake in the liver was also observed. At 24 hours after injection,
the image was dominated by axillary node and liver uptake (Figure A.9c). Correspondingly, in
the Cerenkov imaging with open filter (Figure A.9e), the popliteal node was observed
distinctively with low background. The Cerenkov image shows a superior signal-to-background
compared to the QD fluorescence image, which suffered from high background due to autofluorescence (Figure A.9d). After 2 hours, more nanoparticles drained to and retained in the
popliteal nodes and CL at the node became more intense. At later time points, the nanoparticles
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diffused from the footpad to the leg and interfered with the node signal, and thus no clear lymph
node can be appreciated.

Figure A.9. Lymph node imaging via footpad injection of 89Zr-QD-BP. a-c, 3-dimensional
rendering of PET/CT fusion images of a mouse injected with 89Zr-QD-BP at 30 min (a), 2 h (b)
and 24 h (c) post-injection. Assignment of lymph node are labeled on the images. d, The same
animal imaged by NIR fluorescence imaging with excitation at 600 nm and emission at 720 nm.
e-f, Cerenkov imaging on the same animal. at 2 h (e) and 4 h (f) post-injection.
Next, we performed CL imaging-guided sentinel lymph node resection using dual-labeled
nanoparticles as the imaging agent. Each NP type formulation was injected intradermally in the
periphery of the prostate tumor xenograft to allow the migration of nanoparticles into the
lymphatic system. 24 hours after injection, the mice were imaged using PET/CT, fluorescence
and Cerenkov imaging. The results from

	
  

89

Zr-QD-BP imaging are displayed in Figure A.10.
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PET imaging clearly showed two paths of lymphatic drainage from the tumor: one through
inguinal to axillary LN, the other through the lumbar to renal LN (Figure A.10a). By Cerenkov
imaging, the inguinal and axillary LN were clearly visualized with little background signal. To
the contrary, in the traditional QD fluorescence imaging, the SLN are hardly distinctive among
the high background signal (Figure A.10d). Finally, we performed resection of inguinal and
axillary LN under intraoperative guidance of Cerenkov imaging. The background-free Cerenkov
imaging indicated the precise location of SLN with no ambiguity, which finally led to successful
and clean SLN removal (Figure A.10e, f).

Figure A.10. Sentinel lymph node imaging via peri-tumor injection. a-c, a mouse bearing tumor
on the left flank was injected with 89Zr-QD-BP at peri-tumor area and imaged by PET/CT (a),
Cerenkov imaging (b) and NIRF imaging (c) at 24 h post-injection. d-f, Cerenkov imaging
guided lymph node removal performed on the same animal.Before node removal (d,e), and after
node removal (f).
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A6 Tumor Cerenkov imaging
Before conducting tumor imaging with those dual labeled nanoparticles via intravenously
injection, their basic pharmacokinetics and biodistribution are evaluated. The blood clearance
(determined from radioactive signal in health male nude mice) was clearly different for the three
particles:

89

Zr-QD-BP and 89Zr-QD-MC has relatively longer weighted half-life of 3.9 h and 4.1

h, respectively (Figure A.11a), compared to

89

Zr-QD-NE’s 2.6 h. Biodistribution studies and

tumor imaging were completed on the DU145 prostate tumor bearing male nude mice at 24 h
post-injection. Biodistribution data from selected tissues are presented in Figure A.11b.

89

Zr-

QD-BP in general has higher accumulations in tumor and as well as other organs comparing to
89

Zr-QD-MC and

89

Zr-QD-NE. PET/CT imaging was used to follow NP distribution after

administration (n=3). We found QD-MC-89Zr and QD-NE-89Zr had low tumor accumulation
even at 24 hours after injection. For QD-MC-89Zr, activity was found mainly in the liver and
spleen, and clearly in small and large intestine, suggesting hepatobiliary clearance and excreting
into bile. For QD-NE-89Zr, activity was already seen intensely in the kidneys and bladder at 2 h
post administration, indicating that the nanoemulsion may disintegrate in the circulation and be
cleared renally. These results are consistent with the shorter circulation half-life and lower tissue
accumulations of

89

Zr-QD-NE and

89

Zr-QD-MC, indicates their lower particle or labelling

stability in the circulation, which may be caused by interactions with blood components and
subsequent renal or hepatic clearence.11 To the contrary, we observed clear accumulation of QDBP-89Zr in the tumor as early as one hour after injection. Although the long circulation half-life
of QD-BP-89Zr lead to tumor accumulation of the particle, it also causes high body background
in imaging. Therefore, the best tumor imaging is taken at 24 h post-injection time (Figure A.11c,
d). Correspondingly, similar tumor accumulation information, and imaging pattern can be
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appreciated in the Cerenkov imaging, while in traditional quantum dot fluorescence imaging, the
signal from the tumor imaging can be hardly distinguished from the body auto-fluorescence.
These results shows that although all three dual-labelled NP can be successfully used as LN
imaging agent, only one of them is suitable for tumor imaging through intravenous injection,
possible due to the stability of

89

Zr labelling on the NPs in circulation.

89

Zr-QD-BP has

89

Zr-

DFO moieties conjugated on the QD coating thus is a more stable structure compared to the 89ZrDFO-lipids associated on the corona of QD micelles and 89Zr-DFO-NCS complex loaded in the
MCT oil core.

Figure A.11. Tumor imaging via i.v. injection. a, Circulation half-life and b, radioactivity
biodistribution in selected tissues of 89Zr-QD-BP (blue), 89Zr-QD-MC (green) and 89Zr-QD-NE
(red) in mice bearing DU145 tumor. Mice injected with 89Zr-QD-BP were imaged at 24 h postinjection. c, PET/CT fusion imaging. d, 3-dimensional rendering of PET/CT. e, Cerenkov
luminescence imaging. f, NIRF imaging (excitation 600 nm, emission 720 nm).
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A7 Conclusion
We have proof the concept that using NIR QD as spectral converters can greatly change
the Cerenkov emission spectra by converting UV-blue luminescence into NIR range, hence
resulting insignificantly increases CL’s penetration depth and output signal intensity. To realize
this concept in in vivo imaging applications, we have developed three types of QD and 89Zr duallabeled nanoparticles, including QD lipid micelles, QD containing nanoemulsions and block
copolymer coated QDs that enable co-delivery of radionuclides and QDs to the desired location
for maximized spectral conversion effect. . All three types of pre-synthesized nanoparticles can
be readily labeled with

89

Zr, right before the imaging experiment, in high radiochemical yield.

We demonstrated the application of these dual-labeled self-illuminating nanoparticles for
background-free lymph node Cerenkov imaging and tumor imaging. We found that while all
three types of nanoplatforms can be used for lymph node mapping and Cerenkov guided
recession, only QD-BP-89Zr are suitable for tumor imaging through intravenous injection as it
has the best stability in circulation.
A8 Methods
Synthesis of CdSeTe/CdS/ZnS core-shell-shell (CSS) QD
Water-and-air-stable CdSeTe/CdS/ZnS NIR QD was synthesized through a modified
core-shell two-step method.11,

20

First, CdSeTe alloyed core was synthesized through a hot-

injection method. In a three-neck flask, 0.4 mmol CdO powder (≥99.99%, Sigma), 0.8 mmol
tetradecylphosphonic acid (TDPA, 97%, Sigma), 3.5 ml 1-Octadecene (ODE, 90%, Sigma), 2 ml
Oleylamine (OLA, 70%, Sigma) and 2 ml trioctylphosphine (TOP, 97%, Sigma) were added and
sealed under schlenk line. The reaction mixture was degased three times and filled in N2 at
100 °C and then heat up to 280 °C until the mixture turned into a clear solution. At 280 °C, 0.2
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mmol Se (powder, 99.99%, Sigma) and 0.1 mmol Te (powder, 99.8%, Sigma) dissolved in 1 ml
TOP was swiftly injected into the reaction mixture, and reaction temperature was gradually
cooled down to 230 °C. At this temperature, about 1 ml of 0.1 M Se in TOP was dripped into the
reaction mixture to allow the continue growth of the alloyed core and shifting the emission peak
to 690 nm. The synthesized CdSeTe core was precipitated by adding ethanol and washed twice
by hexane and methanol. For the growth of CdS/ZnS shell, the CdSeTe core in hexane was add
to 5 ml of trioctylamine (TOA, 98%, Sigma) and degassed at 100 °C, removing hexane and
moisture. Then at 230 °C, 0.2 ml of 0.1 M Cd(OA)2, 0.2 ml of 0.1 M S in TOP, 0.2 ml of 0.5M
Zn(OA)2 and 1 ml of 0.1 M S were sequentially slowly dripped into the reaction mixture. The
emission peak shifted to about 710 nm after the shell coating. The final product was washed twic
in hexane/methanol mixture and precipitated with acetone, and redispersed in chloroform for
further use.
Radiochemistry
89

Zr was produced through the 89Y(p,n)89Zr reaction on an EBCO TR19/9 variable-beam

energy cyclotron (Ebco Industries Inc., British Columbia, Canada) at Memorial Sloan-Kettering
Cancer Center. The crude product was purified in accordance with previously reported methods
to yield 89Zr with a specific activity of 5.3−13.4 mCi/µg.31 Dose measurements were made using
a Capintec CRC-15R Dose Calibrator (Capintec, Ramsey, NJ).
Tissue phantom experiment
The tissue phantom was made from gelatin gel including 2% of Intralipid (20%, emulsion,
Sigma) mimicking the scattering from the tissue and 100 µM of hemoglobin (porcelain, Sigma)
mimicking tissue absorption.32, 33 Briefly, 5 g of gelatin, 1 ml of Intralipid (20% emulsion), 320
mg of hemoglobin and 0.5 g glutaraldehyde was dissolved in 50ml Tris buffer (pH=7.4, 50 mM
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Tris, 150 mM NaCl and 0.1% w/v sodium azide) at over 50 °C. The homogenous solution was
then poured to a model with the thickness of 1, 2, 3, and 4 mm. The gel was formed after kept in
fridge for overnight. For the tissue penetration experiment, 80 µCi (2.96 MBq) of

89

Zr and an

increasing concentration of QDs were added to wells in a 96-well plate, reaching a total volume
of 250 µl. The tissue phantoms with different thickness were placed on top of the well plate and
imaged in an IVIS optical imaging system. QD fluorescence was imaged with excitation at 605
nm, emission at 720 nm, and 2 s exposure time. CL was imaged without blocked excitation,
either open emission filter or 720 nm filter, and 2 min exposure time.
Preparation of QD micelle and radio labeling of 89Zr -QD-MC
DSPE-DFO was synthesized through the conjugation of DFO-NCS and DSPE with
details already described elsewhere.23 The QD micelle was synthesized through dripping a 0.5 ml
chloroform solution containing 20 µmol of DSPE-PEG2000, 200 nmol of DSPE-DFO (1% of
total lipids) and 1 nmol of NIR QDs into 5 ml of PBS at over 80 °C under vigorous stirring. The
organic phase was evaporated and the contents were transferred into aqueous phase forming
micelles. The crude product solution was then centrifuged at 4k rpm for 10 min to remove
aggregates and precipitates. To remove empty micelles and free lipids, the product solution was
ultra-centrifuged twice, each for 2 hours, at RCF 480k x g, on a Beckman Coulter Optima
XE100 ultracentrifuge equipped with a 70 Ti fixed angle rotor. The supernatant was removed
after each run, and the precipitation pellet was finally redispersed in PBS. Radiolabeling was
performed by reacting the QD micelles with

89

Zr-oxalate in PBS (pH= 6.8-7.1) at 37 °C for 2

hours at an activity-to-QD ratio of ~ 1 mCi/ nmol. The radiolabeled QD micelle, QD-MC-89Zr
was purified through spin filtration using 100k molecular weight cut-off (MWCO) centrifugal
filters.
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Preparation of QD nanoemulsion and radio labeling of 89Zr-QD-NE
The QDs were first transferred to oil phase through dissolving the 2.5 nmol QD and 50 µl
MCT in chloroform as a homogenous solution, followed with evaporation of chloroform on a
rotavapor. The QD in MCT dispersion was placed under high vacuum for several hours to
remove the trace amount of chloroform. A stock solution of mixed lipids was prepared in ethanol
at 20 µmol/ml, containing DSPC 90 mol % and DSPE-PEG2000 10 mol%. To prepare the QD
nanoemulsion, 10 mg of QD-MCT and 500 µl of lipids stock solution were added into 5 ml PBS
and vortexed. Subsequently, this crude emulsion was sonicated for 30 min using a 150 V/T
ultrasonic homogenizer (BioLogics, Inc., Manassas, VA) at 30% power output. The QD
nanoemulsion was washed 3 times with fresh PBS using spin filtrations. Radiolabeling was
performed by adding

89

Zr-oxalate and DFO-NCS in DMSO subsequently into the QD

nanoemulsion solution in PBS (pH= 6.8-7.1) and reaction at 37 °C for 2 hours at an activity-toQD ratio of ~ 1 mCi/ nmol, and purified through spin filtration.
Preparation of block-copolymer coated QD and radio labeling of 89Zr-QD-BP
The PMAO-PEG-DFO block co-polymer was synthesized by reacting PMAO 35 mg,
PEG2k-NH2 200 mg, and DFO-NH2 1.68 mg (3 mol% of PEG) in 10 ml anhydrous
dichloromethane in a 25 ml round flask. The reaction solution was sealed under N2, and stirred
for overnight. After the reaction, the solvent was removed through rotavapor, and the product
was redispersed in deionized water. After centrifugal removal of aggregates and undissolved
part, the unreacted PEG-NH2 and DFO-NH2 were removed by washing with DI water using 100k
MWCO centrifugal filters. Finally, the PMAO-PEG-DFO product was lyophilized to dry. The
method for the preparation of block copolymer coated QD and the radiolabeling were similar to
that for QD-MC-89Zr.
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HPLC and Radio-HPLC
HPLC and radio-HPLC were performed on a Shimadzu HPLC system equipped with two
LC-10AT pumps and an SPD-M10AVP photodiode array detector. Radioactivity was a detected
by a Lablogic Scan-RAM Radio-TLC/HPLC detector. A Superdex 10/300 column (GE
Healthcare Life Sciences, Pittsburgh, PA) was employed to run size exclusion chromatography
using PBS as eluent at a flow rate of 1 ml/min.
Serum stability
The serum stabilities of QD-MC-89Zr, QD-NE-89Zr and QD-BP-89Zr were evaluated by
incubating 200 µCi (7.4 MBq) of each types of particle with 0.5 ml of pure FBS at 37 °C. At 0
min, 10 min, 1 h, 4 h and 24 h after incubation, 50 µCi (1.85 MBq) of aliquot was sampled and
immediately injected into the HPLC column.
Cell culture and animal models
Four to five week old male NCR/NU mice were obtained from Charles River
Laboratories (Wilmington, MA). The prostate cancer cell line DU145 (ATCC) was cultured as
recommended by ATCC. Briefly, Eagle's Minimum Essential Medium was supplemented with
10% fetal bovine serum (FBS) and 1% penicillin streptomycin. DU145 cells were grown to
confluence and 1.5 x 106 cells in 100 µl matrigel were injected into the left flank of the nude
mice. The animals were used for imaging experiment when the tumor size reached over 400
mm3. All animal experiments were done in accordance with protocols approved by the
Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center and
followed National Institutes of Health guidelines for animal welfare.
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Blood half-life and biodistribution
Healthy male nude mice (8-10 weeks old, n = 3 per type of particle) were administered
with about 50 µCi (1.85 MBq) of NP solution in 200 µl PBS via tail vein. Blood samples were
collected at 5, 15, and 30 min, 1, 2, 4, 6, and 24 h. Biodistribution experiments were conducted
on male nude mice (8-10 weeks old, n = 3) bearing DU145 tumors. Around 300 µCi (11.1 MBq)
of NPs in 200 µl PBS were injected via tail vein. After 24 h, mice were sacrificed and perfused
with 40 ml PBS through heart left ventricle before tissue were harvesed. The blood and tissue
samples were weighted and their radioactivities were measured on a Wizard2 2470 automatic
gamma counter (Perkin Elmer, Waltham, MA).
Lymph node imaging
The QD and 89Zr dual-labeled nanoparticle was concentrated in PBS through centrifugal
filters. For lymph node imaging via footpad injection, about 30 µl of nanoparticles solution with
100 µCi (3.7 MBq) activity was injected at right footpad of nude mice. The injected mice were
subjected to PET/CT, fluorescence and Cerenkov imaging at 30 min, 1 h, 2h, 4h, and 24h. For
sentinel lymph node (SLN) imaging, about 10 µl of nanoparticles solution with 30 µCi (1.11
MBq) activity was injected intradermally at peritumoral area. The injected mice were then
subjected to PET/CT and Cerenkov imaging at 1 h, 4h, and 24h.
For in vivo imaging, animals were anesthetized with isoflurane (Baxter Healthcare,
Deerfield, IL) and oxygen gas mixture (2% for induction, 1% for maintenance. Whole body PET
static scans were performed using an Inveon PET/CT scanner (Siemens), and recording a
minimum of 40 million coincident events, with scan durations of 5-30 min. The energy and
coincidence timing windows were 350−750 keV and 6 ns, respectively. The image data were
normalized to correct for non-uniformity of response of the PET, dead-time count losses,

	
  

160	
  

	
  
positron branching ratio, and physical decay to the time of injection, but no attenuation, scatter,
or partial-volume averaging correction was applied. Images were analyzed using Inveon research
software (Siemens). Whole body standard low magnification CT scans were performed with the
X-ray tube setup at a voltage of 80 kV and current of 500 µA. The CT scan was acquired using
120 rotational steps for a total of 220 degrees yielding an estimated scan time of 120-140 s with
an exposure time of 145 ms per frame.
Tumor imaging
Male nude athymic mice (8-10 weeks old, n = 3) bearing DU145 tumors were injected
with about 300 µCi (11.1 MBq) of NP in 200 µl saline solution via the lateral tail vein. At
predetermined time points (1, 2, 4 and 24h) animals were anesthetized and subjected to PET/CT,
fluorescent and Cerenkov imaging.
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B1 Nuclear Decay Schemes

Figure B1.1. 3H decay scheme. 3H decays via β- decay (βmax=18.7 keV, t1/2=12.32 y). From
reference [1].

Figure B1.2.
reference [2].

	
  

32

P decay scheme.

32

P decays via β- decay (βmax=1711 keV, t1/2=14.27 d). From
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Figure B1.3.
reference [3].

33

P decay scheme.

33

P decays via β- decay (βmax=248.5 keV, t1/2=25.35 d). From

Figure B1.4. 35S decay scheme. 35S decays via β- decay (βmax=167.33 keV, t1/2=87.37 d). From
reference [4].
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Figure B1.5. 64Cu decay schemes. The top figure shows decay via electron capture (43.1 %,
t1/2=12.7 h) and β+ (17.86 %, βmax=653.1keV, t1/2=12.7 h), whereas the bottom shows decay via
β- (βmax=579.4keV, t1/2=12.7 h). From reference [5].
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Figure B1.6. 68Ge decay scheme. 68Ge decays via electron capture (t1/2=270.1 d). From reference
[6].

Figure B1.7. 68Ga decay scheme.
reference [6].

	
  

68

Ga decays via β+ decay (βmax=1899 keV, t1/2=68 m). From
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Figure B1.8. 89Zr decay scheme. 89Zr decays via β+ decay 22.8 % of the time, with 77.2 % decay
via electron capture (βmax= 902 keV, t1/2=78.41 h). Note the 909 keV photon that occurs at >
98%. From reference [7].

Figure B1.9.
reference [8].

	
  

90

Y decay scheme.

90

Y decays via β- decay (βmax=2280 keV, t1/2=64 h). From
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Figure B1.10. 111In decay scheme. 111In decays via electron capture, emitting photons at 171.3
and 245.4 keV (t1/2= 2.80 d). From reference [9].

Figure B1.11. 177Lu decay scheme. 177Lu decays via β- decay (βmax=498.3 keV, t1/2= 6.71 d), also
emitting 112.9 and 208.4 keV photons. From reference [10].
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B2 Production of radionuclides for medical applications
Medical radionuclides need produced and purified, as they do not naturally occur in high
concentrated amounts. There are three main production methods: cyclotrons, generators, and
reactors. As of 2012, there were about 400 research reactors and about 500 cyclotrons [11].
B2.1 Cyclotron production
Cyclotron production of radionuclides involves bombardment of targets with a charge
particle such as a proton. Cyclotron-produced radionuclides are typically proton rich and
therefore typically decay by β+ or electron capture. Examples of cyclotron-produce PET tracers
include 11C, 13N 18F, 64Cu, and 89Zr. 11C is produced via the 14N(p, α) reaction, 13N through the
16

O(p, α) reaction, and 18F through the 18O(p, n) reaction [11]. 89Zr is produced by bombardment

of a

89

Y target via a (p, n) reaction [12]. While cyclotron production allows various types of

radionuclides to be produced, the infrastructure (and cost) necessary limits their numbers.
B2.2 Generator production
Generator-based radionuclides are the most attractive systems for radionuclide
productions due to their ease of use and small footprint. Generators’ basic principle preparing a
column that contains long-lived parent isotope that decays into a shorter-lived daughter isotope,
which is eluted from a column. The prototypical example is the 99Mo/99mTc generator, with 99Mo
the parent radionuclide and 99mTc the daughter. This generator has allowed 99mTc to be the most
common radiotracer in nuclear medicine. 99Mo has a half-life of 66 h and can be milked every 24
hours with saline. The

99

Mo remains on an alumina column as the

99m

Tc is removed as TcO4-,

which is subsequently reduced through various kits, depending on the final product [13]. Other
generator-based systems include

188

W/188Re [14],

68

Ge/68Ga (reviewed in depth in chapter 3)

[15], and 225Ac [16].
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B2.3 Reactor production
Reactor-based production of radionuclides involves bombarding a target with neutrons.
Examples of reactor-generated radionuclides include 3H, 14C, 33P, 35S, 153Sm, 186/188Re, 166Ho, and
177
3

Lu [17]. Reactor-produced radionuclides are typically neutron-rich, which in turn decay via β-.

H (tritium) is produced through the 6Li (n, α) reaction,

33

P via the

33

S(n, p) reaction, and

35

S

through the 35Cl (n, p) reaction on a KCl target.
B3 Nuclear instrumentation
Here we briefly review basic instrumentation used in nuclear chemistry and medicine.
Radioactive decay emits particle at energies ranging from tens of keV to hundreds of MeV.
These may be photons (uncharged), protons, electrons, or nuclei. Detectors are typically
categorized by physical state of the transducer or the mode of operation [18]. The ideal detector
would detect 100 % of incident radiation, have no dead time, and have absolute energy
resolution. The basic setup of a detector is radiation interactions with the detector causes either
excitation or ionization effects that are converted to an electronic signal to be analyzed.
Gas-filled detectors (such as Geiger counters) work through the formation of ion pairs
when ionizing radiation interacts with the gas. Voltage across two electrodes collects the ion
pairs, which results in a current that is related to the number of ion pairs formed. Through
changes in the voltage, secondary ionization and saturation can be accounted for, allowing
proportional counting within the aptly named proportional region [19].
Scintillation detectors operate in the same way as the nanoparticles discussed in chapter
4. Here, visible or UV light is emitted through excitation or ionization of the scintillating
material. On the macroscopic scale, crystals (such as thallium-activated sodium iodide or
bismuth germinate [20]) are often used, along with liquid scintillators (typically organic
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solvents). Crystals doped with activator atoms (such as Eu) lead to electron migration to these
sites, with characteristic photon emission dependent on the activator atom [21].
Semiconductor detectors rely on the band gap of semiconductors, where electrons are
raised to the conduction band when radiation interacts with the detector. Examples of
semiconductor detectors include high-purity germanium detectors and silicon, with band gap
energies of 0.72 and 1.10 ev, respectively [21, 22]. These small band caps require liquid nitrogen
cooling to limit thermal energy raising electrons to the conduction band. As germanium detectors
have a high density, the energy resolution is better than gas-filled detectors. Multichannel
analyzers allow discrimination by incident energy; this is possible as the output signal has
amplitude proportional to the energy deposited [18].
B4 Bioconjugation chemistry
Bioconjugation involves one functional group, such as an amine, reacting with another.
During these reactions, the functionality of the biomolecule (such as an antibody) must remain
intact; therefore, these reactions are typically completed in mild conditions. The most widely
used bioconjugation reactions involve amines and thiols, although click chemistry involving
azides is an increasingly popular route. In this appendix, the most widely used bioconjugation
reactions are reviewed. The three most common reactions also have the reaction mechanisms
included. A full review of bioconjugation techniques is available in the seminal work
“Bioconjugation Techniques” [23].
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B4.1 Amines
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Amine&isothiocyanate.mechanism.
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Isothiourea/bond/

Figure B4.1. Amine-isothiocyanate conjugation. This reaction involves nucleophilic attack by
the amine on the electrophilic carbon, forming an isothiourea bond. This reaction is carried out at
pH > 8 for typical biomolecules to ensure the primary amine is deprotonated. While
isothiocyanate groups can also react with sulfhydryl groups, only primary amine reactions are
stable [24].
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Figure B4.2. Amine-isothiocyanate conjugation mechanism. The nucleophilic amine attacks the
electrophilic carbon.
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Figure B4.3. Amine-NHS ester conjugation. Along with the isothiocyanate reaction, amine-NHS
ester conjugation is one of the most common due to the mild conditions and wide availability of
NHS-functionalized groups. pH > 8.0 are typically used.
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Amine&NHS*ester*mechanism*
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Figure B4.4. Amine-NHS ester conjugation mechanism. The NHS is the leaving group in
reactions with amines.
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Figure B4.5. Amine-isocyanate conjugation. This reaction is much like the amine-isothiocyanate
reaction, except the sulfur is replaced by oxygen. This replacement makes isocyanates more
reactive than isothiocyanates. This makes them too reactive for long-term storage, and therefore
are not widely used.

	
  

174	
  

	
  
O

O

Amine&Sulfonyl-Chloride-reac4onR

HN

R

NH 2

R'

N

R'

N

Acyl*Azide*
Deriva/ve*

Amine*

N

N
H

Amide*bond*

Azide*leaving*
group*

Figure B4.6. Amine-acyl azide bioconjugation. The amine attacks the activated carboxylate
group, with the azide acting as the leaving group.
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Figure B4.7. Amine- sulfonyl chloride conjugation. Amines react with sufonyl chlorides to form
a sulfonamide bond, with the chloride as the leaving group.
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Figure B4.8. Amine-aldyhyde conjugation. Amines react with aldehydes to form a Schiff base,
which is subsequently reduced to form a stable secondary amine bond.
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B4.2 Thiols
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Figure B4.9. Thiol-maleimide conjugation. Maleic acid imides (maleimides) are one of the most
common functional groups used in bioconjugation. Reactions are typically conducted at pH 6.57.5 for specificity for thiols rather than amines (which will react in basic conditions).
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Figure B4.10. Thiol-maleimide conjugation. The nucleophilic thiol attacks the double bond. At
high enough concentrations this reaction may be followed by the disappearance of the double
bond, and therefore absorbance at 300nm.
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Figure B4.11. Thiol-iodoacetyl conjugation. The nucleophilic sulfur attacks the carbonyl with
the iodine as the leaving group.
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Figure B4.12. Thiol-aziridine conjugation. The highly hindered nature of the aziridine makes it
reactive towards nucleophiles such as thiols.
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Figure B4.13. Thiol-arylation conjugation. Thiols can react with reactive aromatics through
nucleophilic substitution. This reaction can occurs with halogens or sulfonates on the benzene
ring.
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Figure B4.14. Thiol-disulfide exchange. Thiols may form disulfide bonds though disulfide
exchange reactions occur over a broad range of conditions. This reaction is reversible and is used
in vivo with glutathione intracellularly for drug delivery.
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Figure B4.15. Disulfide reduction can occur by the use of disulfide interchange. Here, the
disulfide is first cleaved forming a mixed disulfide. This is cleaved again forming reduced
sulfides and the oxidized reducing agent (ex. TCEP).
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Figure B4.16. Thiol-metal surface conjugation. Here, the the unshared pair of electrons on the
sulfur atom forms a coordinate covalent (dative) bond with a metal atom such as gold or silver.
B4.3 Other bioconjugation methods
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Figure B4.17. Azide-alkene conjugation. Here, a 5-membered triazoline ring is formed. Cu(I) is
used a catalyst for room temperature conjugation. These reactions have the advantage of being
specific, without the cross-reactivity possibilities seen in the previous examples. This concept is
known as bioorthogonality.
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Figure B4.18. Azide-alkyne conjugation. Here, a 5-membered triazole ring is formed. Cu(I) is
used a catalyst for room temperature conjugation. As with azide-alkene reactions, this is
bioorthogonal.
B5 Non-nuclear in vivo imaging modalities
While ionizing radiation is used in various imaging modalities, other imaging modalities
are also used. These have the advantage of not using ionizing radiation, but also have drawbacks.
Here, three common imaging modalities are briefly covered: 1) fluorescence imaging, 2)
magnetic resonance imaging, and 3) surface-enhanced Raman imaging.
B5.1 Fluorescence molecular imaging
Fluorescence-based molecular imaging is widely used in preclinical research, although it
is just now being utilized in the clinic. Many dyes are available for facile bioconjugation due to
their use with in vitro tools such as fluorescence microscopy and flow cytometry. Fluorescence
imaging involves visible and near-infrared (NIR) photons, and therefore tissue penetration is an
obvious limitation. The ability to conduct multiplex imaging (i.e. using and distinguishing
multiple fluorescence agents in the same system) is a large upside of fluorescence imaging. The
basics of fluorescence imaging are illustrated by the Jablonski diagram. Electrons are excited,
typically by photons, into an excited state. They then relax through either radiative or nonradiative processes. One of the radiative processes is fluorescence, with the emission of a photon.
The emitted photon will depend on the energy band gap.
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B5.2 Magnetic resonance imaging
Magnetic resonance imaging (MRI) is analogous to nuclear magnetic resonance, first
coming into clinical use in 1971 [25]. MRI takes advantage of atoms that have an odd number of
protons and neutrons (i.e. odd atomic mass) within a static magnetic field that take part in the
Zeeman interaction. The three main components of MRI are a strong magnetic field, a field
gradient, and radio waves at certain frequencies (the resonance frequency) depending on the
nucleus being imaged (ex. 1H vs. 13C) and the strength of the magnetic field. First, the magnetic
fields align the spin of the nucleus, either nuclear spin aligned or spin opposed. As spin aligned
nuclei are of a lower energy, there are slightly more spin aligned than spin opposed. Next, radio
waves are introduced to push nuclei to spin opposed, with the energy necessary dependent on
both the nuclei and the magnetic field strength. The radio waves are then turned off, allowing the
spins to return to their original state; this results in radio waves being emitted. These radio waves
are detected and an intensity of the received signal per time is plotted. MR contrast agents such
as gadolinium and super-paramagnetic iron oxide nanoparticles result in the local magnetic field
being altered [26].
B5.3 Surfaced-enhanced Raman imaging
Surfaced-enhanced Raman spectroscopy (SERS) imaging is a relatively recent arrival in
the molecular imaging field. While the vast majority of photons that interact with matter scatter
elastically, a very small portion scatter inelastically, which is referred to as Raman scattering
[27]. SERS is a vibrational spectroscopy technique that increases Raman signal through the
amplification of electromagnetic fields by the excitation of local surface plasmons [28].
Interactions with electromagnetic radiation with metallic nanoparticles smaller than the incident
wavelength can cause a displacement of the electron cloud and induce polarization of the
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metallic nanoparticle. The field associated with this is called the localized surface plasmon
polariton. This enhancement, when combined with specific molecules on the metallic surface,
results in surfaced-enhanced Raman spectroscopy, with the emitted photons have characteristic
frequencies depending on the incident molecule.
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